Untersuchung der Anwendbarkeit extrazellulärer Vesikel und damit assoziierter microRNAs als klinische Biomarker in Flüssigbiopsien by Buschmann, Dominik Sebastian
 TECHNISCHE UNIVERSITÄT MÜNCHEN 
Lehrstuhl für Tierphysiologie und Immunologie 
 
 
Assessment of extracellular vesicles, associated 
microRNAs, and of their utility as clinical biomarkers in 
liquid biopsies 
 
Dominik Sebastian Buschmann 
 
Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für 
Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung 
des akademischen Grades eines 
 
Doktors der Naturwissenschaften 
 
genehmigten Dissertation. 
 
Vorsitzender:   Prof. Dr. Ulrich Kulozik 
Prüfende der Dissertation:  1. apl. Prof. Dr. Michael W. Pfaffl 
    2. apl. Prof. Dr. Gustav Schelling 
    3. Prof. Dr. Martin Klingenspor 
 
Die Dissertation wurde am 22.01.2019 bei der Technischen Universität München eingereicht 
und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung 
und Umwelt am 30.05.2019 angenommen. 
 
I 
Table of contents 
 
Table of contents ................................................................................................................................. I 
List of abbreviations ......................................................................................................................... III 
Abstract ................................................................................................................................................. V 
Zusammenfassung ............................................................................................................................ VI 
1 Introduction ...................................................................................................................................... 1 
1.1 microRNAs: Powerful regulators of gene expression and cellular signaling .................... 1 
1.2 Liquid biopsy: A breakthrough method in molecular diagnostics? ..................................... 7 
1.3 Extracellular vesicles and exosomes: A new paradigm in intercellular communication . 9 
1.4 Extracellular vesicles in liquid biopsies: Intercepting disease signaling .......................... 16 
1.5 Aim of the study ........................................................................................................................ 17 
2 Methods ........................................................................................................................................... 19 
2.1 Establishing the technical foundations for Next-Generation Sequencing-based analysis 
of microRNAs in extracellular vesicles ........................................................................................ 19 
2.2 Testing the utility of microRNAs in extracellular vesicles as biomarkers in vitro ............ 22 
2.3 Testing the utility of microRNAs in extracellular vesicles as biomarkers in vivo ............ 22 
2.4 Enhancing experimental reproducibility and reporting in extracellular vesicle research
 ........................................................................................................................................................... 23 
2.5 Assessing current and future challenges for extracellular vesicle-based clinical 
biomarkers ....................................................................................................................................... 25 
3 Results and Discussion ............................................................................................................... 26 
3.1 Small RNA-Seq is a promising but challenging technique for extracellular vesicle 
microRNA analysis ......................................................................................................................... 26 
3.2 Precipitation is a highly suitable extracellular vesicle isolation method for downstream 
microRNA quantification ................................................................................................................ 27 
3.3 microRNA profiles in extracellular vesicles from arterial and venous sera can be 
compared for biomarker studies ................................................................................................... 29 
3.4 Extracellular vesicles and their microRNA cargo are not a panacea in molecular 
diagnostics ....................................................................................................................................... 30 
3.5 Extracellular vesicles might help identify high-risk patients prior to cardiac surgery ..... 31 
3.6 Extracellular vesicles carry specific diagnostic information in critically ill patients ........ 33 
3.7 Extracellular vesicle research is hampered by heterogeneity in experimental protocols 
and insufficient reporting ............................................................................................................... 36 
3.8 How to improve extracellular vesicle research: Guidelines for experiments and 
reporting ........................................................................................................................................... 38 
3.9 The promise of extracellular vesicles as clinical biomarkers: Opportunities and 
challenges ........................................................................................................................................ 40 
 
II 
4 Conclusions .................................................................................................................................... 43 
5 References ...................................................................................................................................... 46 
Acknowledgements ......................................................................................................................... 55 
List of scientific communications ................................................................................................ 56 
Appendix ............................................................................................................................................. 60 
 
 
 
 
 
 
 
III 
List of abbreviations 
 
AGO2   Argonaute 2 
ARE   AU-rich element 
BNP   Brain natriuretic peptide  
bp   Base pair 
CABG   Coronary artery bypass graft 
CAR-T   Chimeric antigen receptor T cell 
cfDNA   Cell-free DNA 
CSF   Cerebrospinal fluid 
CTC   Circulating tumor cell 
ctDNA   Circulating tumor DNA 
CVD   Cardiovascular disease 
DGE   Differential gene expression 
DNA   Deoxyribonucleic acid 
dPCR   Digital polymerase chain reaction 
e.g.   Exempli gratia 
ECM   Extracellular matrix 
EGFR   Epidermal growth factor receptor 
EpCAM  Epithelial cell adhesion molecule 
ESCRT  Endosomal sorting complex required for transport 
EV   Extracellular vesicle 
EV-TRACK Transparent Reporting and Centralizing Knowledge in Extracellular 
Vesicle Research 
FDA   Food and Drug Administration 
GR    Glucocorticoid receptor 
HSP   Heat shock protein 
ICU   Intensive care unit 
ILV   Intraluminal vesicle 
ISEV   International Society for Extracellular Vesicles 
isomiR   miRNA isoform 
lncRNA  Long non-coding RNA 
MHC   Major histocompatibility complex 
 
IV 
MIQE Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments 
miRNA  microRNA 
MISEV   Minimal Information for the Studies of EVs 
mRNA   Messenger RNA 
MV   Microvesicle 
MVB   Multivesicular body 
MVE   Multivesicular endosome 
NGS   Next-Generation Sequencing 
NR3C1  Nuclear receptor subfamily 3 group C member 1 
nt   Nucleotide 
NTA   Nanoparticle Tracking Analysis 
P-body  Processing body 
pre-miRNA  Precursor miRNA 
pri-miRNA  Primary miRNA 
QC   Quality control 
RISC   RNA-induced silencing complex 
RNA   Ribonucleic acid 
RNP   Ribonucleoprotein complex 
RT-qPCR  Reverse transcription quantitative polymerase chain reaction 
SEC   Size-exclusion chromatography 
SIRS   Systemic inflammatory response syndrome 
Small RNA-Seq Next-Generation small RNA Sequencing  
SNARE  Soluble N-ethylmaleimide-sensitive-factor attachment receptor 
SNP   Single-nucleotide polymorphism 
SOP   Standard operating procedure 
TEM   Transmission electron microscopy 
TLR   Toll-like receptor 
TNBC   Triple-Negative Breast Cancer 
tRNA   Transfer RNA 
UC   Differential ultracentrifugation 
UTR   Untranslated region 
WB   Western blot 
 
V 
Abstract 
 
Extracellular vesicles (EVs) are secreted by all cells and play crucial roles in long-range and 
short-range intercellular communication. In addition to their involvement in physiological 
contexts, EVs are increasingly recognized for their role in disease pathogenesis, which makes 
them promising diagnostic targets in minimally invasive liquid biopsies. Amongst the 
biomolecules associated with EVs, non-coding RNAs such as microRNAs (miRNAs) are 
particularly attractive analytes because they can be easily isolated and amplified and might 
reflect pathological alterations in EV-secreting cells. The aim of this thesis was to assess the 
applicability and utility of exploiting EVs and their miRNA cargo as molecular biomarkers.  
First, the technical basis for standardized and reproducible miRNA analyses via Next-
Generation Sequencing (NGS) was established. The procedures involved in NGS sample 
preparation and sequencing itself are complex and prone to bias, which makes stringently 
optimized and standardized workflows crucial for experimental success. Next, several methods 
of EV isolation were compared in a cohort of sepsis patients and healthy volunteers in order 
to identify the most suitable approach for downstream experiments. Due to its high RNA yield, 
robust performance in sequencing experiments and flawless classification of patients and 
volunteers, EV isolation by precipitation proved to be particularly suited for our purposes.  
In the next step, disease-associated alterations in vesicular miRNA profiles were assessed in 
several patient cohorts. Distinct miRNA dysregulation was detected in circulating EVs in a 
cohort of critically ill sepsis patients. These alterations were different from those in blood cells 
and total sera and carried specific diagnostic information. Interestingly, expression levels of 
several vesicular miRNAs correlated with patient survival, which points towards their potential 
applicability as biomarkers. Additionally, the prognostic utility of EV miRNAs was assessed in 
a cohort of cardiovascular disease patients scheduled for bypass surgery. Preoperative 
concentrations of several miRNAs significantly correlated with clinical variables that indicate 
cardiac instability during surgery, suggesting a potential advantage for the identification of 
high-risk patients.  
Furthermore, initiatives to increase transparency and reproducibility of EV experiments, which 
are cornerstones of translating basic EV science into clinical applications, were established. 
While the developed guidelines provide directives and minimal requirements for EV 
experiments, the EV-TRACK platform evaluates the completeness of reporting crucial 
experimental parameters and offers a comprehensive knowledgebase on current EV studies.  
Finally, experimental, logistical, and regulatory challenges for the utilization of EVs as clinical 
markers were assessed. Despite several anticipated obstacles, careful optimization of 
methods and technologies and standardization of analytical and pre-analytical steps will help 
to increase the reliability and reproducibility of experiments across all areas of EV science and 
thus facilitate the development of EV-based biomarkers. 
 
 
VI 
Zusammenfassung 
 
Extrazelluläre Vesikel (EVs) werden von lebenden Zellen in den extrazellulären Raum 
sekretiert und spielen eine elementare Rolle in der Kommunikation zwischen Zellen und 
Geweben. Neben ihrer eigentlichen physiologischen Bedeutung können die Konzentration und 
Zusammensetzung von EVs bei der Entstehung von Krankheiten verändert sein, was sie zu 
attraktiven Kandidaten für den Einsatz als Biomarker in minimal invasiven Flüssigbiopsien 
macht. Nicht-kodierende RNAs wie microRNAs (miRNAs) sind dabei von besonderer 
Bedeutung, da sie eine potenzielle Reflexion krankhafter zellulärer Veränderungen darstellen. 
Zielsetzung dieser Arbeit war es, die Anwendbarkeit und Nützlichkeit von EVs und den darin 
enthaltenen miRNAs als molekulare Biomarker abzuschätzen.  
Zunächst wurden die technischen Voraussetzungen für eine standardisierte und 
reproduzierbare miRNA-Analyse per Next-Generation Sequencing (NGS) geschaffen. Die für 
die Probenvorbereitung und das NGS selbst benötigten Arbeitsabläufe sind komplex und 
können Artefakte produzieren, daher sind optimierte und standardisierte Verfahren essentiell 
für den experimentellen Erfolg. Im nächsten Schritt wurden in einer Stichprobe von Sepsis-
Patienten und Gesunden verschiedene Methoden der EV-Isolation verglichen, um den 
bestmöglichen Ansatz für nachfolgende Experimente zu identifizieren. Aufgrund hoher RNA-
Ausbeute, guter NGS-Performance und fehlerfreier Klassifikation von Patienten und Kontrollen 
erwies sich die EV-Isolation per Präzipitation als besonders geeignet für unsere Zwecke. 
Anschließend wurden krankheitsbedingte Veränderungen im EV-miRNA-Profil verschiedener 
Patientenstichproben untersucht. In einer Kohorte kritisch kranker Sepsis-Patienten ließen 
sich spezifische Veränderungen im miRNA-Profil zirkulierender EVs nachweisen, die sich von 
denen in Blutzellen und Serum unterschieden. Dabei war von besonderem Interesse, dass die 
Expressionslevel bestimmter miRNAs mit der Überlebensrate der Patienten korrelierten, was 
auf eine potentielle Nutzbarkeit als Biomarker hinweist. Ferner wurde das prognostische 
Potenzial von EVs in einer Kohorte von Patienten mit koronarer Herzerkrankung, die sich einer 
Bypass-Operation unterziehen mussten, untersucht. Hier ließen sich die präoperativen 
Konzentrationen bestimmter miRNAs mit klinischen Variablen korrelieren, die auf eine 
Instabilität der Herzfunktion im Verlauf der Operation hindeuten.  
Des Weiteren konnten Maßnahmen etabliert werden, um die Transparenz und 
Reproduzierbarkeit von EV-Experimenten zu verbessern. Abschließend wurden 
experimentelle, logistische und regulatorische Herausforderungen für die Translation 
akademischer EV-Forschung in klinisch nutzbare Biomarker evaluiert. Obwohl diverse 
Schwierigkeiten zu antizipieren sind, lassen sich Belastbarkeit und Reproduzierbarkeit der EV-
Forschung durch Optimierung verwendeter Methoden und Technologien sowie 
Standardisierung aller analytischen und präanalytischen Verfahren erhöhen, was die 
Entwicklung EV-basierter klinischer Marker begünstigt. 
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1 Introduction 
 
1.1 microRNAs: Powerful regulators of gene expression and cellular signaling 
microRNAs (miRNAs) are short, non-coding RNAs that generally range from 18 to 22 
nucleotides (nt) in length. After they were first discovered in 1993, early interest in miRNAs 
was limited, and it took them until 2001 to be formally recognized as an independent class of 
RNA [1]. In stark contrast, however, miRNA research has accelerated rapidly after unveiling 
their role in post-transcriptional regulation of gene expression via RNA interference and might 
now be at an all-time high.  
In the nucleus of a mammalian cell, miRNAs are transcribed from genomic loci as primary 
miRNAs (pri-miRNAs) with several hundred nt in length by RNA polymerase II and III [2, 3]. 
After cropping the transcript to a stem-loop structure of about 70 nt by the type III ribonuclease 
Drosha, the resulting precursor miRNA (pre-miRNA) is exported into the cytosol by the energy-
dependent Exportin-5 protein (Figure 1). The pre-miRNA’s stem joins the complementary 3’- 
and 5’-arms, which will, upon further processing, generate the -3p and -5p variant of a 
particular miRNA, respectively. The next step in miRNA biogenesis includes trimming of the 
pre-miRNA’s loop by Dicer, resulting in a duplex of about 22 nt in length. After being 
incorporated into the multi-component RNA-induced silencing complex (RISC), the duplex is 
unwound, and the guide strand is retained as a mature miRNA, while the complementary 
passenger strand is degraded. It was initially assumed that guide strand selection strand relies 
entirely on the thermodynamic stability of hydrogen bonds within the duplex, leading to the 
selection of the strand with lower stability at the 5’-end. Arm selection preference was therefore 
postulated to be an inherent feature of each pre-miRNA duplex, which should result in the 
dominant expression of either the -3p or -5p miRNA variant. We now know, however, that 
miRNA arm selection is a dynamic process, and that preferences for one of either arms change 
not only between species, but also between various tissues and even different 
pathophysiological tissue states [4]. The expression of a particular miRNA does therefore not 
solely depend on the expression of its precursor and the resulting duplex’s stability but is 
biologically regulated according to a cell’s demands at the time [5]. Consequently, the initial 
concept of a dominant arm has been adjusted, and it is widely recognized that both the -3p 
and -5p arm are expressed at comparable levels for many miRNAs [6].  
In addition to this canonical pathway, several other routes of miRNA biogenesis have been 
discovered. For instance, some pre-miRNAs are cleaved by Argonaute 2 (AGO2) in a Dicer-
independent manner before further processing by exonucleases [7]. The relative contributions 
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of different biogenesis pathways to the final pool of mature miRNAs are currently unknown and 
a subject of ongoing investigation.  
 
 
Figure 1. The canonical pathway of mammalian miRNA biogenesis. Primary miRNA transcripts are 
generated and processed in the nucleus before energy-dependent export of precursor miRNAs into the 
cytoplasm. Subsequent steps include production of miRNA duplexes by cleavage of the precursor’s 
hairpin, loading into effector protein complexes, degradation of passenger strands and post-
transcriptional repression of target mRNAs by mature miRNAs. RNA Pol: RNA polymerase; pri-
microRNA: primary miRNA; pre-microRNA: precursor miRNA; AGO2: Argonaute 2; RISC: RNA-induced 
silencing complex; mRNA: messenger RNA. Figure reprinted from Winter et al. [8]. 
 
In animals, the canonical mode of action for mature miRNAs, regardless of their prior 
biogenesis, relies on binding to messenger RNA (mRNA) by Watson-Crick base pairing and 
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inhibiting their translation into proteins. Guided by RISC, mature miRNAs target 
complementary sequences in the 3’-untranslated region (UTR) or coding regions of mRNAs 
and negatively modulate their expression [9]. This process requires the concerted actions of 
several proteins, which are recruited to act as a multicomponent ribonucleoprotein 
complex (RNP). Crucial RNP components serve individual and coordinated functions such as 
binding the 5’-end of miRNAs (Argonaute proteins) and recruiting downstream 
effectors (GW182).  
Efficiency and specificity of post-transcriptional repression rely heavily on a miRNA’s seed 
region, which stretches from nucleotide two to nucleotide seven. While the 5’-end of miRNAs 
is anchored in a deep binding pocket of AGO2, the seed sequence is displayed on the protein’s 
surface in a semi-helical conformation, thereby making it accessible for complementary mRNA 
sequences [10]. Upon attachment of miRNA RNPs, translation of target mRNAs is commonly 
repressed at the initiation step by impaired recognition of the 5’-methylguanosine cap, 
interference with translation initiation factors and inhibition of ribosome assembly [11-13]. 
Additionally, translation can also be repressed at post-initiation steps by mechanisms such as 
premature termination of protein synthesis or recruitment of proteolytic enzymes that degrade 
the nascent polypeptide chain [14].  
Perfect complementarity between the seed sequence and its target usually leads to the 
enzymatic degradation of mammalian mRNAs. The mRNA decay machinery, recruited by 
miRNA RNPs, sequentially removes the 3’-Poly(A) tail and the 5’-cap, followed by 
exonucleolytic mRNA degradation [15]. Deadenylation and decapping were shown to be co-
translational events, indicating that repression of translation might precede mRNA decay [16]. 
While miRNA-mediated repression seems to be initiated in the cytosol, repressed mRNAs 
accumulate in distinct, microscopically visible foci called processing bodies (P-bodies). As 
P-bodies were shown to be enriched in proteins of the decay machinery, it is likely that they 
are also the location of ultimate mRNA degradation [17]. Although a perfect seed match is the 
most effective way of mRNA repression, partial sequence matches between miRNA and 
mRNA can still stifle translation by blocking the assembly of essential translation machinery 
components and promoting premature termination of translation due to ribosome  
drop-off [18-20]. This canonical way of mRNA targeting has been expanded by more recent 
findings that describe an alternate mode of target recognition. Some protein-coding transcripts 
can bulge out a nucleotide, usually a guanosine, which allows base pairing with the entire seed 
sequence despite imperfect complementarity of primary miRNA and mRNA sequences. This 
“G-bulge” mechanism might account for a significant proportion of miRNA-mediated repression 
events and expands the repertoire of target sites for a given miRNA [21].  
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In addition to mediating canonical repression of protein synthesis, some miRNAs were found 
to also increase translation of target mRNAs. In 2007, Vasudevan et al. reported enhanced 
translation of specific mRNAs that was contingent on base pairing with miRNAs and 
recruitment of AGO2 [22]. The initially counterintuitive ability of miRNAs to stimulate protein 
synthesis was described to depend on physiological context and to oscillate during the cell 
cycle. Whereas the conventional downregulation of translation prevailed in proliferating cells, 
cell cycle arrest-inducing stress conditions such as nutrient deprivation increased translation 
of specific mRNA transcripts via miRNAs. Similarly, miR-10a, which regulates global protein 
synthesis by modifying the production of ribosomal proteins, was found to activate translation 
of specific targets usually repressed in starvation conditions [23]. In contrast to conventional 
3’-UTR binding, miR-10a binds a particular sequence motif (5 TOP sequence) in the 5’-UTR 
of its targets, many of which are mRNAs for ribosomal proteins.  
Additionally, AU-rich elements (ARE), decay sequences that target mRNAs for rapid cytosolic 
degradation, were found in the 5’-UTR of many protein-coding transcripts, particularly those of 
cytokines and proto-oncogenic transcription initiators. By competing with ARE-binding decay 
factors, some miRNAs can stabilize mRNAs and thus indirectly foster their translation [24]. In 
contrast to a direct activation of translation, this mode of action is more regulatory in nature, 
as it mediates relief of repression rather than activation itself [25]. Similar mechanisms were 
reported for miRNAs that decoy repressive proteins in a seed sequence-independent manner, 
which also leads to mRNA stabilization [26]. Importantly, the actions of a particular miRNA are 
not confined to be exclusively inhibitory or stimulatory: depending on cellular context, a single 
miRNA transcript represses some mRNAs while increasing the translation of others.  
Regardless of the specific molecular interaction, transcriptional regulation by miRNAs is a 
highly sophisticated mechanism that appears to be essential for fundamental physiological 
processes such as cellular development and differentiation, metabolism and  
apoptosis [27, 28]. Dysregulation of miRNA expression and activity has been associated with 
a wide range of diseases including most types of cancer [29, 30]. While an individual miRNA 
putatively targets up to several hundreds of different mRNAs, a single mRNA is also regulated 
by many different miRNAs, leading to a complex network of regulatory interactions [31, 32]. 
Indeed, it was demonstrated that many mammalian mRNAs are highly conserved miRNA 
targets and that the majority of human protein-coding genes is targeted by miRNAs [33].  
While canonical upregulation and downregulation of transcription are predicated on a miRNA’s 
interaction with other nucleic acids, an additional mode of action, resembling hormonal 
signaling, was proposed in a 2018 publication by Fabbri [34]. Partly fueled by the finding that 
miRNAs can be detected in biofluids, where they mediate intercellular communication, it 
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suggested endocrine and paracrine activities of miRNAs. The existence of dedicated protein 
receptors, essential for hormone-like modes of action, has been documented for several 
miRNA transcripts. miR-21 and miR-29a were found to bind to and activate members of the 
Toll-like receptor (TLR) family in human and murine immune cells, leading to downstream 
signaling through the NF-κB pathway and increased secretion of proinflammatory 
cytokines [35, 36]. Similar findings were reported for miRNA let-7b, which fosters 
neurodegeneration by binding to TLR7 [37]. As the hormone-like action of miRNAs is a very 
novel field of investigation, many open questions remain to be elucidated, particularly which 
features of a miRNA determine receptor binding, the proportions of miRNA allocated to acting 
on mRNAs or protein receptors, respectively, and which additional non-coding RNA receptors 
are yet to be detected.  
In addition to the various ways in which a miRNA can exert its biological function, sequence 
variants of miRNAs add another layer of complexity to the network of transcriptomic regulation. 
The advent of Next-Generation Sequencing (NGS) has increased both the throughput and 
granularity of transcriptomic analyses, allowing the inspection of transcripts at single-
nucleotide resolution. Even though miRNA variants had been detected in a multitude of NGS 
data sets, they were initially thought to be sequencing artefacts. Due to the use of exogenous 
spike-in controls, we now know that detection rates of varied miRNA sequences far surpass 
the frequency of sequencing errors, and have come to appreciate the existence of genuine 
miRNA variants, so-called isomiRs [38]. Just as canonical miRNAs, isomiRs are loaded into 
RISC and associate with mRNAs in polysomes, indicating their significance in the regulation 
of the translation machinery.  
isomiRs can display variations at the ends of a transcript or within internal nucleotides and 
oftentimes stem from imprecise cleavage by Drosha, Dicer and other proteins involved in 
miRNA biogenesis [39]. Although these enzymes have preferred cleavage sites in precursor 
sequences, positional shifts of exonucleolytic activity, which lead to templated miRNA variants, 
are commonly observed. Even canonical miRNAs, cut at dominant cleavage sites, can 
subsequently be modified by nibbling of exonucleases or addition of nucleotides by nucleotidyl 
transferases, resulting in shorter or longer non-templated isoforms, respectively. Finally, RNA 
editing and single-nucleotide polymorphisms (SNPs) also contribute to the multitude of 
isomiRs, albeit to a lesser extent [40, 41]. For a number of reasons, variations at the 3’-end 
are much more common than those at the 5’-end, which is buried in Argonaute’s binding pocket 
and thus less accessible to modifying enzymes [42]. Even though much remains to be learned 
about biogenesis and functions of isomiRs, we now know that many, if not most, miRNA loci 
generate several isoforms, and that isomiR profiles are dynamically regulated depending on 
the respective tissue and developmental stage. In fact, the canonical miRNA sequence 
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annotated in dedicated databases might not be the dominantly expressed variant in many 
instances [39].  
The vast majority of isomiRs displays only minor modifications compared to the canonical 
miRNA, indicating a role in fine-tuning of gene expression rather than inducing major shifts. It 
has been demonstrated that modifying miRNA sequences impacts their stability (reducing or 
increasing their half-life), loading into Argonaute proteins (changing strand selection and 
preferential loading of isoforms into different Ago family members) and target repertoire. The 
latter is an obvious consequence of variation at the 5’-end: modifying the crucial first few 
nucleotides of a miRNA has a seed-shifting effect that directly changes the mRNA target 
repertoire. 3’-isomiRs, which are observed much more frequently, have a subtler effect on 
target selection, indicating that they drive similar biology as their canonical miRNAs with a 
common seed sequence [43]. An elegant model of isomiR function proposes the cooperative 
targeting of core biological processes by several isoforms, increasing the repressive pressure 
on target mRNAs while distributing the effects on off-target transcripts more broadly 
(Figure 2) [7]. By generating different isomiRs on an as-needed basis, gene expression can 
be precisely modified with increased specificity compared to regulation by canonical miRNAs 
alone.  
 
 
Figure 2. Cooperative repression of core targets by miRNAs and isomiRs. A: Increasing levels of a 
single miRNA affect core biological functions and off-targets alike. B: Cooperative action of a miRNA 
and its isomiRs with slightly different target repertoires increases repression of core biological functions 
while distributing off-target effects more broadly. Figure adapted from Cloonan et al. [7]. 
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1.2 Liquid biopsy: A breakthrough method in molecular diagnostics? 
In disease management, the ability to adequately treat patients depends on precise and timely 
diagnosis. Accurately identifying and characterizing disease states is crucial, as the majority 
of clinical decisions is based on analytical tests. Sampling cellular material in tissue biopsies 
is the gold standard for accessing disease-related information in many pathologies, particularly 
cancer. While undoubtedly useful, biopsies harbor several disadvantages. In addition to 
generally being invasive, costly and not free from risk, tissue sampling is not feasible for some 
maladies such as lung cancer [44]. Even for successful biopsies, subsequent analyses are 
cumbersome, and specimens must be evaluated by skilled pathologists.  
Using material sampled from biofluids, most commonly serum or plasma, as a surrogate 
marker for tissue-derived information has been a highly anticipated development in modern 
medicine. These so-called liquid biopsies are minimally invasive, affordable and allow serial 
sampling, which is a crucial prerequisite for assessing treatment response. As most tissues 
throughout the body secrete biomolecular material into the circulation, sampling blood also 
allows remote surveillance of tissues inaccessible to needle biopsies. In oncology, a field 
historically struggling with the heterogeneity of tumors, liquid biopsies may provide significant 
diagnostic value, as they capture material from the entire tumor and potential metastases, as 
opposed to the specific section obtained from a tissue biopsy [45]. Potentially even lending 
themselves to preventive screening programs, liquid biopsies might help reach the holy grail 
of oncology: detecting and characterizing tumors in the early stages of development, when 
they are easier to treat and more susceptible to clinical interventions. 
One of the first sample types to be utilized in liquid biopsies were circulating tumor 
cells (CTCs). Originally discovered in 1869, CTCs were intensely studied in the past few 
decades, as technological advances improved their detection, isolation and analysis. CTCs 
are generated by a multitude of tumors, but are rarely found in the circulation of healthy 
individuals or patients with non-malignant tumors, which lead to an initial euphoria for their use 
as diagnostic markers [46]. Even though CTCs reflect the mutational profile of the primary 
lesion, correlate with tumor burden and provide a higher predictive value than conventional 
imaging, their utilization has proven to be difficult. CTCs are extremely rare cells, with 
estimates of 1 – 10 CTCs per ml blood even for metastatic tumors. The same volume of blood 
contains billions of leukocytes, erythrocytes and other blood cells that generate an enormous 
level of background noise for CTC detection. Deciphering their genomic and transcriptomic 
profiles is highly informative, but despite continuous advances in both CTC isolation and 
sequencing technologies, gathering sufficient quantities of nucleic acids remains 
challenging [47]. 
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Another type of material frequently assessed in liquid biopsies is cell-free DNA (cfDNA). It was 
first described in 1947 and can be detected in various biofluids including blood, urine and 
saliva [48]. cfDNA is known to be released from cells undergoing apoptosis and necrosis, but 
active secretion from living cells has also been proposed [49, 50]. Even though they are also 
detectable in biofluids from healthy individuals in low concentrations, cfDNA levels are much 
higher in disease states, particularly cancer [51]. In cancer patients, circulating tumor 
DNA (ctDNA) captures a quantitative and qualitative snapshot of both the primary tumor and 
potential metastases, which is of tremendous interest for diagnostic purposes. ctDNA has been 
detected in many types of cancer including breast cancer, colorectal cancer and lung cancer, 
and offers unique advantages that make it useful for oncology [52-54]. Levels of ctDNA were 
shown to correlate with tumor burden and thus allow the monitoring of disease progression. 
As the half-life of ctDNA was estimated at approximately two hours, much shorter than that of 
many protein biomarkers, it can be used to very precisely assess cancer progression and 
treatment success [55].  
Even though ctDNA makes up only 1 – 40 % of all circulating DNA, it provides highly useful 
information, particularly on somatic genetic changes of the tumor cells it was shed from [56]. 
Screening actionable mutations in tumor driver genes such as epidermal growth factor 
receptor (EGFR), BRAF, KRAS and TP53 allows remote phenotyping of primary tumors and, 
importantly, prediction of treatment response. In fact, the first ctDNA-based liquid biopsy 
assay, commercialized by Roche to assess EGFR mutations in lung cancer patients, was 
approved by the American Food and Drug Administration (FDA) in 2016 [57]. Concordance 
between mutations detected in ctDNA and tissue biopsies is typically high, and ctDNA has 
been reported to detect more mutations than a single needle biopsy would [45]. It is therefore 
not only used to detect a disease state, but also to profile the respective tumor and monitor the 
dynamic evolution of its genome, generating valuable leads for treatment decisions and 
disease management. The assessment of druggable mutations in circulating tumor-derived 
DNA is particularly important for making decisions about endocrine treatments in hormone-
sensitive tumors such as breast cancer [58, 59]. Although the clinical utilization of ctDNA 
benefited tremendously from recent advances in nucleic acid quantification technologies, it is 
hampered by minimal analyte concentrations and low signal-to-noise ratios in much the same 
way that CTCs are. Additionally, ctDNA fragments are usually rather short (< 200 base 
pairs (bp)), which impedes the detection of some genetic variations such as copy number 
variations and gene translocations [60].  
While CTCs and ctDNA have been on the scene for decades, extracellular vesicles (EVs) just 
recently emerged as new and exciting players in liquid biopsies.  
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1.3 Extracellular vesicles and exosomes: A new paradigm in intercellular 
communication 
“Extracellular vesicle” is an umbrella term for a broad variety of vesicles that are actively or 
passively released from cells. While our knowledge in the field is still evolving, EVs are 
generally categorized into three major classes: apoptotic bodies, microvesicles and exosomes. 
Despite sharing some similarities, these EV types differ significantly in their biogenesis, 
physiochemical properties, molecular composition and biological function (Table 1). 
 
Table 1. Characteristic features of the three major classes of extracellular vesicles. mRNA: messenger 
RNA; ncRNA: non-coding RNA; ESCRT: endosomal sorting complex required for transport. 
 Apoptotic bodies Microvesicles Exosomes 
Size 0.5 – 5 µm 100 nm – 1.5 µm 30 – 120 nm 
Biogenesis Cellular blebbing 
Pinched off at plasma 
membrane 
Endosomal pathway 
Release Passive Active Active 
Cargo 
Nuclear fragments, 
organelles, cytosol 
DNA, mRNA, ncRNA, 
soluble proteins, 
membrane receptors 
DNA, mRNA, ncRNA, 
soluble proteins, 
membrane receptors 
Function Cellular decay 
Intercellular 
communication 
Intercellular 
communication 
Markers 
Phosphatidylserine 
exposed in outer leaflet 
ARF6, flotillin-1, 
VAMP3, CD40, 
integrins 
Tetraspanins, ESCRT 
components, Rab 
GTPases 
 
Apoptotic bodies, generally the largest type of EV, are generated by cells undergoing 
programmed cell death. As apoptotic cells shrink, intracellular cascades degrade organelles, 
destroy mRNAs and ultimately fragment the cell’s nucleus and cleave the DNA contained 
therein. During cellular disassembly, parts of the plasma membrane protrude outwards and 
pinch off, generating vesicles that are called apoptotic bodies or apoptotic blebs. These are 
subsequently incorporated by phagocytic cells, ensuring controlled degradation of cells without 
releasing their content into the extracellular space. Apoptotic bodies strongly differ in size, 
ranging from 0.5 µm to 5 µm in diameter. They contain cytoplasm, organelles and nuclear 
fragments as well as nucleic acids. As they are directly pinched off from plasma membranes, 
their membrane composition is similar to that of their parent cells. In contrast to healthy cells 
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and other classes of EVs, however, they display phosphatidylserine in the outer leaflet of their 
membrane. Initially thought to be rather inert byproducts of cellular degradation, apoptotic 
bodies have been shown to have biological functions such as horizontal DNA transfer [61].  
In contrast to apoptotic bodies, microvesicles (MVs), sometimes also referred to as 
microparticles, are produced by living cells. They, too, are shed from the plasma membrane 
by outward budding and subsequent fission, which generates vesicles of 100 nm – 1.5 µm in 
diameter. Biogenesis of MVs takes place at designated membrane sites and involves specific 
lipids, membrane proteins and contractile cytoskeleton components. While composition and 
topology of MV membranes resemble the secreting cell’s plasma membrane, they are 
additionally enriched in phosphatidylserine and lipid raft-like structures. Besides displaying 
surface receptors, adhesion molecules and other membrane-associated proteins, MVs also 
carry cargo in their lumenal space. MV-encapsulated biomolecules include enzymes, signaling 
molecules, cytokines, cytoskeletal components and nucleic acids. Whereas apoptotic bodies 
seem to enclose a random assortment of degraded cellular components, cargo packaging into 
MVs is a specific process [62]. Several studies have reported an enrichment of proteins related 
to adhesion and signal transduction, as well as mitochondrial, ribosomal and cytoskeletal 
proteins. While several key players in the recruitment of specific cargo to MVs have been 
identified, the underlying machinery is yet to be fully elucidated [63].  
Nucleic acid cargo of MVs includes DNA and mRNA, as well as non-coding RNAs such as 
miRNAs. MV-encapsulated cargo is protected from degradation and biologically functional in 
recipient cells, representing a novel way of horizontal biomolecule transfer. Generally 
speaking, secreted MVs have the capacity to modify nearby extracellular matrix (ECM) as well 
as to physiologically impact proximal and distant cells. As the composition of MVs shed from 
different tissues varies, there is an ensuing heterogeneity of MV subpopulations with different 
biological functions. For instance, MVs were shown to mediate both pro-inflammatory and anti-
inflammatory functions, depending on their cytokine cargo and the effects provoked in target 
cells [64, 65]. Additionally, MVs were implicated to play a role in coagulation, immunity and 
drug resistance [66-68]. MVs shed from tumor cells were shown to degrade ECM, induce 
angiogenesis and aid in cancer immune evasion [69].  
While interest in MVs has steadily increased over the past decade, exosomes remain the most 
studied class of EVs. After their discovery in 1983, exosomes were initially regarded as the 
“garbage bin of the cell”; a system to remove waste, misfolded proteins and harmful 
substances by expulsion into the extracellular space [70, 71]. After the stunning 2007 discovery 
that they contain functional RNA molecules that can be transferred to recipient cells, where 
they induce phenotypic changes, however, exosome research increased exponentially [72]. 
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Realizing their role in physiology and pathophysiology has brought about a paradigm shift in 
intercellular communication, and exosomes are now highly studied for both their biological 
functions and their potential biotechnological applications.  
Compared to other EV types, exosomes stand out due to their molecular composition, 
physiochemical properties and biogenesis. While both apoptotic bodies and MV are pinched 
off at the plasma membrane, exosomes have an intracellular origin (Figure 3). They are 
generated in the endosomal trafficking pathway, the cell’s major mechanism for internalizing 
and processing extracellular material [73]. During endocytosis, parts of the plasma membrane 
engulf extracellular fluid and bud inwards, eventually pinching off from the cell surface to create 
endosomes. Within these vesicles, the newly internalized cargo is sorted and some of the 
endocytosed membrane, including protein receptors, is recycled to the plasma membrane. 
During maturation from early endosome to late endosome, the vesicle’s lumen is acidified in 
preparation for cargo degradation. Endosomal maturation is a highly dynamic process, in 
which parts of the vesicle’s membrane can bud inwards to generate intraluminal vesicles (ILVs) 
within the endosome, which is now referred to as a multivesicular body (MVB) or multivesicular 
endosome (MVE). ILVs are enclosed by endosomal membranes and carry cytosolic material 
previously incorporated during inward budding. Typical MVBs range from 250 nm to 1 µm in 
diameter and contain up to several dozens of ILVs [74]. While most MVBs subsequently fuse 
with lysosomes, which leads to disintegration of the vesicle and degradation of its cargo, some 
MVBs escape this fate and instead fuse with the plasma membrane. This fusion process 
releases ILVs of 30 – 120 nm in diameter into the extracellular space, where they are now 
called exosomes. Exosome secretion is a highly conserved mechanism employed by virtually 
all mammalian cells, and exosomes have consequently been detected in a variety of biofluids 
including serum and plasma, breast milk, urine, saliva and cerebrospinal fluid (CSF) [75-77].  
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Figure 3. Schematic representation of the biogenesis of extracellular vesicles. While microvesicles bud 
off from the plasma membrane, exosomes are generated by inward budding of endosomal membranes, 
forming multivesicular bodies (MVB). During maturation, MVBs are either targeted to lysosomes for 
degradation or fuse with the plasma membrane to release enclosed exosomes into the extracellular 
space. ESCRT: endosomal sorting complex required for transport; SNARE: soluble N-ethylmaleimide-
sensitive-factor attachment receptor. Figure reprinted from Kowal et al. [78]. 
 
Even more so than for MVs, cargo selection for exosomes is not a random event, but a specific 
process orchestrated by complex macromolecular mechanisms. The endosomal sorting 
complex required for transport (ESCRT) is the main machinery of MVB biogenesis and seems 
to be at least partly involved in sorting cargo into ILVs. Due to experiments in which ESCRT 
deletion did not completely abrogate exosome secretion, we now know that there are 
additional, ESCRT-independent mechanisms of MVB formation, potentially working 
competitively on the same MVB [79]. Many molecules have been associated with specific 
cargo sorting into ILVs, and mechanisms based on tetraspanins, posttranslational protein 
modification and lipid raft structures are discussed in the literature. A comprehensive 
understanding of MVB biogenesis and incorporation of various types of cargo into ILVs, 
however, remains elusive.  
Due to their unique mode of biogenesis, exosomes carry marker proteins that might distinguish 
them from MVs [80]. Endosomal proteins involved in MVB biogenesis (Alix, TSG101) are 
enriched in exosomes, as are proteins related to membrane trafficking (Rab GTPases) and 
cell membrane-derived tetraspanins such as CD63, CD81 and CD9 (Figure 4). In addition to a 
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set of generic markers, exosomes also carry soluble proteins and surface receptors specific 
for their secreting cells. Depending on the parental cell, they might carry enzymes, cytokines 
and heat shock proteins as well as proteins involved in antigen presentation, signal 
transduction and cellular adhesion and targeting. Exosomal membranes are enriched in 
cholesterol, sphingomyelin, lipid raft-like structures and phospholipids carrying short saturated 
fatty acids, which render them highly stable and protect cargo from harsh conditions such as 
acidity, hypoxic environments and the presence of nucleases [81-83].  
 
 
Figure 4. Schematic structure of a canonical exosome. Exosomal membranes carry integral and 
transmembrane proteins such as tetraspanins and major histocompatibility complexes (MHC). Soluble 
cargo enclosed by the phospholipid bilayer includes enzymes, cytoskeletal components and signaling 
factors. In addition to their protein cargo, exosomes also carry nucleic acids including DNA, mRNA and 
non-coding RNA. HSP: heat shock protein. Figure reprinted from Kourembanas et al. [84]. 
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An important feature of exosomes is that they also carry nucleic acids, including small amounts 
of genomic and mitochondrial DNA, mRNA, but particularly non-coding RNAs such as transfer 
RNAs (tRNAs), miRNAs and long non-coding RNAs (lncRNAs). Early studies reporting that 
exosomal RNA is biologically active and can be translated to proteins (mRNA) or modulate 
gene expression (miRNA) in recipient cells have generated considerable interest in the 
selection and function of RNA in circulating exosomes. Exosomal RNA profiles are often 
reported to differ from those in their parental cells, hinting at selective cargo sorting [85]. 
Additionally, RNA profiles in exosomes from a given cell type differ depending on the 
physiological state of the cell. For instance, alterations in cargo were reported for exosomes 
secreted by hypoxic cells as well as cells undergoing inflammatory stress or oncogenic 
transformation [86-88]. Even though various mechanisms of how cytosolic RNA might be 
targeted to ILVs, ranging from specific sequence motifs to affinity-based interaction with MVB 
membranes, have been proposed, a comprehensive understanding of the underlying principles 
remains elusive [89-91]. 
In order to convey a biological function, exosomes must interact with target cells in one of 
several ways (Figure 5). The first and most direct way of interaction includes fusion of exosome 
membranes with plasma membranes, which releases vesicular cargo into the recipient cell’s 
cytosol. Mechanistic studies on direct membrane fusion indicate a “rolling adhesion” process, 
during which exosomes initially attach to and roll across plasma membranes until reaching 
dedicated sites of internalization [92]. Even though little is known about its molecular 
mechanisms, the process was postulated to involve specific recognition of proteins on 
vesicular and cellular membranes, followed by protrusion of fusogenic proteins, lipid 
reorganization, a hemifusion transition state and, finally, full fusion of both membranes [93]. 
Secondly, intact exosomes can be internalized by several mechanisms including endocytosis, 
pinocytosis and macropinocytosis. Previous research demonstrated the involvement of both 
clathrin-dependent and -independent endocytosis, as well as lipid raft-mediated 
internalization [94-96].  
Similar to competitive modes of exosome biogenesis, several mechanisms of internalization 
might simultaneously be at play. Alternatively, different subpopulations of exosomes might be 
taken up by distinct mechanisms, depending on the surface proteome of vesicles and recipient 
cells. Even though uptake kinetics differ between cell types, internalization was shown to be 
active and energy-dependent [97]. During internalization, exosomes enter recipient cells in 
endocytic vesicles, from which they can escape via back-fusion with the endosomal 
membrane. This “endosomal escape” releases exosomal cargo into the cytosol, enabling 
interaction with various cellular machineries [98].  
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In addition to targeting vesicles to specific tissues, surface proteins on exosomes also mediate 
signal transduction in a third way of interaction with recipient cells [99]. Exosomal surface 
ligands can bind to and activate plasma membrane receptors, which in turn initiates 
intracellular signaling cascades that lead to phenotypic changes by, e.g. altering the cellular 
transcriptome [100]. In its most extreme form, this mechanism can go as far as exosomes 
inducing apoptosis of immune cells via the ligands FasL and TRAIL displayed on their 
surface [101]. 
 
 
Figure 5. Schematic summary of modes of interaction for exosomes and recipient cells. Exosomes can 
initiate signaling cascades via cell surface receptors (1) or release their cargo into the cytosol by fusion 
with the recipient cell’s plasma membrane (2). Alternatively, intact exosomes can be internalized by 
macropinocytosis (3) or endocytosis (4-6). Figure adapted from [102]. 
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Initially regarded as a mere garbage disposal system, exosomes are now known to be involved 
in a myriad of biological functions ranging from immune modulation and antigen presentation 
to inflammation and tissue polarity [103-105]. Beside their role in physiology and homeostasis, 
pathological functions of exosomes have attracted particular interest. For instance, exosomes 
secreted from various tumor cells were shown to modulate ECM, suppress the anti-tumor 
immune response and foster the development of pre-metastatic niches [106]. Research on 
neurodegenerative diseases proved exosomes to propagate Alzheimer’s Disease and 
Parkinson’s Disease by spreading toxic amyloid-beta and α-synuclein, respectively [107, 108]. 
Additionally, exosomes were recently implicated in the pathogenesis of diabetes, 
cardiovascular disease (CVD) and infectious disease [109-111]. As they mirror both 
physiological and pathological conditions, circulating exosomes are intensely studied to 
understand molecular mechanisms of disease as well as to develop novel diagnostic, 
prognostic and predictive biomarkers. 
 
1.4 Extracellular vesicles in liquid biopsies: Intercepting disease signaling 
As the composition and concentration of EVs from infected, transformed and otherwise 
pathological cells differ from those of healthy tissues, EVs are a promising source of clinical 
biomarkers. Due to their protective shell, EVs harbor a stable and concentrated repertoire of 
biomolecules that lend themselves to quantification in downstream analytical assays. Indeed, 
nucleic acids including DNA, mRNA and miRNA as well as proteins and combinations thereof 
have been suggested as clinical markers in various types of cancer [112-114]. Similar to 
ctDNA, DNA in tumor EVs reflects the genomic makeup of secreting cells, thus allowing the 
remote screening of actionable mutations. Importantly, however, analysis of tumor EVs 
provides the additional benefit of deciphering the tumor’s transcriptome, including aberrations 
such as fusion transcripts, in the same sample. By revealing malignant neoantigens, EVs might 
turn out to yield crucial clues for the development of personalized cancer immunotherapies, 
particularly those based on chimeric antigen receptor T cells (CAR-T) [115]. Indeed, combined 
analysis of ctDNA and EV RNA was recently demonstrated to increase detection rates of 
growth factor receptor mutations in lung cancer patients [116].  
The ability to specifically enrich EVs from malignant cells represents additional benefits 
compared to other sample types used in liquid biopsies. Capturing EVs based on disease-
specific surface proteins drastically reduces the background noise typically encountered when 
analyzing bulk populations of circulating vesicles and might provide a more concentrated 
source of biomarker candidates. For instance, tumor antigens were exclusively detected in 
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EVs isolated from patient sera using melanoma-specific antibodies as opposed to EVs from 
healthy tissues [117]. In a study on ovarian cancer, miRNA profiles in tumor EVs enriched by 
immunoaffinity to surface epithelial cell adhesion molecule (EpCAM) were suggested as a 
diagnostic marker in screening programs [118].  
As the development of new drugs heavily relies on identifying patient populations that might 
benefit from a particular treatment and subsequently monitoring their response to it, the need 
for reliable biomarkers stretches beyond mere diagnostic purposes. In the age of precision 
medicine, developing effective personalized therapies is contingent on molecular disease 
profiling to guide clinical decisions. In the same vein, assessing a patient’s response to therapy 
on a regular basis could indicate the potential need to change therapeutic approaches and 
thus improve favorable outcomes. Results from EV-based clinical trials are scare but 
encouraging, as demonstrated by a recent report on the utility of EVs to monitor therapy 
response in glioma patients [119].  
Despite the undeniable interest in using EVs as clinical biomarkers, many questions remain to 
be answered before their potential can be fully realized. First, there is no consensus on which 
biofluid to sample for a given disease, which method of EV isolation is most suitable for various 
downstream assays, and how these might be affected by pre-analytical variables [96]. Second, 
given the stunning heterogeneity of EV classes and subtypes, it is unclear which EV fraction 
in a given biofluid is most informative of the disease state. For instance, a recent study on 
prostate cancer reported that larger tumor vesicles (oncosomes) carried significant amounts 
of high molecular weight DNA, which reflected tumor-specific genetic aberrations [120]. 
Exosomes from the same patients, on the other hand, contained only negligible amounts of 
DNA and might be a less suitable source of biomarkers. Third, different types of EV cargo, or 
combinations thereof, might harbor the most informative analytes for different diseases [121]. 
Fourth, the majority of promising biomarker candidates never make it to the clinic because they 
fail validation in larger cohorts, lack clinical utility or cannot be integrated into easily automated 
high-throughput analytical platforms [122, 123]. The success or failure of EVs as clinical 
biomarkers will ultimately be determined by how well they fare in facing these challenges.  
 
1.5 Aim of the study 
The goal of this study was to take a three-pronged approach to assess the utility of EVs and 
their miRNA cargo as disease biomarkers. Initially, a robust and reproducible workflow for the 
quantification of miRNAs via high-throughput Next-Generation small RNA Sequencing (small 
RNA-Seq) was to be established as the basis for evaluating disease-specific changes in 
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miRNA expression. Next, various methods for isolating EVs from human sera were to be 
compared in order to identify the most suitable approach for downstream small RNA-Seq 
experiments. Third, the utility of analyzing vesicular miRNA profiles for biomarker studies was 
to be examined in vitro and in vivo using the previously established techniques.  
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2 Methods 
 
2.1 Establishing the technical foundations for Next-Generation 
Sequencing-based analysis of microRNAs in extracellular vesicles 
To initially assess current methods and best practices for small RNA-Seq, a comprehensive 
literature review was performed. Special focus was put on miRNAs, which are arguably the 
most heavily researched type of small non-coding RNA. We aimed at establishing a robust and 
reproducible workflow, covering all aspects from pre-analytical variables to sequencing and 
data analysis, and identifying potential hurdles along the way (Figures 6 and 7). Additionally, 
measures to standardize experimental and analytical variables and thus enhance 
reproducibility and comparability of small RNA-Seq were highlighted in Buschmann et al. [124] 
(Appendix I). In line with the anticipated goal of analyzing miRNAs in EVs, a particular 
emphasis was put on handling and sequencing RNA from cell-free samples including material 
gathered in liquid biopsies.  
 
 
Figure 6. Schematic overview of small RNA-Seq experiments: Experimental design, pre-analytical 
procedures, library preparation and sequencing. Figure reprinted from Buschmann et al. [124] 
(Appendix I).  
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Figure 7. Schematic overview of small RNA-Seq experiments: Data pre-processing, alignment, 
normalization and biomarker-centric analysis. QC: quality control; DGE: differential gene expression 
analysis. Figure reprinted from Buschmann et al. [124] (Appendix I). 
 
Next, several methods of isolating EVs from human sera were assessed regarding their 
suitability for downstream small RNA-Seq experiments. Specifically, approaches based on 
size-exclusion chromatography (SEC; qEV Columns, Izon Science, Oxford, UK; Exo-spin Midi 
Columns, Cell Guidance Systems, Cambridge, UK), precipitation (miRCURY Exosome 
Isolation Kit, Exiqon, Vedbaek, Denmark), membrane affinity (exoRNeasy Serum-Plasma Midi 
Kit, Qiagen, Hilden, Germany) and sedimentation (differential ultracentrifugation, Beckman 
Coulter, Brea, CA, USA) were compared in a cohort of sepsis patients (n=9) and healthy 
volunteers (n=10). EV isolation, small RNA-Seq and data analysis were carried out as 
published in Buschmann et al. [125] (Appendix II). Differential gene expression (DGE) analysis 
using DESeq2 [126] was performed to detect miRNAs dysregulated between patients and 
volunteers (Figure 8). Library sizes, miRNA profiles and relative mapping frequencies to 
several other classes of small non-coding RNA as well as results from DGE analysis were 
utilized to evaluate the suitability of each method for sequencing-based miRNA biomarker 
analysis. Additionally, EVs from each isolation method were analyzed by Nanoparticle 
Tracking Analysis (NTA; NanoSight LM10, Malvern Instruments, Malvern, UK) to assess 
method-specific differences in size and concentration. Purity, morphology and protein marker 
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composition of EVs from patients and volunteers were determined by transmission electron 
microscopy (TEM; Zeiss EM900, Carl Zeiss Microscopy, Jena, Germany) and Western 
blotting (WB; XCell SureLock Mini-Cell Electrophoresis System, Thermo Fisher Scientific, 
Waltham, MA, USA), respectively. 
 
 
Figure 8. Schematic summary of EV isolation, RNA extraction and small RNA-Seq (left). EVs were 
isolated from patient sera sampled on the day of admission to the intensive care unit (day 0). In a 
subgroup of sepsis patients and volunteers, EVs were isolated and biologically characterized (right). For 
characterization experiments, patient EVs were isolated from sera sampled after 24 hours of 
hospitalization (day 1). EV: extracellular vesicle; UC: differential ultracentrifugation; NGS: small RNA-
Seq; DGE: differential gene expression analysis; WB: Western blot; NTA: Nanoparticle Tracking 
Analysis; TEM: transmission electron microscopy. Figure reprinted from Buschmann et al. [125] 
(Appendix II). 
 
Biomarker studies, particularly those focusing on critically ill patients, are frequently carried out 
using arterial or venous sera, but little is known about potential differences in concentration 
and composition of EVs isolated from these biofluids. Assessing the comparability of small 
RNA-Seq experiments based on arterial and venous EVs was therefore the next step. In a 
cohort of heart disease patients (n=20), paired sera were sampled from the radial artery and 
internal jugular vein of individual patients prior to coronary artery bypass graft (CABG) surgery. 
After precipitation-based isolation (miRCURY Exosome Isolation Kit, Exiqon, Vedbaek, 
Denmark) of EVs from these sera, associated miRNAs were profiled by small RNA-Seq as 
described in [127]. Potential differences in the abundance of miRNAs from arterial and venous 
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EVs were assessed via DGE analyses using DESeq2 and validated by reverse transcription 
quantitative polymerase chain reaction (RT-qPCR; miRCURY LNA miRNA PCR Kit, Exiqon, 
Vedbaek, Denmark). Additionally, EVs from both types of biofluid were biologically 
characterized to detect potential differences in size, concentration and composition.  
 
2.2 Testing the utility of microRNAs in extracellular vesicles as biomarkers in 
vitro 
Overexpression of the glucocorticoid receptor (GR) in Triple-Negative Breast Cancer (TNBC), 
which does not express receptors for estrogen, progesterone and human epidermal growth 
factor 2, is associated with therapy resistance and increased mortality. To assess the potential 
manifestation of this particularly oncogenic phenotype in secreted miRNAs, EVs shed from 
TNBC cells were analyzed in an in vitro model of GR overexpression. Three human TNBC cell 
lines (MDA-MB-231, MDA-MB-436, MDA-MB-468) were transfected with plasmids coding for 
the nuclear receptor subfamily 3 group C member 1 (NR3C1). The ensuing overexpression of 
GR and its target genes was validated by RT-qPCR (QuantiTect Reverse Transcription 
Kit (Qiagen, Hilden, Germany), Sso Advanced Universal Supermix and SsoFast EvaGreen 
Supermix (Bio-Rad Laboratories, Munich, Germany)). Next, EVs were isolated (miRCURY 
Exosome Isolation Kit, Exiqon, Vedbaek, Denmark) from culture media of transfected and 
control cells and analyzed by small RNA-Seq as published in Buschmann, González et 
al. [128] (Appendix III). DGE analysis and validation of dysregulated miRNAs were carried out 
using DESeq2 and RT-qPCR (miScript II RT Kit and miScript SYBR-Green PCR Kit, Qiagen, 
Hilden, Germany), respectively. Additionally, cellular RNAs from transfected and control cells 
were analyzed in parallel to compare GR-dependent intracellular and extracellular changes in 
miRNA profiles.  
 
2.3 Testing the utility of microRNAs in extracellular vesicles as biomarkers in 
vivo 
Despite being a commonly performed medical procedure, open heart surgery carries 
substantial risks for adverse outcomes including postoperative organ failure and increased 
mortality. Early identification of patient populations at risk for perioperative cardiac instability 
might help to improve patient care and reduce adverse outcomes. The utility of EV miRNAs 
for patient stratification was assessed in a cohort of heart disease patients (n=19) and healthy 
volunteers (n=20) as described in [129]. EVs were isolated (miRCURY Exosome Isolation Kit, 
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Exiqon, Vedbaek, Denmark) from patient sera sampled prior to open heart surgery and from 
matched volunteers. EV-associated miRNAs were profiled by small RNA-Seq and compared 
in DGE analyses to detect miRNA species dysregulated between surgical patients and 
volunteers. Expression levels of these candidate miRNAs were then correlated to prospectively 
recorded perioperative clinical variables such as inflammation, intraoperative epinephrine 
dosing, serum lactate levels and duration of surgery.  
In a separate study, the utility of cellular and extracellular miRNAs for disease detection was 
assessed in a cohort of patients in septic shock and matched healthy volunteers (n=7 each). 
Sepsis and septic shock represent the clinical manifestation of a massively derailed immune 
reaction to pathogens such as bacteria, fungi or viruses. Early disease detection, particularly 
the distinction between a septic state and a sterile inflammatory state, are critically important 
to administer appropriate clinical care and reduce mortality. Blood cells (PAXgene RNA Kit, 
PreAnalytiX, Hombrechtikon, Switzerland), total serum (S-Monovette, Sarstedt, Nürnbrecht, 
Germany) and serum-derived EVs (miRCURY Exosome Isolation Kit, Exiqon, Vedbaek, 
Denmark) were sampled from patients upon admission to the intensive care unit (ICU; day 0) 
and on the fourth day of treatment (day 4) if available. For each sample type, miRNAs were 
analyzed by small RNA-Seq and compared between patients and volunteers as published 
in [130] (Appendix IV). Dysregulated miRNAs in each sample type were further analyzed in a 
separate cohort of sepsis patients (n=9), septic shock patients (n=6) and matched 
volunteers (n=16) by RT-qPCR (miRCURY LNA miRNA PCR Kit, Exiqon, Vedbaek, Denmark). 
In addition to evaluating blood compartment-specific diagnostic information, samples were 
grouped according to disease severity and patient survival to detect miRNAs with expression 
levels correlated to progressive organ damage. Expression of miRNAs correlating with disease 
severity on day 0 was additionally evaluated by RT-qPCR in samples drawn on day 4 to detect 
potential markers for disease progression.  
 
2.4 Enhancing experimental reproducibility and reporting in extracellular vesicle 
research 
In order to assess current practices in experimental procedures and reporting thereof, an 
international consortium of researchers performed an extensive review of 1,226 manuscripts 
on EVs published between 2010 and 2015. Articles were distributed amongst participants and 
evaluated regarding a checklist of 115 parameters focusing on technical aspects of EV 
research; particularly pre-analytical variables and methods for EV isolation and 
characterization. Resulting data were used to create a crowdsourcing online 
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knowledgebase (http://evtrack.org) and analyzed to identify current practices in EV research. 
Additionally, the EV-TRACK (Transparent Reporting and Centralizing Knowledge in 
Extracellular Vesicle Research) platform was set up to assist EV researchers with designing 
and performing experiments, increase experimental reproducibility and enhance reporting as 
detailed in [131] (Figure 9). Briefly, researchers are encouraged to upload experiments and 
publications, which subsequently receive a numerical score (EV-METRIC) based on the 
completeness of reporting crucial experimental details regarding EV isolation and 
characterization. Non-public sections of the EV-TRACK platform were established to provide 
reviewers and editors with experimental details of unpublished manuscripts during the 
peer-review process. Additionally, a comprehensive search tool was implemented to allow 
researchers to browse the database for specific experimental details in published experiments. 
 
 
Figure 9. The seven enabling features of the EV-TRACK platform. EV-TRACK was established to 
improve methodology and reporting through community-driven coaching for researchers, experimental 
guidelines and objective scoring of published experiments. Uploading new experiments to EV-TRACK 
will ultimately expand the field’s level of knowledge on EV biology, different subpopulations and suitable 
methods for their isolation and characterization. Figure adapted from [131].  
 
In addition to the EV-TRACK initiative, a community-driven effort was made to improve 
research on EVs by providing specific recommendations for their isolation, characterization 
and functional analysis. Based on a previous initiative published in 2014 [132], current 
technological developments, novel biological insights and challenges in the rapidly evolving 
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EV field were assessed to assemble a comprehensive update of the recommended Minimal 
Information for the Studies of EVs (MISEV) as published in the MISEV2018 guidelines [133]. 
Along with updated guiding principles for separation, concentration and analysis of marker 
proteins, new recommendations regarding EV nomenclature and topology of analytes were 
made to adapt to the growing appreciation of EV heterogeneity and diverse subpopulations of 
vesicles with potentially distinct cargo and functionality.  
 
2.5 Assessing current and future challenges for extracellular vesicle-based 
clinical biomarkers 
Despite the potential utility of EV-based biomarkers, various obstacles need to be faced on the 
road from discovery research to the clinic. To highlight both the bright sides and challenges in 
the EV biomarker field, the International Society for Extracellular Vesicles (ISEV) held a 
workshop in Birmingham, UK, in 2017. Researchers from within the EV field discussed current 
achievements and problems, while participants not themselves working with EVs provided a 
general perspective on the challenges of moving biomarkers from bench to bedside. As 
published in [123], discussions were centered around biospecimen collection and 
pre-analytical procedures as well as challenges relating to EV heterogeneity and the detection 
of rare analytes, the need for more technically sophisticated analytical tools and how EVs can 
be integrated into routine clinical assays.  
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3 Results and Discussion 
 
3.1 Small RNA-Seq is a promising but challenging technique for extracellular 
vesicle microRNA analysis 
Current methods for small RNA-Seq were assessed in a comprehensive literature review as 
published in Buschmann et al. [124] (Appendix I). NGS-based techniques of transcriptomic 
analysis were found to provide exceptional advantages over previous technologies such as 
RT-qPCR. Specifically, its high throughput and sensitivity, ability to profile all transcripts 
without a priori sequence knowledge and single-nucleotide resolution have made small 
RNA-Seq invaluable for applications such as quantification of disease-related miRNAs and 
detection of novel transcripts [134, 135]. Indeed, miRNA-based biomarker signatures have 
been presented for a wide array of diseases including colorectal cancer, CVD and 
neurodegenerative disorders [136-138]. At the same time, various challenges and sources of 
technical bias were identified for small RNA-Seq experiments as demonstrated in 
Buschmann et al. [124] (Appendix I). Briefly, reliable and replicable experiments are contingent 
on sound study design and standardized pre-analytical procedures including sampling as well 
as RNA extraction, quality control and quantification. Circulating cell-free miRNAs and miRNAs 
in EVs present additional challenges due to yielding particularly low amounts of starting 
material. Furthermore, virtually all steps of library preparation protocols, ranging from the 
addition of adaptor and barcode sequences to PCR amplification and size selection of target 
fragments, were found to be prone to bias [139-141]. Even for technically sound sequencing 
experiments, strategies for normalization and data analysis need to be tailored for the 
respective study requirements, and results should be validated by orthogonal techniques such 
as RT-qPCR or digital PCR (dPCR). Crucial steps in the pre-analytical and analytical phase of 
small RNA-Seq experiments as well as corresponding recommendations to reduce bias and 
enhance reproducibility are summarized in Buschmann et al. [124] (Appendix I, Tables 1 
and 2).  
Recent reports claimed that biomedical science is facing an alarming reproducibility crisis and 
argue that a large proportion of research funding is wasted on studies that yield inaccurate or 
unreplicable findings [142, 143]. An analytical tool as complex and widely used as small 
RNA-Seq needs to be utilized correctly to not contribute to the multitude of invalid or 
inconclusive studies. In the context of biomarker research, reliable and reproducible results on 
disease-related alterations in miRNA expression can only be generated by rigorous 
standardization of pre-analytical factors and experimental workflows. Similar to the 
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recommendations made in Buschmann et al. [124] (Appendix I), previous guidelines such as 
the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) 
were implemented to improve experimental practices in PCR-based nucleic acid quantification 
[144]. Indeed, adoption of the frequently-cited MIQE guidelines was shown to improve 
reporting in the qPCR literature [145].  
 
3.2 Precipitation is a highly suitable extracellular vesicle isolation method for 
downstream microRNA quantification 
In a comparative study on sepsis patients and healthy volunteers, different commercial 
methods to isolate EVs from serum were assessed regarding their suitability for downstream 
analysis of EV-associated miRNAs by small RNA-Seq. EVs were isolated from patient and 
volunteer sera using methods based on SEC, precipitation, membrane affinity and 
sedimentation. As demonstrated in Buschmann et al. [125] (Appendix II), sequencing small 
RNA in kit-specific isolates generated libraries of vastly different size and composition for each 
method (Figure 10). Of the commercial approaches, precipitation and membrane affinity 
yielded the largest libraries in both sepsis patients and volunteers, clearly surpassing 
SEC-based methods. When assessing mapping frequencies to various classes of small non-
coding RNA, precipitation distinctly outperformed its competitors with 27.56 % and 35.08 % of 
reads mapping to miRNAs for patients and volunteers, respectively.  
 
 
Figure 10. Library sizes and miRNA mapping in EVs isolated from volunteers (A) and sepsis patients 
(B). Mapping frequencies to miRNAs (red diamonds) are plotted against the right x-axes. EV isolation 
by precipitation (miRCURY) yielded the highest enrichment of miRNAs, while SEC-based methods 
(qEV, Exo-spin) resulted in smaller libraries and fewer miRNA reads. miRNA mapping percentages are 
mean for 10 volunteers and nine patients. UC: differential ultracentrifugation. Figure adapted from [125] 
(Appendix II) 
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In line with increased miRNA mapping rates, libraries from precipitation-based EV isolation 
also performed excellently in DGE analyses and accurately separated patients and volunteers 
in hierarchical clustering (Figure 11).  
 
 
Figure 11. Hierarchical clustering of miRNAs in EVs isolated by commercial methods and UC. Primary 
clustering separated samples from precipitation (miRCURY), membrane affinity (exoRNeasy) and UC 
from SEC-based methods (qEV, Exo-spin). Volunteers (darker shades, V) and sepsis patients (lighter 
shades, S) were accurately distinguished by miRCURY and exoRNeasy, while miRNAs from qEV and 
Exo-spin isolation displayed noticeable heterogeneity and did not fully separate healthy and diseased 
individuals. UC: differential ultracentrifugation. Figure reprinted from [125] (Appendix II). 
 
Biological characterization of isolated EVs revealed significant differences in particle size and 
concentration, with precipitation-derived samples featuring both the highest concentration and 
smallest diameter of EVs [125] (Appendix II, Figure 6). Immunoblot analysis of kit-specific 
isolates demonstrated an enrichment of common EV markers in preparations from SEC and 
membrane affinity but not from precipitation and sedimentation. As demonstrated by additional 
experiments using density gradient centrifugation, and in line with findings from other 
groups [146, 147], the latter methods co-isolated large amounts of serum albumin and other 
soluble proteins that diluted EV markers. These findings indicated a differential suitability of 
isolation methods for downstream analytical assays: isolates from SEC-based approaches 
were comparatively pure and low in non-EV proteins but yielded suboptimal results in small 
RNA-Seq and ensuing DGE analyses. EV preparations isolated by precipitation, on the other 
hand, were heavily contaminated with serum proteins but clearly outperformed SEC-based 
methods in sequencing and miRNA-based patient classification. These data suggested that a 
substantial proportion of miRNAs in precipitation-derived samples might not be associated with 
genuine EVs but rather co-precipitate in non-EV miRNA carriers such as lipoproteins and 
circulating Argonaute proteins. Indeed, previous studies demonstrated that significant amounts 
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of circulating miRNAs are associated with AGO2 [148] and that vesicle-free miRNAs are the 
dominant population in precipitation-derived EV isolates [149]. Similar findings were reported 
for urinary EVs, which indicates that despite being prone to co-isolate soluble proteins, 
precipitation is highly suitable for downstream small RNA-Seq as long as crude preparations 
are acceptable for the respective research question [150]. Additionally, impurities in EV 
preparations were shown to have little effect on subsequent miRNA quantification [151]. As 
biomarker applications generally aim at identifying circulating miRNA signatures that reliably 
detect diseases or separate patient populations rather than at attributing miRNAs to their 
specific carriers, precipitation was selected as an appropriate method to isolate serum EVs in 
further studies.  
 
3.3 microRNA profiles in extracellular vesicles from arterial and venous sera can 
be compared for biomarker studies 
As detailed above, reliable biomarker research relies on replicable studies and 
well-characterized biospecimens. Blood-derived biofluids such as serum and plasma are the 
most commonly used sample types in liquid biopsies and might be sampled from arterial or 
venous blood vessels, depending on the respective patient population. As a prerequisite to 
compare these sample types within a given study and across studies on either sample matrix, 
miRNA profiles in matched arterial and venous EVs were analyzed in a cohort of cardiac 
surgery patients (n=20). Analysis of resulting arterial and venous sequencing libraries revealed 
highly similar frequencies of reads mapped to miRNAs and other classes of small non-coding 
RNA [127]. As evidenced in unsupervised clustering, miRNA profiles in all samples overlapped 
significantly and tended to cluster by patient rather than by sampling site (Figure 12). 
 
 
Figure 12. Principal component analysis (A) and hierarchical clustering (B) of miRNAs in EVs isolated 
from arterial (red, A) and venous (blue, V) sera.  Individual miRNA profiles displayed significant overlap 
and did not reveal any systemic variation depending on sampling site. Figure reprinted from [127]. 
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Additionally, EVs from venous and arterial sera were highly similar regarding particle size and 
concentration as well as morphology and marker protein profiles [127]. Even though a previous 
study on rats reported different miRNA profiles in total arterial and venous sera [152], 
differences in human serum-derived EVs were marginal. With the caveat of lung disease, 
which might skew arteriovenous balances due to altered interaction with arterial blood, it 
therefore seems feasible to sample arterial or venous blood and to compare studies utilizing 
either biofluid for biomarker studies on EV miRNAs.  
 
3.4 Extracellular vesicles and their microRNA cargo are not a panacea in 
molecular diagnostics 
Extracellular vesicles are heavily studied diagnostic candidates in various types of cancer. 
Dysregulated miRNA signatures in EVs have been proposed to indicate breast, colon and 
prostate cancer [153-155]. Beyond mere disease detection, they might also prove to be useful 
prognostic markers for patient survival and recurrence [156, 157]. Profiling DNA and RNA in 
EVs from pancreatic cancer patients was shown to detect actionable mutations that might 
guide treatment decisions in personalized medicine [115, 158]. Within the spectrum of breast 
cancers, variants that do not express receptors for estrogen, progesterone and human 
epidermal growth factor 2 are particularly difficult to treat due to their unresponsiveness to 
commonly used hormonal therapies. In these Triple-Negative Breast Cancers (TNBC), 
overexpression of the glucocorticoid receptor (GR) additionally correlates with therapy 
resistance and increased mortality. As GR impacts the expression of both protein-coding and 
non-coding RNAs, we assessed the potential extracellular reflection of GR overexpression by 
analyzing miRNA profiles in EVs shed from different TNBC cell lines in vitro. As published in 
Buschmann, González et al. [128] (Appendix III), artificially induced GR expression prompted 
only minor changes in secreted miRNAs. While EVs from individual cell lines were clearly 
distinguishable based on their miRNA composition, profiles in EVs from parental and 
transfected cells overlapped substantially. When assessing differentially regulated miRNAs 
between the two groups, statistical significance was not reached for any transcript. 
Additionally, GR overexpression induced only slight changes in intracellular miRNA profiles 
[128] (Appendix III, Figures 6 and 7). Even though transfected TNBC cells overexpressed 
functional GR that significantly upregulated downstream target genes, increased GR levels 
had little effect on intracellular and vesicular miRNA profiles. The glucocorticoid receptor 
mRNA itself is targeted by multiple miRNAs [159, 160] but little is known about the impact of 
GR signaling on miRNA expression [161]. Given our data, increased aggressiveness and 
therapy resistance in GR-overexpressing TNBC does not seem to be mediated by downstream 
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miRNA signaling. Additionally, quantifying miRNA levels in TNBC EVs is not informative about 
GR expression status. In a clinical situation, where phenotyping the hormone receptor 
repertoire of a tumor is crucial to devise a therapeutic strategy, analyzing EVs might not be an 
appropriate diagnostic tool. Despite their general utility as analytes in breast cancer liquid 
biopsy, circulating miRNAs do therefore not hold the answer to every clinical question.  
 
3.5 Extracellular vesicles might help identify high-risk patients prior to cardiac 
surgery 
The potential utility of EV miRNAs for risk stratification was assessed in a cohort of CVD 
patients undergoing open heart surgery (n=19). As detailed in [129], serum EVs were isolated 
prior to surgery, and miRNA profiles in EVs from patients and healthy volunteers (n=20) were 
analyzed by small RNA-Seq. Even though EVs from patients and volunteers did not differ in 
size, morphology and expression of marker proteins, levels of 29 miRNAs were significantly 
changed between the groups. In patient EVs, 15 miRNAs were downregulated with log2 fold 
changes between -1.03 and -1.76, while 14 miRNAs were upregulated with log2 fold changes 
between 1.02 and 2.34. Differentially regulated miRNAs were correlated with clinical variables 
recorded during and after surgery, revealing a subset of miRNAs that correlated significantly 
with intraoperative epinephrine dosing requirements (p=0.008), serum lactate levels (p=0.036) 
and decreased urine excretion (p=0.031) (Figure 13), which indicate perioperative cardiac 
instability and potential kidney damage, respectively. Patient demographics (e.g. age, body 
mass index) and clinical variables unrelated to organ dysfunction (e.g. duration of surgery, 
duration of postoperative ICU therapy, inflammation, intraoperative volume requirements) did 
not significantly correlate with miRNA expression.  
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Figure 13. Differential expression of miRNAs that correlated with outcome-relevant variables (A). 
Positive log2 fold changes indicate miRNAs upregulated in patient EVs compared to volunteer EVs. 
Correlation of miRNA expression with intraoperative epinephrine requirements (B), serum lactate 
levels (C) and low urine excretion (D). Red dots indicate miRNAs with mean expression levels ≥ 50 
reads and log2 fold changes ≥ |1|. Figure adapted from [129]. 
 
Cardiac failure during heart surgery is a rare but disastrous occurrence associated with a 
mortality of up to 50 % [162] and additional short- and long-term detrimental consequences 
including acute and chronic multiple organ failure [163]. Risk assessment prior to surgery is 
therefore essential to identify patients at increased risk for perioperative cardiac events. Once 
identified, appropriate risk mitigation measures such as close perioperative monitoring, careful 
selection of anesthetics, attendance of highly trained staff, use of specialized critical care 
facilities, advanced use of perioperative echocardiography, mechanical circulatory assist 
devices and customized pharmacologic management can be taken. As many risk factors such 
as age, comorbidities, hypertension, renal insufficiency and vascular disease stem from patient 
demographics and medical history, questioning and physical examination of patients prior to 
cardiac surgery is crucial [164]. The availability of circulating biomarkers for risk assessment, 
however, is scarce. Brain natriuretic peptide (BNP), a hormone secreted by stressed and 
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injured cardiomyocytes, was recently suggested for preoperative risk stratification in 
non-cardiac surgery [165]. In cardiac surgery, high postoperative levels of BNP were 
associated with longer hospitalization and early mortality [166]. A robust biomarker for 
identification of high-risk patients could mitigate adverse outcomes and enhance patient 
survival. While assessing miRNA profiles in EVs failed to reflect the GR expression status of 
TNBC, it might prove to be useful in preoperative patient stratification for cardiac surgery.  
 
3.6 Extracellular vesicles carry specific diagnostic information in critically ill 
patients 
The utility of EV miRNAs for disease detection was assessed in a cohort of septic shock 
patients and healthy volunteers. As published in [130] (Appendix IV), miRNA profiles in 
circulating EVs, total serum and blood cells were analyzed by small RNA-Seq and compared 
between patients and volunteers to identify differentially regulated transcripts. Across blood 
compartments, a total of 77 and 103 miRNAs was down- and upregulated in patients, 
respectively. The majority of regulated miRNAs was detected in blood cells with little overlap 
between compartments (Figure 14). Three miRNAs each were simultaneously down- and 
upregulated in EVs, serum and cells.  
 
 
Figure 14. Compartment-specific changes in miRNA expression between septic shock patients and 
volunteers. In total, 77 miRNAs were downregulated in patients (A), whereas 103 miRNAs were 
upregulated (B). Despite some overlap between blood compartments, there was significant sample 
type-specific miRNA regulation. 
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In order to validate our findings from small RNA-Seq, a selection of 20 dysregulated miRNAs 
was analyzed by RT-qPCR in an independent cohort of sepsis patients (n=9), septic shock 
patients (n=6) and volunteers (n=16). In the validation study, nine miRNAs (EVs: two; serum: 
one; cells: six) were significantly dysregulated between volunteers and both sepsis patients 
and patients in septic shock upon admission to the ICU (Figure 15). Additionally, expression 
levels of several miRNAs were found to correlate with disease severity [130] (Appendix IV, 
Figure 4).  
 
 
Figure 15. Expression levels of nine miRNAs in EVs, sera and blood cells were significantly increased 
or decreased in both sepsis patients and septic shock patients. Lower normalized Cq values indicate 
higher expression levels. *: p<0.05; **: p<0.01; ***: p<0.001.  
 
In a separate analysis of RT-qPCR data, patients were grouped by outcome 
(survivors/non-survivors) regardless of disease severity upon hospitalization. Three miRNAs 
in extracellular samples, but not blood cells, were able to significantly distinguish between 
survivors and non-survivors (Figure 16).  
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Figure 16. Survival prediction by extracellular miRNAs. Expression of three miRNAs in EVs 
(miR-30a-5p, miR-125b-5p) and sera (miR-193a-5p) sampled upon hospitalization correlated 
significantly with outcome in sepsis patients. Lower normalized Cq values indicate higher expression 
levels. NS: not significant; ***: p<0.001. Figure reprinted from [130] (Appendix IV). 
 
Sepsis is a complex, life-threatening disease and a major cause of death in hospitals. 
Tragically, hospitalization rates for sepsis have continuously increased in the past decade, 
reaching approximately 970,000 annual admissions in the US alone [167]. In sepsis, the initial 
infectious insult is answered by a dysregulated inflammatory and oxidative host response, 
which can lead to sequential organ failure and death if it does not abate during treatment. 
Mortality in sepsis correlates with disease severity and ranges as high as 40 – 80 % for 
patients in septic shock [168]. The financial costs of sepsis management are disproportionally 
higher than for any other disease and increase for patients with delayed diagnosis and higher 
disease severity [167]. Delaying diagnosis and administration of appropriate treatment also 
accelerates disease progression and increases mortality [169, 170]. Despite being a frequently 
encountered condition in hospitals worldwide, sepsis poses significant diagnostic challenges. 
Due to its complex and only partially understood pathogenesis, heterogeneity of causative 
pathogens and lack of specific biomarkers, sepsis is oftentimes not immediately diagnosed 
upon hospitalization. Its pronounced inflammatory component further complicates the crucial 
distinction from non-infectious inflammatory conditions such as the systemic inflammatory 
response syndrome (SIRS).  
Circulating EVs in sepsis are intensely studied for their role in pathogenesis [171] and as 
potential diagnostic and therapeutic agents [172]. Given the success of related efforts in 
oncology, it is no surprise that the utilization of EVs and their cargo as diagnostic biomarkers 
has gained traction in sepsis research. Similar to the results presented above, several studies 
reported dysregulated miRNA profiles in total plasma and circulating EVs sampled from sepsis 
patients [173, 174]. In our RT-qPCR data, the miRNA most significantly dysregulated in both 
sepsis and septic shock (miR-199b-5p) was detected in blood cells, which, in this case, might 
be the superior sample type for disease detection. A correlation with patient survival, on the 
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other hand, was only found for extracellular miRNAs (Figure 16), which underlines the 
compartment-specific miRNA signaling in sepsis. In a recent study on plasma exosomes from 
sepsis patients, Real et al. presented a signature of differentially regulated miRNAs that relate 
to cell cycle regulation and discriminate between survivors and non-survivors [174]. 
Interestingly, both EV miRNAs correlated with survival in our data (miR-30a-5p, miR-125b-5p) 
were also found to negatively regulate cell cycle and proliferation [175, 176].  
As described in our study, disease-associated regulation of miRNAs is specific to individual 
blood compartments, and EVs might not be the most suitable sample type for all biomarker 
purposes. Analyzing miRNAs in blood cells could prove to be particularly useful for disease 
detection in sepsis, where the overshooting host response is bound to be reflected in 
circulating immune cells. Should EV miRNAs be selected as the sample type of choice for a 
given disease or clinical question, it is crucial to utilize appropriate methodology and 
standardize analytical assays. As detailed in 3.1 and 3.2, reliable small RNA-Seq studies are 
predicated on careful experimental design, stringently controlled laboratory workflows and 
consideration of the impact that different methods of EV isolation have on downstream miRNA 
quantification. To ensure specificity, miRNA candidates need to be validated in larger cohorts 
of sepsis patients and, optimally, patients with an inflammatory but non-infectious phenotype. 
Due to significant postoperative inflammation, patients undergoing CABG surgery (see 3.5) 
might be an appropriate control group to validate the specificity of potential sepsis markers for 
pathogen-associated inflammation.  
 
3.7 Extracellular vesicle research is hampered by heterogeneity in experimental 
protocols and insufficient reporting 
Current experimental practices and reporting thereof were assessed in 1,226 research articles 
published between 2010 and 2015. A total of 1,742 individual experiments was extracted from 
the articles and analyzed based on 115 parameters pertaining to sample type and 
pre-analytical variables as well as methods for EV isolation and characterization. As detailed 
in [131], our analyses detected 1,038 unique isolation protocols, with differential 
ultracentrifugation being used in 45 % of experiments. In addition to this multitude of isolation 
protocols, significant heterogeneity in reporting vital experiment details on experimental 
parameters and biochemical features of isolated vesicles was discovered. Regardless of 
sample type, many studies failed to provide specific information on the equipment and 
chemicals used in the experiments and did not extensively characterize EVs. In 17 % of 
experiments, EVs were not characterized at all, while characterization was limited to analysis 
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of proteins or particles in 29 % and 39 % of studies, respectively. Based on these findings, we 
developed the EV-METRIC, which is a reporting index that consolidates nine experimental 
parameters crucial for interpretation and reproducibility of experiments into a numerical score. 
The score ranges from 0 % to 100 % and reflects the completeness of reporting for EV isolation 
methods, protein analysis and particle analysis [131]. Across all sample types, reporting was 
found to be generally insufficient, with less than 6 % of experiments receiving an EV-METRIC 
above 50 % (Figure 17). Of all simple types included in the study, reporting was worst in 
experiments with serum EVs, as reflected by an average EV-METRIC of 11 %.  
 
 
Figure 17. Cumulative EV-METRIC stratified by sample type (A). On average, experiments on serum-
derived EVs obtained the lowest scores. Average adherence to each EV-METRIC parameter stratified 
by sample type (B). Characterization of EV-enriched proteins was more commonly reported than details 
on non EV-enriched proteins or antibodies used in the experiment. EV: extracellular vesicle; 
UC: differential ultracentrifugation. Figure adapted from [131]. 
 
As the EV-METRIC is intended as a tool to improve experimental rigor and reproducibility 
rather than a recommendation on which experiments to perform, higher scores could 
oftentimes be achieved by merely providing extensive experimental details. Indeed, 81 % of 
experiments analyzed in this study could have obtained a better score by improved reporting 
without performing any additional experiments.  
EV research is a new and rapidly evolving area of science. Biogenesis, composition, functional 
activity and biotechnological applications of EVs from various biofluids are studied by many 
groups around the globe, which advances our understanding of EV biology and potential 
clinical uses. As demonstrated in EV-TRACK [131], the accelerated interest in EVs has brought 
about a vast heterogeneity of protocols and techniques. Both inappropriate methodology and 
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insufficient reporting hamper the interpretation of individual studies and the comparability of 
results across experiments. By making researcher aware of crucial experimental details and 
improving reporting in articles, the introduction of EV-TRACK and the EV-METRIC might 
elevate all areas of EV research regardless of sample type and scientific question. Even though 
average EV-METRIC scores improved over the past few years (Figure 18), it is too early to tell 
if EV-TRACK will have a positive impact on EV science. Still, the fact that EV-TRACK has now 
been cited in well over 100 articles from various branches of EV research indicates that there 
is at least an increased awareness throughout the community.  
 
 
Figure 18. Number of experiments added to the EV-TRACK knowledgebase (blue, left x-axis) and 
average EV-METRIC (red, right x-axis) over the past nine years. While fewer articles were added after 
the initial release of EV-TRACK, rising EV-METRIC scores indicate improved reporting in publications. 
Data extracted from http://evtrack.org, accessed in January of 2019. 
 
3.8 How to improve extracellular vesicle research: Guidelines for experiments 
and reporting 
The initial guidelines on Minimal Information for the Studies of EVs (MISEV) were published 
in 2014 with the goal of sensitizing the EV community to crucial experimental and reporting 
requirements and providing recommendations for reliable experiments [132]. As the field 
evolved rapidly, the guidelines were now revisited and adapted to recent technological 
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advances and the increase in biological knowledge accumulated after their first release. As 
published in MISEV2018 [133], recommendations on EV isolation and characterization were 
updated and supplemented by new chapters on nomenclature and topology of analytes. 
Prompted by the growing recognition of many different types and subpopulations of EVs, the 
exosome-centric view of MISEV2014 was amended, and suggestions for markers to classify 
specific EV types were removed. Still, MISEV2018 provides actionable references for isolation 
and quantification of EVs as well as characterization of associated biomolecules and the study 
of EVs in functional assays. Furthermore, the updated guidelines specifically endorse 
submission of experimental details to EV-TRACK (discussed above in 3.7) and deposition of 
EV profiling data to appropriate public repositories. Major aspects of MISEV2018 were 
summarized in a checklist that allows researchers to quickly assess how well their experiments 
comply with the updated guidelines (Table 2).  
 
Table 2. Quick-reference checklist summarizing key aspects of EV research discussed in the 
MISEV2018 guidelines. Table adapted from [133]. 
Section of MISEV2018 guidelines Subsection 
Nomenclature Generic or specific description of EV populations 
Collection and pre-processing of 
specimens 
Tissue culture medium 
Biofluids or tissues 
Storage and recovery 
EV separation and concentration Experimental details of isolation method 
EV characterization 
Quantification 
Characterization of bulk EVs 
Characterization of single EVs 
Functional studies Quantitative assessment of EV-specific activity 
Reporting 
Data submission to EV-TRACK and relevant 
repositories 
 
Results of a survey released to the EV community in 2016 revealed that the vast majority of 
researchers agreed on the importance of minimal requirements in experimental procedures 
and reporting thereof [177]. Similarly, most participants felt a need for both the continued 
revision of guidelines and community participation in updating these recommendations. 
MISEV2018 is therefore based on involvement of the ISEV community and reflects 
wide-ranging consensus wherever possible. As many participants perceived the guidelines in 
MISEV2014 to be too restrictive, MISEV2018 provides detailed explanations of mandatory and 
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optional recommendations as well as suggestions for experiments in which only limited 
adherence to the guidelines can be achieved.  
Human biofluids and clinical applications are still areas of significant interest in EV science, 
but many groups also work on non-mammalian EVs and their role in various scientific contexts. 
While some of the recommendations made in MISEV2018, particularly those on protein 
markers, relate to EVs from specific species, the general principles can be applied to all 
experiments regardless of organism and research focus. In addition to these underlying 
minimal requirements, comprehensive guidelines for various biofluids [178] and EV-associated 
analytes [179] were recently published elsewhere.  
While the EV-TRACK initiative (discussed above in 3.7) aims at improving reporting and 
building a comprehensive knowledgebase for EV studies, MISEV2018 provides updated 
guidelines for essential experimental parameters. In conjunction, both are intended to advance 
the field by improving reliability, reproducibility and our understanding of EV biology. Given that 
MISEV2014 was widely cited in articles from various areas of EV research and that 
publications citing the guidelines achieved significantly higher EV-METRIC scores [177], it is 
likely that the updated recommendations in MISEV2018 will have a positive impact on the field.  
 
3.9 The promise of extracellular vesicles as clinical biomarkers: Opportunities 
and challenges  
To assess current and future challenges for EV-based clinical biomarkers, a workshop 
involving researchers from within the community as well as participants with a strong 
background in biomarker development was held in 2017. Participants presented their research 
and compiled accomplishments and pitfalls in round table discussions. As published in [123], 
there was an overall agreement on the potential usefulness of EVs as diagnostic and 
prognostic biomarkers. Utilizing EVs for mutational profiling in cancer, remote detection of liver 
injury, and distinction between benign prostate hyperplasia and prostate cancer were but a few 
of the promising presented applications. Several contributions centered on miRNAs as 
EV-associated analytes with diagnostic value and emphasized the importance of 
high-throughput technologies such as small RNA-Seq (discussed above in 3.1) to establish 
biomarker signatures.  
On the other hand, considerable challenges in moving EV-based biomarkers from academic 
research to a marketable product were identified (Figure 19). Special emphasis was put on the 
importance of well-characterized and properly handled biospecimens, which constitute the 
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very basis for all subsequent experiments. Unfortunately, the accessibility of suitable patient 
samples is often limited, and current biobanking practices might not be optimal for EV analysis. 
As discussed above in 3.2 and 3.7, participants also agreed that sampling, pre-analytical 
factors and methods of EV isolation impact results in downstream analytical assays, and that 
there is an urgent need for stringently standardized workflows.  
 
 
Figure 19. Topics of discussion at the ISEV workshop on EVs as disease biomarkers, which covered a 
wide range of aspects in the process of moving EV biomarkers from bench to bedside. Crucial goals 
and anticipated challenges as well as approaches to overcome them were compiled for each step. 
Figure reprinted from [123]. 
 
Additional challenges compiled in the workshop related to EV isolation from limited sample 
volumes, the absence of suitable reference standards, and the detection limits of current 
analytical devices. While novel technologies are developed concurrently with our evolving 
understanding of EV biology, participants reported having to modify established platforms 
according to their needs until more suitable solutions are presented. Accordingly, closer 
collaboration of academic researchers and biotech companies would likely accelerate the 
development of specialized equipment to study bulk and even single EVs.  
In the same vein, collaborations between research groups, sharing of standard operating 
procedures (SOPs), and a common understanding of anticipated obstacles were stated to be 
necessary to overcome the current compartmentalization of the EV biomarker field. Taking 
advantage of platforms such as EV-TRACK and MISEV (discussed above in 3.7 and 3.8, 
respectively) was emphatically endorsed in order to increase transparency and reproducibility, 
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which have been a particular challenge in the biomarker field [180]. Major efforts to develop 
novel biomarkers, particularly in oncology, have prompted exciting academic findings, many 
of which could not be validated or translated into viable products. Despite initial enthusiasm, a 
comparably small number of markers is regularly used in medicine, and most seemingly 
promising candidates ended up never being approved for clinical application [181]. The 
reasons for this failure are manifold. A large proportion of studies on early miRNA biomarkers 
is underpowered and carried out using small sample sizes, increasing rates of both false 
positive and false negative findings and additionally inflating observed effect sizes [182]. 
Indeed, the effect sizes in many highly cited biomarker publications were shown to be larger 
than those in subsequent validation studies, which indicates that studies reporting extreme 
changes might receive more attention regardless of their validity [183]. Outsized effect sizes 
and unreliable conclusions gathered in underpowered studies hamper the selection and 
validation of biomarker candidates, as does a strong publication bias in this field. The tendency 
to selectively publish significant and exciting results at the expense of negative ones, as 
documented for cancer biomarkers [184] and CVD biomarkers [185], is bound to add to the 
overall unreliability in the early biomarker literature. 
In addition to these general challenges, there are additional obstacles to be overcome for 
miRNA-based biomarkers. Circulating miRNAs are usually detected at low concentrations, and 
specialized techniques might have to be implemented for their isolation and quantification. 
Many demographic and lifestyle factors such as age [186], gender [187], diet [188] and activity 
levels [189] impact miRNA expression, resulting in high interindividual variability. This 
patient-to-patient variability, as well as small study populations and amply documented 
methodological challenges including the choice of sample type, profiling platform and 
appropriate normalization strategy, contribute to the heterogeneity of results from miRNA 
biomarker studies [190-192]. Consequently, reports of seemingly disease-specific miRNAs 
oftentimes failed to be reproduced even when the same disease was studied in highly similar 
experiments [193]. Furthermore, changes in several frequently studied circulating miRNAs 
were found to be associated with a number of unrelated diseases [194], prompting the notion 
that circulating miRNAs might be nonspecific indicators of a general pathological state rather 
than a reflection of altered expression in diseased tissues [195]. Compared to other 
transcriptomic biomarkers, disease-associated changes in miRNA expression are also 
generally small, and their functional relevance is hard to interpret due to the complexity of 
miRNA-mediated transcriptional regulation [196].  
 
 
 
43 
 
4 Conclusions 
 
The historical development of disease diagnosis reflects a fascinating progression towards 
ever-increasing magnification and granularity. While early medicine was restricted to 
symptom-based patient evaluation, advances in biology and technology soon moved the 
diagnostic focus to specific organs and tissues, populations of cells and, eventually, single 
cells. Facilitated by the advent of precise high-throughput profiling technologies, the 
exploration of even smaller structures, such as EVs, is progressively taking on greater 
significance for establishing molecular biomarkers, which are a fundamental requirement for 
precision medicine.  
As our understanding of EV biology increased rapidly over the past decade, so did the interest 
in exploiting them for biotechnological applications. EVs are now studied for their utility as 
vaccines, therapeutics and diagnostic targets. Several unique features, including their ubiquity 
in easily accessible biofluids, stability in circulation, and compositional reflection of secreting 
cells, moved EVs to the forefront of clinical biomarker research. Accordingly, the analysis of 
EVs in liquid biopsies is commonly thought of as a breakthrough technique in molecular 
diagnostics. As vesicular miRNAs are stable, can be easily detected and amplified, and might 
reflect specific disease-induced alterations in malignant cells, they are amongst the most 
promising analytes associated with EV-based liquid biopsies. Yet, both the study of EVs and 
their translation into approved clinical markers are fraught with obstacles.  
The track record of molecular biomarkers is historically poor, with many promising candidates 
failing due to low sensitivity and specificity or irreproducibility in follow-up experiments. As 
these limitations became apparent, individual markers were increasingly superseded by 
biomarker signatures. The information gathered from a single marker is limited and might not 
be able to sufficiently capture the complexity of a disease. Facilitated by advances in profiling 
platforms and computer science, disease-related changes in multivariate data sets can be 
explained by the combined contribution of a set of markers. These biomarker signatures are 
often more robust and allow a more accurate disease detection.  
For EV-based biomarkers, additional challenges are to be expected on the road from bench to 
bedside. Our incomplete understanding of EV biogenesis, secretion, biodistribution and uptake 
complicates the selection of appropriate sample types, EV populations and analytes as well as 
the association of disease-related molecules with EVs. As the specificity of altered miRNA 
expression and secretion for individual diseases seems to be low, panels of several miRNAs 
or combined analyses of miRNAs and other EV-associated analytes such as proteins or lipids 
might be more suitable to establish robust biomarker signatures. Furthermore, diagnostic 
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markers need to be validated in prospective studies, which are generally laborious, 
time-consuming, and costly [197]. Serial prospective sampling will be a particular challenge for 
EV-based biomarker candidates because current practices for biobanking might not be 
optimally suited for subsequent EV analysis, and it is not clear to which extent various 
pre-analytical variables and storage parameters impact results in downstream assays [198]. 
Nevertheless, there might be a bright future for EVs as clinical markers. As our knowledge of 
basic EV biology evolves, crucial issues such as sampling the most suitable biofluid to 
diagnose a given disease and identifying the most informative EV populations in said biofluid 
will be resolved. Some of the challenges for utilizing circulating miRNAs as biomarkers might 
be circumvented by only sampling expedient EV types or even EVs secreted by a particular 
tissue, once appropriately specific surface markers are identified.  
This work and many others aimed at characterizing altered vesicular miRNA profiles and 
correlating changes to the presence of disease, or even different levels of severity. Although 
this seems to be a promising approach, additional classes of EV-associated biomolecules 
should not be neglected. Potential diagnostic utility has been ascribed to vesicular 
proteins [113], mRNAs [199], and lipids [200], and it is currently not clear which of these will 
be the most suitable analyte in different disease scenarios. Virtually all types of molecules 
associated with EVs, particularly RNA, DNA, proteins and metabolites, lend themselves to 
analysis by high-throughput technologies. As many diseases are a manifestation of complex 
aberrations in different layers of cellular biology, it is likely that they cannot be accurately 
captured by a single biomarker. Combining genomic, transcriptomic, lipidomic and 
metabolomic profiles to establish integrative biomarker signatures will help to detect complex 
diseases more sensitively and specifically [201]. Algorithm-driven data integration will also 
uncover relationships and synergies between single markers that were not initially obvious. 
Additionally, the combination of multi-omics data with clinical parameters might further improve 
the performance of marker signatures. 
Regardless of the EV populations and associated molecules to be analyzed, standardization 
of pre-analytical variation and careful optimization of procedures for EV isolation and 
characterization are crucial to realize their potential as clinical biomarkers. If adhered to, the 
experimental guidelines and reporting criteria presented in MISEV2018 and EV-TRACK, 
respectively, will enhance transparency and reproducibility of EV studies. As biomarker 
development is increasingly data-driven, critical evaluation of frequently used profiling 
technologies such as RNA-seq [202] and RT-qPCR [203] is equally important. 
At this time, the initial enthusiasm for EVs as biomarkers appears to be dampened by the 
growing appreciation of various experimental, analytical and regulatory obstacles. If the 
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necessary measures to standardize experiments, avoid biases, and validate findings are 
undertaken, however, the potential utility of EVs as clinical markers is immense.  
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ABSTRACT
Small RNA-Seq has emerged as a powerful tool
in transcriptomics, gene expression profiling and
biomarker discovery. Sequencing cell-free nucleic
acids, particularly microRNA (miRNA), from liquid
biopsies additionally provides exciting possibilities
for molecular diagnostics, and might help estab-
lish disease-specific biomarker signatures. The com-
plexity of the small RNA-Seq workflow, however,
bears challenges and biases that researchers need
to be aware of in order to generate high-quality data.
Rigorous standardization and extensive validation
are required to guarantee reliability, reproducibility
and comparability of research findings. Hypotheses
based on flawed experimental conditions can be in-
consistent and even misleading. Comparable to the
well-established MIQE guidelines for qPCR experi-
ments, this work aims at establishing guidelines for
experimental design and pre-analytical sample pro-
cessing, standardization of library preparation and
sequencing reactions, as well as facilitating data
analysis. We highlight bottlenecks in small RNA-Seq
experiments, point out the importance of stringent
quality control and validation, and provide a primer
for differential expression analysis and biomarker
discovery. Following our recommendations will en-
courage better sequencing practice, increase exper-
imental transparency and lead to more reproducible
small RNA-Seq results. This will ultimately enhance
the validity of biomarker signatures, and allow reli-
able and robust clinical predictions.
INTRODUCTION TO BIOMARKERS AND LIQUID
BIOPSIES
The importance of biomarkers in molecular diagnostics is
undisputed. A valid biomarker should be able to reveal a
specific biological trait or a measurable change, which is di-
rectly associated with a change in the physiological condi-
tion of an organism. At the molecular and cellular levels,
analysis of gene expression changes is the first step of explo-
ration for any regulatory activity. Activating early response
genes is a very dynamic process, allowing the organism to
rapidly adapt to external or internal stimuli (1,2). Thus,
gene expression profiling is the technique of choice to dis-
cover and identify transcriptional biomarkers that describe
these changes affecting cells, tissues or the entire organism
(3,4). Accessing this molecular information via biomark-
ers in tiny biopsies is a common procedure for many ma-
lignancies, but sampling tissues can be costly, painful and
potentially impose additional risks on the patient (5). The
readout of transcriptional biomarker signatures from mini-
mally invasive sampling methods is therefore highly valued
(6). Sampling patient biofluids, such as blood, urine, sweat,
saliva ormilk in liquid biopsies is currently being thought of
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as a crucial next step in biomarker research and molecular
or clinical diagnostics (7).
The existence of extracellular DNA has been acknowl-
edged for decades, and finds applications ranging from on-
cology to prenatal diagnostics (8,9). In 2005, the first study
indicating the importance of microRNAs (miRNAs) in tu-
mor diagnosis and monitoring was published (10). Ever
since, the dysregulation of miRNAs in diseased tissues has
gained significant prominence and expanded to an interest
in extracellular miRNA as reflections of the malignant or
dysfunctional alterations. The easy accessibility by blood
sampling and remarkable stability of circulating miRNAs
make them promising candidates in biomarker discovery.
Numerous diseases and disorders, such as tumors, cardio-
vascular diseases, multiple sclerosis and liver injury have
now been associated with altered extracellular miRNA pro-
files (11). Still, levels of circulating miRNA are presum-
ably non-specific, and few overlapping reports of studies
on the same disease have been published, possibly due to
technical or methodological inconsistencies (12). Further-
more,miRNA levels seem to be associatedwith awide range
of conditions and outcomes in cancer research (13). It has
therefore been hypothesized that changes in the profile of
circulatingmiRNAs indicate a general state of disease or in-
flammation and rather derive from a non-specific response
to the disease than the malady itself (14).
To date, gene expression profiling is the approach of
choice for detecting diagnostic and prognostic biomarkers,
or predicting drug safety. Reverse transcriptase quantitative
real-time polymerase chain reaction (RT-qPCR) is consid-
ered the gold standard for exact and valid gene expression
measurements, either for mRNA or small RNA specimens
(15). More recently, digital PCR has emerged as a power-
ful and sensitive technique for absolute quantification of
DNA molecules without the need for external calibration
curves. Since RNA is converted into cDNA with varying
efficiency, however, its applicability for RNA quantification
is limited mostly by the reverse transcription (RT) reac-
tion, which might lead to a skewed representation of initial
RNA (16). Nowadays, the discovery and identification of
potential new transcriptional biomarkers by RNA sequenc-
ing (RNA-Seq) is the holistic state of the art technique. The
evaluation and validation of miRNA biomarkers by small
RNA-Seq is now routinely being adopted for the identifica-
tion of physiological or dysregulated miRNAs. Neverthe-
less, the subsequent validation of identified biomarker sig-
natures by RT-qPCR is mandatory (17–19). But there is a
lack of consensus regarding optimal methodologies or tech-
nologies for miRNA detection in liquid biopsies, their sub-
sequent quantification and standardization strategies when
different sequencing technologies or platforms, and library
preparation chemistries are used.
Goal of this review
In this review we present a standardization procedure to
discover and validate new biomarkers from liquid biopsies
with focus on the entire small RNA-Seq workflow - from
experimental design, sample stabilization, RNA extraction
and quality control to library preparation, next generation
RNA sequencing and all steps of small RNA-Seq data anal-
Figure 1. An overview of the small RNA library preparation workflow.
ysis, including validation and interpretation (Figure 1 and
2). Our goal is to point out the importance of experimen-
tal standardization and validation (20). The review will ex-
plain why and where problems in the small RNA-Seq work-
flow arise, discuss the real bottlenecks, and how one can re-
solve or at least circumvent them. We want to improve the
quality of small RNA-Seq results by optimizing and stan-
dardizing the entire quantification procedure to receive bet-
ter and more reproducible results. As a broader goal, the
outcome of this expression profiling should result in valid
biomarker signatures in order to make better predictions in
molecular diagnostics. The review should follow the ‘gen-
eral MIQE and dMIQE idea’ as published earlier, describ-
ing optimization strategies in the qPCR and dPCR work-
flow (21,22). Following our recommendations will encour-
age better experimental sequencing practice, lead to more
reproducible results, and hence allow unequivocal interpre-
tation of small RNA-Seq results. In summary, the outcome
of miRNA analysis in liquid biopsies should be more reli-
able and valid for future predictions.
PRE-NGS AND PRE-PCR - THE SAMPLING BIAS
Experimental design and replication
The first step in planning a small RNA expression exper-
iment is to set up a meaningful experimental design, in-
cluding a reasonable number of replicates on the biolog-
ical as well as technical level. Both biological and techni-
cal replicates have their place in biomarker discovery using
RNA sequencing experiments. Biological replicates are cru-
cial to correct for endogenous variability between experi-
mental groups in order to ultimately draw generalized bi-
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Figure 2. An overview of the small RNA-Seq data analysis workflow.
ological conclusions, whereas technical replicates can help
assess the man-made bias introduced by the entire experi-
mental setup and sequencing process itself.
Replicates in realitymean either biological replicates, rep-
resenting the number of real individuals per experimental
group, or technical replicates, repeated measurements of a
biological sample with the goal of reducing technical noise.
Technical replicates can be further subdivided and intro-
duced either on the level of extraction, RT reactions per
sample, sequencing depth, or the number of technical repli-
cates in the sequencing step. Regarding biological sample
size, one has to consider inter-individual genetic variation
within the studied population. Within the human popula-
tion, genetic variation is elevated in contrast to highly stan-
dardized and inbred animal models. This high variation in
human populations as such is based on various factors. Hu-
man study groups can be standardized by age, weight or
sex, but never by genetic background or lifestyle habits,
which might have a remarkable impact on gene expression
(nutrition e.g. coffee, alcohol, nicotine consumption, daily
rhythms, sleep, stress and more). Regarding domesticated
animals such as cattle or pigs, genetic variation is interme-
diate due to controlled reproduction with a limited num-
ber of male semen donors. Laboratory animals, including
mice, rats or insects show very low genetic variation within
one highly standardized and inbred animal strain. Genetic
variation in cell-culture is dependent on the kind of cells
used. Primary cell cultures from distinct, genetically differ-
ent donors show species-specific biological variance, while
the largely used permanent cell lines derived from one clone
or one individual are genetically identical, and show no bi-
ological variance at all.
Different researchers already dealt with the question
whether a higher number of biological replicates or a higher
sequencing depth leads to better outcomes in RNA-Seq ex-
periments. Increasing sequencing depth results in a higher
number of reads, and thereby increases statistical power for
the detection of differential gene expression (23). Hart et
al. and Liu et al. concluded that a sequencing depth of 10
million (10M) reads is sufficient formRNAexpression anal-
ysis, and that increasing sequencing depth over 10M reads
does not improve statistical power significantly. Both pub-
lications, however, stated that increasing the number of real
biological samples significantly enhances statistical power
of the experiment (24,25). Therefore, a higher number of bi-
ological samples is preferable over deeper sequencing. Pre-
vious reports further suggested including at least three bio-
logical replicates per group, depending on the inherent bi-
ological variation (26). For experiments involving samples
with higher variability, such as human biofluids or spec-
imens from diseased patients, even more replicates might
be needed to correctly assess differential gene expression
without detecting false-negative reads frombiological noise.
When biological variability is low, increasing replicates ren-
ders statistical power to the experiment. It has been shown
that increasing the number of biological replicates in RNA-
Seq experiments from two to five facilitates the detection of
differential gene expression, but extensive biological repli-
cation to improve statistical power is still not utilized in
most experiments (27). A recent publication on RNA-Seq
additionally reported that experiments entailing only three
biological replicates severely lack power to detect themajor-
ity of differentially expressed genes, and are only suited to
identify transcripts with major fold changes (28). Increased
replication markedly improved the correct assessment of
differential expression. The authors suggested including at
least 12 replicates in order to detect more than 90% of all
truly differentially expressed genes.
Technical replicates are useful to characterize the techni-
cal variation of an experiment. In general, variability be-
tween technical replicates derives from the random sam-
pling nature of sequencing and matches a Poisson distri-
bution (29). Even though it can therefore be accounted for
in downstream statistical analysis, some genes are known
to deviate from Poisson sampling and thus falsely increase
intra-group variability (30).
Another point that has to be considered is whether tech-
nical replicates are generally mandatory in gene expression
analysis. Liu et al. stated that RNA-Seq shows a high repro-
ducibility, concluding that technical replicates are not nec-
essary (25). Due to fairly high library preparation and se-
quencing costs, technical replicates in RNA-Seq are mostly
not realized. Comparing this with replicates in RT-qPCR
analysis, Tichopad et al. investigated the effect of replicates
on different levels of the RT-qPCR quantification workflow
(31). The authors stated that replicates in qPCR are not es-
sential, because inhibiting molecules should have been re-
moved before qPCR takes place. The bias introduced by
RT was multiple times higher compared to qPCR, where-
fore RT replicates are reasonable and necessary (32).
To summarize, inter-individual or biological variation
seems to have the highest impact, therefore replicates in bi-
ological samples are advisable. The authors recommend in-
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troducing replicates early in the quantification workflow by
including as many biological replicates as possible (31).
Tissue and RNA sampling and storage
When working with cell-culture, RNA sampling and
later storage is unproblematic due to working directly in
the molecular biology laboratory in a clean and non-
contaminated environment. In contrast, if one collects di-
agnostic samples in the field, the sampling process cannot
be performed under clean and safe laboratory conditions.
Therefore, optimal tissue preservation, and thus total RNA
preservation and stabilization, are essential points in the
experimental workflow. Widely used methods include snap
freezing tissues in liquid nitrogen, formalin fixation or stor-
ing tissues in RNAlater (Life Technologies), a solution that
preserves tissue RNA from degradation, ‘freezes’ the RNA
profile and allows storage of conserved tissue for several
hours or days at room temperature.
In clinical research, tissue conservation is routinely per-
formed by formalin fixation and paraffin embedding. Those
formalin-fixed paraffin-embedded (FFPE) samples are ad-
vantageous for a number of downstream applications. But
RNA analysis in FFPE samples is problematic because
RNA is cross-linked and partly degraded. RNA extracted
fromFFPE is thereby of lesser quality for further expression
studies (33,34). Due to the growing field of RNA expres-
sion analysis in clinical samples, the generation of biobanks
for non-fixed frozen tissue is coming into focus (35). There-
fore, snap freezing in liquid nitrogen or storage in RNA-
preserving agents are the preferred methods for conserva-
tion of intact RNA. Publications dealing with the influ-
ence of both methods on RNA integrity concluded that
high quality RNA can be extracted from tissues conserved
in both ways (35,36). The method of tissue fixation has to
be planned in detail for each individual experiment accord-
ing to the given preconditions, which for instance means
whether working with liquid nitrogen is generally possible.
RNA quality and RNA integrity
Good RNA quality and high RNA integrity are of great
importance in any quantitative gene expression measure-
ment. Degradation of RNA by RNAses, freezing and thaw-
ing, UV-light or heat leads to RNA fragmentation. Any
RNA degradation influences the results obtained by quan-
titative downstream applications (37). Several methods to
measureRNA integrity and quality exist.Mostmethods are
based on high resolution agarose gel electrophoresis, mon-
itoring the intensity of the major ribosomal 18S and 28S
bands. High RNA quality is indicated by a 28S:18S ratio
around 2.0 (37). In the past, results of RNA degradation
relied on vague human interpretation of the agarose gel im-
age. Nowadays, there are fully automated methods allow-
ing digital interpretation and automatic estimation of the
RNA integrity results. With those systems, minor amounts
of RNA are labeled with an intercalating dye, and RNA
is separated according to its molecular weight using cap-
illary electrophoresis in a microfluidic device. By measuring
laser-induced fluorescence detection, the retention time of
RNA molecules is displayed in an electropherogram. Ap-
plying digital data analysis software, the 18S and 28S ri-
bosomal intensity peaks in an electropherogram are auto-
matically analyzed by a specific algorithm, and a numerical
RNA quality score is calculated, whereby a score of 10 in-
dicates intact RNA and a score of 1 completely degraded
RNA. It should be mentioned, however, that the concept of
RNA Integrity Number (RIN) values is optimized for total
RNAprofiles from higher eukaryotes, which inherently lim-
its its applicability for studies on other species. Since RIN
calculation is majorly based on ribosomal RNA subunit
peaks, researchers working with samples differing from the
prototypical mammalian RNA need to pay close attention
to potentially shifted ribosomal bands. Integrity analysis of
plant RNA is further complicated by the presence of ad-
ditional chloroplast-derived ribosomal RNA that could be
recognized as a degradation product and thus falsely lead
to lower RIN values. Still, the assessment of RNA quality
by measuring RIN has been successfully applied to a vari-
ety of non-mammalian organisms such as plants and bacte-
ria (38–40). Although the importance of RNA integrity on
downstream applications is well established, even excellent
RIN values do not guarantee experimental success since
they are unable to report the potential presence of contam-
inants that might inhibit further RNA processing.
An alternative way of determining transcript integrity is
the so-called 3′/5′assay which is based on the quantification
of mRNAs at the 3′-end and at the 5′-end. The ratio of the
two fractions indicates themRNAdegradation status of the
sample (41). The assay, however, is more labor-intensive and
has another weakness due to unbalanced RT efficiency at
the 3′-end and at the 5′-end.
There are various publications confirming the impor-
tance of high RNA quality for mRNA expression profiling
studies using microarray and RT-qPCR assays (42–44). For
RNA-Seq experiments, high quality RNA is of great impor-
tance as well. Degraded RNA leads to decreased quality of
RNA-Seq data (45). Particularly the 3′ bias observed in de-
gradedRNAhas been shown to have an impact on the qual-
ity of RNA-Seq experiments (46). Feng et al. developed an
algorithm that calculates an RNA quality parameter––the
mRIN number–– for each sample by quantifying the 3′ bias
of read coverage for each measured gene (46).
Small RNAs include the highly prominent miRNAs,
which are proven to show higher stability compared to
longer RNAs, in particular mRNAs. Due to their short
length they are less susceptible to RNA degradation by
RNAses (47). The impact of RNA quality on small RNA-
Seq has not been evaluated up to now, but it is well known
that a high level of RNA degradation in a sample leads
to a seemingly increased percentage of small RNAs due to
degradation products. It is therefore likely thatwith decreas-
ing RNA quality, short fragments are included in the se-
quencing library more frequently, and could thereby lead to
a higher number of ambiguous hits after datamapping. The
impact ofRNAquality onmiRNAquantification by SYBR
green-based RT-qPCR was shown previously: decreasing
RNA quality/integrity is correlated with an increasing Cq
value (47).
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Circulating RNA and microvesicles
Circulating RNAs are the preferred target in liquid biop-
sies, and are therefore highly accessed in molecular diag-
nostics. The RNA, mainly small RNA, found in cell-free
blood plasma/serum is either packaged in microvesicles
(e.g. exosomes, apoptotic bodies), associated to lipopro-
teins such as HDL (high-density lipoprotein) particles, or
bound by stabilizing proteins (48). Circulating miRNAs are
partly bound to proteins such as Argonaute 2 and lipopro-
teins, which contributes to their enhanced stability (49,50).
A seminal paper published in 2007 reported functional
miRNA encapsulated in extracellular vesicles (mainly ex-
osomes) secreted by human and murine mast cell lines (51).
Soon thereafter, additional reports described the applica-
bility of extracellular vesicular miRNA as biomarkers in
blood (52,53). The term circulating miRNA thus has to
be used with caution, since it does not state whether the
RNA is bound or encapsulated. Circulating ormicrovesicle-
derived RNAs have already shown to be promising diag-
nostic biomarker for various diseases such as cardiovascu-
lar diseases or different kinds of cancer (54).
The composition of circulating vesicles reflects the phys-
iological and pathological status of a patient, and is there-
fore of considerable diagnostic interest (55). Extracellular
vesicles act as a protective shield and delivery vehicle for
RNA, and are a treasure trove of easily accessible biological
information. Both vesicular RNA and protein were shown
to be potential targets for biomarker research (56). Even
though considerable advances have been made in the field
of extracellular vesicles, there is still no universal consen-
sus on vesicle nomenclature (57). Despite inconsistent ter-
minology, many researchers consider exosomes, the small-
est class of extracellular vesicles, as a newly discovered and
important mediator in intercellular communication. Since
most circulating miRNAs derive from blood or endothe-
lial cells and the contribution of diseased cells is arguably
low, exosomes might provide a sampling fraction enriched
in tissue-specific biomolecules (14).
There are numerous protocols and commercially avail-
able kits for the isolation of extracellular vesicles and ex-
traction of circulating RNAs, in majority from human
blood. Principles for isolating vesicles from biofluids in-
clude, among others, ultracentrifugation, precipitation, size
exclusion chromatography, ultrafiltration, immunopurifica-
tion and microfluidic approaches (58–61). While differen-
tial ultracentrifugation in conjunctionwith density gradient
centrifugation is still considered the gold standard in vesicle
isolation and generally yields preparations of high purity, it
is labor-intensive, time-consuming and requires substantial
sample material, rendering it unsuitable for many clinical
and diagnostic applications. Choosing an appropriate iso-
lation method for the particular study has been a topic of
extensive debate, and multiple investigations have provided
insights into the suitability of respective methods (62–65).
Even though most methods were found to be able to isolate
extracellular vesicles from various biofluids, yield and pu-
rity often differ substantially. Similarly, isolation methods
also impact downstream applications: profiles of mRNA
(66), miRNA (67) and vesicular protein (68) were shown to
vary depending on the respective isolation. Generating pure
isolates is complicated by both the complexity of biofluids
and the tremendous heterogeneity of extracellular vesicles
that even within a particular size range present various sub-
populations with different molecular constitution (69,70).
Although time-consuming, density gradient centrifugation
is highly efficient in removing contaminating proteins and
protein complexes, leading to reasonably pure vesicle prepa-
rations (62). Polymer-based precipitation methods, on the
other hand, require less hands-on time, but suffer from co-
isolating non-vesicular contaminants and residual precipi-
tation reagents that can interfere with downstream process-
ing and reduce the vesicle’s biological activity (71). Recently,
size exclusion chromatography has emerged as a less tedious
alternative able to generate vesicles of purity comparable to
density gradient-basedmethods, albeit with low throughput
and yield (61,71). Excellent in-depth comparisons of meth-
ods for isolating extracellular vesicles from various biofluids
can be found elsewhere (63,64,72). Regardless of the par-
ticular isolation approach, extraction of RNAs from liq-
uid biopsies is well established. Measuring their concentra-
tion is nevertheless challenging due to low concentrations in
biofluids. New advances in both sequencing and vesicle re-
search, including careful optimization and standardization
of techniques and protocols, will certainly foster progress
toward highly specific biomarker signatures.
Blood sampling
Inmolecular diagnostics, blood is the primary andmost im-
portant matrix for RNA expression analysis. In humans,
minimally invasive sampling is of great advantage, hence
blood is the matrix of choice for so-called liquid biopsies.
Different and highly standardized methods and kit systems
are available for the extraction of high quality RNA from
blood, including total circulating RNA and microvesicular
RNA. Which sampling system is applicable depends on the
particular sample type (whole blood or only a cellular frac-
tion, e.g. white blood cells, red blood cells or platelets), or
whether cell-free circulating RNAs of interest are obtained
from plasma or serum. For conservation of whole blood
for RNA expression analysis, integrated systems for RNA
degradation protection and freezing of the current RNA
profile are available; namely the PAXgene System (PreAna-
lytix) and the Tempus System (Life Technologies). Both al-
low storage of whole blood samples at room temperature for
several days or frozen formonths without losingRNAqual-
ity. For both systems, dedicated kits are commercially avail-
able for extraction of RNA longer than 200 nt, or extraction
of total RNA including small RNAs (<20 nt). Ha¨ntzsch et
al. andNikula et al. compared the two conservation systems
and concluded that both result in high quality RNA sam-
ples (73,74). LeukoLock (Life Technologies) allows the ex-
traction of leukocyte RNAs. Within this system, leukocytes
are collected in a filter, and RNA is fixed using RNAlater
which allows storage and extraction of high quality RNA
from white blood cells (75–77).
Quantification of minimal amounts of RNA
The quantification of minimal amounts of total RNA from
biopsies or microvesicle isolates is challenging. The de-
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tection limit of conventional photometric RNA quantifi-
cation methods is around 2 ng/l (78). Due to dimin-
ished specificity in the lower concentration range, absorp-
tion and therefore quantification is mostly unspecific, be-
cause DNA contaminations cannot be distinguished from
RNA.Fluorescence-based quantificationmethods use a flu-
orescent dye that specifically intercalates or associates with
RNA, enabling precise quantification down to as little as 1
pg/l (78). This method is based on conversion of the fluo-
rescence signal of an unknown sample to a standard curve
created from samples with known concentration. The Bio-
analyzer 2100 small RNA assay (Agilent Technologies) also
allows quantification of small RNAs, especially miRNAs.
As mentioned above, this method is only valid in samples of
high RNA quality and reasonable RNA quantity. It might
result in false positive signals due to contamination of mea-
sured small RNAbyRNAdegradation products with ongo-
ing RNA degradation (47). Due to very low concentrations
in RNA samples extracted from plasma or microvesicles,
fluorescence-based methods are preferable for small RNA-
Seq studies.
How to improve RNA extraction
The extraction of extracellular small RNAs from serum,
plasma or other biofluids such as urine or saliva is chal-
lenging due to low RNA concentrations. Using carriers to
increase RNA output is helpful, whereby glycogen, yeast
tRNA, or MS2 phage RNA are widely used. Due to po-
tential interference of biological carrier RNAs with down-
stream applications, glycogen is the carrier of choice. The
use of glycogen increases total RNA yield using most
commercially available small RNA extraction kits (79,80).
When establishing an extraction method, spiking starting
material with known quantities of artificial or exogenous ri-
bonucleotides, so-called spike-in controls, and quantifying
their recovery is an easy way to assess the efficacy and repro-
ducibility of the respective approach. Spike-in controls for
miRNA extraction are, for example, artificial short RNAs
in the length range of miRNAs or miRNA extracts from
other species, such as Caenorhabditis elegans. Indeed, Bur-
gos et al. (81) optimized RNA extraction from human cere-
brospinal fluid by measuring the recovery of three previ-
ously spiked-in C. elegans miRNAs and found significant
variation between commercially available kits, and even
within technical replicates (81). It is recommended to add
spike-in controls directly to the extraction buffer instead of
adding it to the plasma or serum sample due to the pres-
ence of RNAses in biological samples, which might lead to
degradation of the spike-in miRNA (79,80). Spike-in con-
trols can be easily quantified by RT-qPCR in order to deter-
mine extraction recovery rate, and appropriately normalize
resulting expression data (79). Furthermore, such spike-in
controls are also useful to test the efficiency of the RT reac-
tion step or to control for qPCR inhibitors.
LIBRARY PREPARATION - THE RT AND LIBRARY
PREPARATION BIAS
The biases based in library preparation
Ultra-high-throughput sequencing allows global sequence
profiling of the small RNA transcriptome. To this end,
transcriptional targets need to be converted into sequenc-
ing libraries, entailing molecular modifications to make tar-
gets suitable for the small RNA-Seq chemistry. This pre-
sequencing library preparation, however, introduces tech-
nical bias into the fine-tuned transcriptional screening and
de novo discovery of transcripts (82).
In this chapter, we examine critical steps in preparing se-
quencing libraries from total RNA, and highlight the chal-
lenge of creating them in high quality. For the implementa-
tion ofNext-Generation Sequencing (NGS) of small RNAs,
the main task is to convert native small RNAs into sequen-
cable molecules while minimizing technical bias. Prepar-
ing small RNA for expression profiling requires multiple
enzymatic manipulation steps. These typically include se-
quential adaptor ligations to both ends of small RNAs, RT,
and PCR-based amplification. The 3′-adaptor ligation in-
troduces primer binding sites for first strand cDNA syn-
thesis. The PCR step specifically enriches functional small
RNAs with adaptors on both ends, and permits multiplex-
ing through introducing unique barcodes to each sample.
Ultimately, a size selection step ensures that only fragments
pertaining to small RNAs are included in the final library.
In the interest of comparing datasets generated in multiple
RNA-Seq experiment with minimal distortion, the problem
of pre-sequencing bias needs to be addressed according to
the idea of the widely acceptedMIQE guidelines (21). Previ-
ously, published experimental data showed that using iden-
tical starting RNA led to entirely different results concern-
ing small RNA expression ratios due to the implementation
of different library preparation strategies (83). Surprisingly,
the choice of sequencing platform contributed little to the
reported differences (Spearman’s ρ = 0.79–0.95). Library
replicates to test for reproducibility yielded comparable re-
sults (ρ = 0.84–0.99), indicating that data distortion was
likely caused by differences inherent to cDNA construction
protocols.
Bias resulting from low RNA input
Besides the quality of extracted total RNA (as discussed
above), RNA quantity available for the particular experi-
ment is crucial for successfully generating high-quality se-
quencing libraries. Various sample types such as plasma,
serum or urine contain limited concentrations of small
RNA due to lack of cellular material, which complicates li-
brary preparation. However, several efficient and sensitive
methods for preparing libraries from sparse input material
address this problem (84,85). Generally, it is recommended
to use RNAs of similar quality and quantity for each sam-
ple within an experiment (54,86). Additionally, the capture
efficiency of small RNAs from cell-free samples might be
limited: Kim et al. reported that biological samples with
low RNA concentration lack GC poor or highly structured
miRNAs when extracting with the phenol/guanidine isoth-
iocyanate reagent Trizol (Thermo Fisher Scientific) (87).
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They hypothesized that small RNAs base pair with longer
RNA species acting as carrier molecules, and thus compen-
sate their limited capacity to precipitate in RNA extraction.
Small RNAs with low GC content and stable secondary
structures might interact with carriers less efficiently, reduc-
ing their representation in RNA preparations. For samples
with low total RNA content, such as a small number of cells
or biofluid specimens, the availability of longer RNAs that
serve as carriers might be limiting the efficient recovery of
this specific fraction of small RNAs. In order to minimize
this bias, they recommended to avoid Trizol extractions, or
to only compare samples with similar concentrations of to-
tal RNA. It was additionally suggested to stabilize RNA–
RNA interactions by addingMgCl2 in an attempt to equal-
ize the extraction efficiency of all small RNA species.
The challenge of adapter and barcode ligation
Since the ligation step introduces the largest bias in RNA-
Seq results, several studies investigated the effect of ligating
5′- and 3′-adapter or barcodes (88–93). Hafner et al. con-
cluded that ligation efficiency depends on the sequence and
secondary and tertiary self-structure of miRNAs and/or
miRNA/adapter products (94). To reduce ligation bias,
many researchers suggest using randomized adaptor pools
containing various adapter sequences adjacent to the liga-
tion junction (89,91,93,95). A recently published follow-up
paper, however, observed that it is not necessary to design
the randomized region near the ligation junction (96). In-
stead, this might complicate identification of the end of a
miRNA sequence with an unknown sequence directly at-
tached to it. Furthermore, the authors found out that miR-
NAs prefer to ligate to adapters with which they can form
a particular structure, whereas the primary sequence is not
themain contributor to ligation bias. Even better results can
be achieved when the 5′- and 3′-adapter have complemen-
tary regions. The only commercial kit employing a similar
strategy is the new NEXTflex Small RNA-Sequencing Kit
(Bioo Scientific). It uses randomized sequences at the liga-
tion site in massive concentrations to present small RNAs
their optimal adapter. According to recent work by Baran-
Gale et al., theNEXTflex protocol has shown a great reduc-
tion in bias and the best differential expression correlation
to RT-qPCR (97).
Barcodes are very short distinct sequences which can be
introduced in the sequence of interest to enable distinc-
tion of multiple samples at the same time and in the same
lane of a flow cell. To enable multiplexing, a variety of bar-
code sets are commercially available (e.g. Illumina TruSeq
Small RNA Library Preparation Kit: 48 unique indexes,
New England Biolabs NEBNext R© Multiplex Small RNA
Library Prep Set for Illumina: 24 unique indexes, Bioo Sci-
entific NEXTflexTM Illumina Small RNA-Sequencing Kit
v3: 48 unique indexes). Depending on the library prepara-
tion kits used, barcodes can be introduced at three points
in the library preparation: (i) during adapter ligation (94),
(ii) during RT (89) or (iii) during PCR (98). Beside the
fact that barcoding is a very useful tool, it causes techni-
cal bias by influencing the ligation efficacy, RT efficiency
and PCR amplification (92,98). The above findings about
the strong impact of base compositions in the core adapter
sequence prove that it is crucially important to include bar-
codes only during RT or later in PCR (89,92,96). When
carefully designing the library preparation strategy, it is
therefore highly recommended to avoid barcode sequences
near primer annealing sites, and to include barcodes only
downstream of ligation reactions. It is, however, well de-
scribed thatmultiple-template PCR amplification can result
in sequence-dependent amplification bias due to template
differences (18,89,99). In order to measure the PCR ampli-
fication bias resulting from barcodes, Van Nieuwerburgh
et al. designed a new strategy named post-amplification
ligation-mediated (PALM) barcoding, where the ligation
of barcodes occurs after PCR without further purifica-
tion of the library. No bias was observed when comparing
PALMwith Illumina’s TrueSeqmiRNAprotocol, which in-
troduces barcodes during the PCR step (98).
RNA modifications lead to ligation and RT bias
A simultaneous library construction for all small RNA
species is challenging because of their different modified
ends. Small RNAs possess different 5′- and 3′-modifications
depending on their classes (e.g. miRNA or piRNA) and
species origins (e.g. mammals, insects, or plants). While
miRNAs in mammals carry a 2′-OH-modification at the
3′-end, many mammalian piRNAs or plant-derived miR-
NAs feature a 2′-O-methyl group on the ribose at the 3′-end
(100,101). This may influence the efficiency of enzymes in-
volved in ligation and cDNA synthesis. To minimize bias, it
is important to notice that polyadenylation-based libraries
are less suited for 2′-O-methylated RNAs. RNA tailing with
poly(A) or poly(C) is significantly less efficient for mod-
ified 3′-ends, which might conceivably lead to the under-
representation or even absence of some RNA species in
cDNA libraries (82).
In ligation-based libraries, the ligation efficiency of
RNAs with 2′-O-methyl groups can be significantly im-
proved by a longer incubation time, reduced temperature,
and the use of T4 RNA Ligase2 instead of T4 RNA Lig-
ase1 (102,103).
Choosing appropriate enzymes for the RT step can also
tone down the bias because of their known sensitivity
to 2′-O-methyl groups. It is recommended to use avian
myeloblastosis virus RTase or murine leukemia virus RTase
to prevent favoring the transcription of some RNAs over
others (103).
PCR amplification bias in library preparation
The efficiency of PCR amplification depends on the base
composition of different types of templates, type of poly-
merase, PCR buffer composition, and potential presence
of any inhibitory substances (104). It is well known that a
varying GC-content is associated with unequal PCR am-
plification efficiencies and leads to template-specific pref-
erences (105–108). To avoid that RNAs with high GC-
content remain under-represented, one can perform an op-
timized PCR program with an extended initial denatura-
tion time of 3 min and subsequent melt cycles of 80 s (109).
Furthermore, choosing an appropriate polymerase will not
only minimize GC-bias, but also narrow the length dis-
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Table 1. Crucial steps and recommendations for small RNA sampling and library preparation
Step To consider Recommendation
Experimental design and replication Type and number of samples Employ sufficient replication for question at hand
Outcome of interest Favor biological replicates over technical ones
Variance within samples
Sequencing depth Outcome of interest Replication For a rough snapshot of gene expression or
analysis of high-level transcripts, lower coverage is
sufficient
Sequencing depth needs to be increased for
analysis of rare transcripts
Sampling and storage Sampling environment Sample type
Embedding/fixation Freezing/storage
Keep sampling conditions as clean as possible
Choose an appropriate sampling system for the
particular sample type
Use agents to preserve and stabilize RNA
Freeze samples as quickly as possible and store at
appropriate temperature
RNA extraction Quantity of input material Type of extraction
kit Use of a carrier
Carefully optimize the method of extraction for the
particular type and quantity of starting material
Carrier material might be considered to increase
small RNA yield
Total RNA Expected yield and quantification system
Quality of extracted RNA
Opt for fluorescence-based quantification of
extracted RNA
Check RNA quality and integrity by capillary
electrophoresis
Addition of adapter Type of RNA (e.g. miRNA, piRNA) modified
ends
Be aware of ligation biases
For small RNAs with modified 3′-ends avoid
poly(A) or poly(C)-based approaches or modify
protocol accordingly
Reverse transcription Type of enzyme Introduction of barcodes Choose appropriate enzyme for given experimental
conditions
Introduce barcodes during PCR
PCR amplification Necessity Type of enzyme Number of cycles Choose pre-amplification strategy based on the
quantity of starting material
Opt for high fidelity polymerases with low error
rates
Perform as few PCR cycles as possible
Size selection Appropriate size range Precision of selection
system
Select for cDNA fragments that reflect the size of
the RNA of interest
High-resolution gel electrophoresis to effectively
separate small RNA species
Library purity and quantification Contamination with adapter dimers Assess library purity by capillary electrophoresis
Accurate quantification for precise flow cell
loading
Quantify library by fluorimetric assays or
qPCR/dPCR
Quality control Quality and purity of samples at each step of
the workflow
Control for sample quality throughout workflow:
purity and integrity of initial sample, extracted
RNA, cDNA library before and after size selection
tribution of generated PCR products. Several PCR poly-
merases such as Kapa HiFi (Kapa Biosystems) or Ac-
cuPrime Taq DNA Polymerase High Fidelity (Life Tech-
nologies) are recommended because of their ability to am-
plify difficult templates with higher efficiency and lower er-
ror rates (109,110). It was furthermore demonstrated that it
is of high importance to select a suitable polymerase/buffer
system, which can significantly reduce the PCR-mediated
bias. In an attempt to optimally amplify DNA sequencing
libraries, Dabney and Meyer tested 10 commercially avail-
able DNA polymerase/buffer systems and recommended
theHerculase II Fusion enzyme as the best performer (107).
Generally, it is recommended to use as few PCR cycles as
possible for library amplification, and to compare only tech-
nical or biological replicates with the identical number of
PCR cycles, since PCR noise accumulates with higher cycle
number (110).
Library preparation of samples with limited starting ma-
terial is challenging: researchers have to make a compro-
mise between introducing PCR bias and not detecting lowly
expressed transcripts that might not have been sufficiently
amplified. Okino et al. recently presented a highly multi-
plexed pre-amplification approach that massively increases
the abundance of target genes while keeping amplification
bias at bay (111). Since gene expression patterns were main-
tained throughout up to 14 PCR cycles, analysis of pre-
amplified samples yielded similar results to samples not un-
dergoing pre-amplification. Gene expression profiling stud-
ies on low input samples might greatly benefit from such a
distortion-free enrichment strategy. Recently, more sophis-
ticated library preparation strategies to avoid PCR bias al-
together were developed for both bulk and single cell anal-
yses (112,113). By introducing unique molecular identifiers
(UMI), researchers are able to detect absolute numbers of
DNA or RNA molecules, since each nucleic acid in the
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Table 2. Crucial steps and recommendations for small RNA-Seq data analysis
Step To consider Recommended tools or algorithms
Data pre-processing Trimming adapters Btrim, FASTX-Toolkit
Removing short reads
Quality control Library size and read distribution across
samples
Btrim, FASTX-Toolkit, FaQCs
Per base/sequence Phred score
Read length distribution
Assess degradation
Check for over-represented sequences
Read alignment (Filtering) Reference database or genome Bowtie, BWA, HTSEQ, SAMtools, SOAP2
Annotation
Mismatch rate
Handling of multi-reads
Normalization Library sizes and sequencing depth DESeq2, EdgeR, svaseq
Batch effects
Read distribution
Replication level
DGE analysis Data distribution DESeq2, EdgeR, SAMSeq, voom limma
Replication level
False discovery rate
Target prediction of miRNAs / siRNAs Insilico prediction or experimental validation miRanda, miRTarBase, TarBase
Canonical and non-canonical target regulation
Biomarker identification Sensitivity Specificity Classification rate DESeq2, Simca-Q, Numerous R packages: base,
pcaMethods, Mixomics
starting material is tagged with a unique sequence during
RT. After sequencing and mapping, UMI are counted to
infer absolute copy numbers without including PCR du-
plicates in the analysis. Even though UMI-based library
preparation has only been applied to mRNA sequencing so
far, similar approaches might also be developed for small
RNA-Seq in the future.
Gel size selection
The fragmentation of DNA by acoustic shearing, soni-
cation or enzymatic digestion to attain the desired target
length of 100–500 bp fragments is not necessary for se-
quencing small RNAs, which are usually considered to be
shorter than 200 nt (110). For miRNA sequencing, frag-
ment sizes of adaptor–transcript complexes and adaptor
dimers hardly differ in size. An accurate and reproducible
size selection procedure is therefore a crucial element in
small RNA library generation. To assess size selection bias,
Locati et al. used a synthetic spike-in set of 11 oligoribonu-
cleotides ranging from 10 to 70 nt that was added to each
biological sample at the beginning of library preparation
(114). Monitoring library preparation for size range biases
minimized technical variability between samples and exper-
iments even when allocating as little as 1–2 % of all se-
quenced reads to the spike-ins. Potential biases introduced
by purification of individual size-selected products can be
reduced by pooling barcoded samples before gel or bead pu-
rification.
Since small RNA library preparation products are usu-
ally only 20–30 bp longer than adapter dimers, it is strongly
recommended to opt for an electrophoresis-based size selec-
tion (110). High-resolution matrices such as MetaPhorTM
Agarose (LonzaGroupLtd.) orUltraPureTM Agarose-1000
(Thermo Fisher Scientific) are often employed due to their
enhanced separation of small fragments. To avoid sizing
variation between samples, gel purification should ideally
be carried out in a single lane of a high resolution agarose
gel.Whenworking with a limited starting quantity of RNA,
such as from liquid biopsies or a small number of cells, how-
ever, cDNA libraries might have to be spread across mul-
tiple lanes. Based on our expertise, we recommend freshly
preparing all solutions for each gel electrophoresis to ob-
tain maximal reproducibility and optimal selective proper-
ties. Electrophoresis conditions (e.g. percentage of the re-
spective agarose, buffer, voltage, run time, and ambient tem-
perature) should be carefully optimized for each experimen-
tal setup. Improper casting and handling of gels might lead
to skewed lanes or distorted cDNA bands, thus hampering
precise size selection. Additionally, extracting the desired
product while avoiding contaminations with adapter dimers
can be challenging due to their similar sizes. Bandsmight be
cut from the gel using scalpel blades or dedicated gel cut-
ting tips. DNA gels are traditionally stained with ethidium
bromide and subsequently visualized by UV transillumi-
nators. It should be noted, however, that short-wavelength
UV light damages DNA and leads to reduced functional-
ity in downstream applications (115). Although the suscep-
tibility to UV damage depends on the DNA’s length, even
short fragments of <200 bp are affected (116). For size se-
lection of sequencing libraries, it is therefore preferable to
use transilluminators that generate light with longer wave-
lengths and lower energy, or to opt for visualization tech-
niques based on visible blue or green light which do not
cause photodamage to DNA samples (117,118). In order
not to lose precious sample material, size-selected libraries
should always be handled in dedicated tubes with reduced
nucleic acid binding capacity.
Precision of size selection and purity of resulting libraries
are closely tied together, and thus have to be examined care-
fully. Contaminations can lead to competitive sequencing
of adaptor dimers or fragments of degraded RNA, which
reduces the proportion of miRNA reads. Rigorous quality
control checkpoints and size selection steps are therefore
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crucial. In order to assess length distribution and potential
contaminations, it is recommended to use high sensitivity
capillary gel electrophoresis assays. The size profile of final
library preparation products is dictated by the initial small
RNA’s size distribution extended with respective sequenc-
ing adapters.
Library quantification and flow cell loading
Methods of quantitating final cDNA libraries are still
highly debated in the field, and have a significant impact on
the sequencing experiment since precise loading of flow cells
is crucial for optimal cluster densities. Overloading results
in overlapping clusters, reduced quality of reads, and ulti-
mately diminishes the data output of the experiment (119).
Low numbers of clusters, or underclustering, on the other
hand, yields high-quality data, but a less-than-ideal out-
put. Impurities in sequencing libraries not only skew library
quantitation, but also affect cluster generation: shorter frag-
ments such as adapter dimers cluster more efficiently and
thus restrict clustering of target RNAs. Capillary gel elec-
trophoresis is a useful tool to assess library integrity, in-
sert size and contaminations, but detects both amplifiable
and non-amplifiable molecules (120). Spectrophotometri-
cal methods of nucleic acid quantification are not sensi-
tive enough to precisely quantitate cDNA libraries, and suf-
fer from also measuring single-stranded DNA and free nu-
cleotides. Fluorometric assays such as PicoGreen (Thermo
Fisher Scientific) or Qubit (Thermo Fisher Scientific) are
more applicable due to increased sensitivity, and specif-
ically quantify double-stranded DNA. Another common
approach is quantifying cDNA libraries via qPCR with
primers designed to adaptor sequences. Since only func-
tional molecules are captured in the analysis, qPCR and its
derivatives seem to precisely predict actual cluster densities
(121). Increasingly sensitive methods of library quantifica-
tion allow for both less input material and fewer PCR cy-
cles, which in turn facilitates sequencing of limited samples
and reduces distortion of the initial sequence distribution.
Although more costly than other methods, calibration-free
absolute quantification of cDNA libraries by digital PCR
was found to be a highly accurate tool for quantification of
amplifiable molecules in sequencing libraries (122,123).
Loading precision can also be increased by using artificial
or exogenous spike-ins. Adding known quantities of a syn-
thetic sequence to samples and quantifying their read count
allows for additional control of sequencing parameters. Ad-
ditionally, technical biases and sequencing errors can be as-
sessed by correlating the amount of spiked-in RNA to read
counts mapping to those standards. Fahlgren et al. spiked
sequencing libraries with three synthetic 21-nt sequences,
and found a linear correlation between spike-in concentra-
tion and mapped spike-in reads that reached saturation at
10 pmol spike-in per 100 g of total RNA (124). Another
publication using poly-A-tailed mRNA-mimetic standards
reported a linear correlation spanning six orders of magni-
tude while suggesting that the detection of standards is ro-
bust to the endogenous complexity of RNA samples (125).
As for the analysis of target transcripts, the recovery of stan-
dard readswas limited by sequence abundance and sequenc-
ing depth, both of which increased spike-in detection.
Critical steps in small RNA-Seq experimental design,
sampling and library preparation as well as recommenda-
tions by the authors are summarized in Table 1.
SEQUENCING - THE SEQUENCING BIAS
Introduction to sequencing bias
While researchers used to increase sequencing depth rather
than introduce additional biological replicates, the ever-
subsiding costs of sequencing assays nowadays allow for
more replication (126). This, in turn, increases specificity
and sensitivity of NGS experiments, and helps correct for
biases that cannot be mitigated by bioinformatics meth-
ods, such as batch or library preparation effects. Merely
increasing sequencing depth in order to improve the speci-
ficity of experiments might seem a straightforward strategy,
but in reality does not help alleviate sequencing-specific er-
rors (126). Even though a major cause of bias lies in the
library preparation of small RNA samples, the sequencing
reaction itself can also lead to substantial errors in NGS
data. A great number of factors pertaining to the sequenc-
ing reaction have to be considered when conceptualizing
RNA-Seq experiments. Regardless of the particular exper-
imental question, fundamental aspects such as randomiza-
tion, replication and blocking need to be properly addressed
(127). The most basic decisions relate to choosing a par-
ticular sequencing platform and type of flow cell, and de-
signing an experiment that tailors the sequencing chemistry
specifically to the question at hand. Additionally, insuffi-
cient replication, unsatisfactory sequencing depth and PCR
errors are known to increase bias in sequencing data. It is
also important to notice that batch effects may result from
different kits, reagents, chips, platforms, instruments, han-
dling by different technicians, and day-to-day variations.
Batch effects may even occur between different lanes on an
Illumina flow cell, or between sequencing runs (110,128).
In light of Illumina’s dominance in the NGS market, most
types of bias discussed in this review are focused on this par-
ticular sequencing chemistry.
Batch, lane- and flow cell effects
A major concern in all experiments is detaching biologi-
cal from technical variation since confounding both makes
it impossible to interpret changes in data. For RNA-Seq
experiments, it was shown that library preparation intro-
duces the largest bias. This so-called batch effect is an of-
ten underestimated problem in high-throughput techniques.
As shown above, variations in cDNA preparation from a
singular biological source can arise from laboratory con-
ditions, varying quality and reagent lots, skills of the par-
ticular operator, changes in personnel, or more subtle fac-
tors such as laboratory temperature or ozon levels (128).
Quality and quantity of input material, primer concentra-
tion, size selection and number of PCR cycles are only a few
of many critical parameters of an RNA-Seq protocol that
can lead to profound batch effects. A recent article even re-
ported that the composition of small RNA sequencing li-
braries is more heavily influenced by RNA extraction than
by library preparation itself (129). Confounding batch ef-
fects with the question of interest, e.g. preparing sequenc-
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ing libraries of all treated and control samples on differ-
ent days or by different operators, can skew the data and
directly lead to false biological conclusions. While shown
to be of less impact than batch effects, there are also lane
and flow cell effects that need to be taken into considera-
tion when designing RNA-Seq experiments (29). These ef-
fects pertain to technical variations arising after the cDNA
library is loaded onto the sequencer.Marioni et al. reported
a high replicability in Illumina sequencing data with only a
small percentage of genes featuring a systematic difference
between different lanes of a flow cell (30). Ross et al., on the
other hand, found substantial variation between separate
flow cells, but not between lanes within a flow cell (130). It
should be noted, though, that intra- and inter-assay varia-
tion was shown to be less prominent than variation between
sequencing platforms.
Multiplexing
The ability to multiplex––adding specific barcodes to sepa-
rate samples and sequencing themon the same lane of a flow
cell––nowadays allows researchers to mitigate lane effects
and create more effective experimental designs. Auer et al.
proposed creating ‘balanced blocks’ by subjecting all sam-
ples to the same experimental conditions, including library
preparation and sequencing (i.e. equal proportions of all
samples are loaded onto all lanes of the flow cell) (131). For
more sophisticated and larger experiments, it is advisable
to spread library preparation batches, sequencing lanes and
flow cells across all biological groups and replicates to min-
imize technical variability. Multiplexing and pooling sam-
ples as early as possible is advantageous since they can then
be processed through the library preparation workflow to-
gether, which further alleviates batch effects. Multiplexing
also helps to reduce sampling bias when loading the cDNA
library onto the flow cell. Loading entails a large dilution
step since only a fraction of the cDNA pool is used for clus-
ter generation. An uneven distribution of molecules results
in skewed library representation on the flow cell, and thus
profoundly alters data output (132).Multiplexing and pool-
ing all samples tones down sequencing errors by reducing
sampling bias to only one dilution step.
Paired-end versus single-end sequencing
Paired-end sequencing is a powerful innovation in tran-
scriptomics, yielding more information on transcripts at the
same sequencing depth (29). While useful for detection of
alternative splice variants and chimeric transcripts, paired-
end sequencing usually offers no advantage in small RNA-
Seq. Since inserts are short, most experiments do not ex-
ceed 50 cycles of sequencing even for small RNA discovery
applications. Illumina in fact suggests lowering cycle num-
bers to 18–36 for miRNA expression profiling studies. Even
for profiling of protein-coding genes, 50-bp single-end reads
were previously recommended in the literature (26).
Sequencing depth
Since the amount of binding sites on a flow cell is a fi-
nite resource, the number of samples in a sequencing run
and the sequencing depth are intimately connected. While
depth usually refers to the number of reads contributing to
an assembly, the respective coverage depends on the abun-
dance of the transcript of interest. For high-level transcripts,
even a lower depthmight be sufficient to analyze differential
gene expression, whereas low-level transcripts require much
higher sequencing depths to yield sufficient coverage. Since
small RNA copy numbers span a wide range of expres-
sion, higher depth is usually required to accurately capture
less abundant transcripts. When designing RNA-Seq exper-
iments, sequencing depth has to be tailored to the outcome
of interest: a rough snapshot of gene expression requires
far lower coverage than the analysis of rare transcripts. For
miRNA discovery, Illumina nowadays recommends at least
10Mmapped reads.Metpally et al. found that while increas-
ing sequencing depth facilitates the detection of new miR-
NAs, even a moderate depth of only 1.5M mapped reads
reliably represents the miRNA distribution in the sample
(133). For a given sample type, increasing sequencing depth
seems to positively correlate with increasing the proportion
of mapped reads. Previous RNA-Seq studies stated that in-
creasing sequencing depth reduces errors in differential gene
expression experiments with the caveat of diminishing re-
turns at a certain level of coverage (134). For mRNA-Seq
experiments, a stable detection of transcripts seems to be
reached at coverage of about 30×with greater coverage only
yielding marginal error reduction rates (23). These guide-
lines could also be applied to small RNA-Seq studies. Since
the percentage of initial reads mapping to known miRNAs
varies across sample types and library preparation batches,
it might be advisable to run a small pilot study in order to
determine how many mapped reads are appropriate for the
particular biological problem, and how much coverage is
needed to generate those reads (133). This ultimately also
determines how many samples can be multiplexed on each
flow cell of the main experiment. The decision as to whether
increase sequencing depth or includemore samples depends
on the outcome of interest, and is oftentimes limited by the
given research budget.
Systematic PCR error
While careful experimental design, library preparation, and
loading of the flow cell support bias reduction, the sequenc-
ing reaction itself bears additional risk for skewing NGS
data. PCR errors induce bias not only during library prepa-
ration, but also affect cluster generation and sequencing by
synthesis chemistry. Even in the days of high-fidelity DNA
polymerases, false incorporation of nucleotides cannot be
prevented completely, resulting in DNA strands deviating
from the original template. Sequence errors during clus-
ter generation are particularly detrimental since erroneous
molecules are exponentially amplified and impair base call-
ing during the subsequent sequencing reaction, ultimately
resulting in poor read quality. Growing mixed clusters from
more than one template molecule results in a heterogeneous
colony of PCR products, and thus an inconclusive fluores-
cence signal during imaging (135). While amplification effi-
ciency is a significant cause of bias in library preparation,
differences in template-specific amplification during clus-
ter generation do not majorly skew read count results since
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only the fluorescence intensity of the respective cluster is af-
fected.
Polymerase errors also occur during the sequencing re-
action itself. Phasing, the lagging behind of a strand that
failed to incorporate a base, hampers base-calling since a
more heterogeneous fluorescence signal of the cluster is
recorded in each imaging cycle. The enzyme can also erro-
neously insert multiple bases, which is referred to as pre-
phasing (136). Both of these problems are independent of
the template DNA sequence, and lead to an increased fre-
quency of base-calling errors toward the end of a read since
more and more noise from preceding and ensuing cycles is
introduced. Imaging is further impeded by cross-talk, the
partial overlap of emission spectra of the four dyes used
in Illumina sequencing technology. This additional noise
factor seems to be cycle-dependent and also increases er-
ror rates in later cycles (137). Further factors contributing
to sequence-independent base-calling errors are dead fluo-
rophores and uneven signal intensities across each tile of
the flow cell (138,139). Base-calling algorithms need to be
aware of and account for these biases. After signal detec-
tion and error correction, the base with the highest inten-
sity is chosen. Remaining uncertainties about called bases
are then expressed in quality metrics such as the widely
adopted Phred score (140). Originally published in 1998,
Phred employs log-transformed error probabilities to gener-
ate ASCII-encoded quality scores for each nucleobase. Ac-
cording to the algorithm q = −10 × log10 (p) where p is
the probability of an incorrect base-call, high quality scores
equal low error probabilities and the ubiquitous benchmark
of Q30 reads corresponds to an error probability of 0.001.
The better a base-caller works, the higher the accuracy of se-
quencing, which ultimately reduces coverage requirements.
Sequence-specific PCR errors in Illumina sequencing
In addition to the abovementioned systematic errors, there
are also several sequence-dependent biases in sequencing
by synthesis. It is well-known that miscalls on the Illumina
platform occur more frequently in GC-rich regions and in-
crease in later cycles (141). Sequence-related biases result-
ing in failed single-nucleotide elongation might be induced
by altered substrate preference of the DNA polymerase
or specific inhibition of the enzyme. Indeed, Nakamura
et al. identified sequence-specific dephasing triggered by
GGC sequences to be a consistent bias in Illumina datasets
(142). Another cause of sequence-specific errors in Illumina
sequencing, albeit potentially of less relevance for small
RNA-Seq, are secondary structures of the flow cell-bound
single-strandedDNA (ssDNA). According toNakamura et
al., ssDNA folding induced by inverted repeats contributes
to polymerase inhibition, while Stein et al. illustrated how
secondary structures can facilitate or hinder priming during
Illumina bridge amplification (142,143). Sequence-induced
errors are not only detrimental for applications such as SNP
detection or transcriptome assembly, but can also interfere
with small RNA-Seq due to the close homology of miR-
NAs.
Platform-specific error profiles
Previous publications about NGS error rates reported that
a majority of miscalled bases is not associated with insuf-
ficient coverage, but rather stems from systematic biases in
the respective sequencing chemistry (144). It is well known
that single base substitutions are the dominant error in Il-
lumina data, while pyrosequencing and ion semiconductor
sequencing are more prone to insertions and deletions (in-
dels) (145). In a recent comparison of common platforms,
IlluminaMiSeq sequencing was shown to produce the high-
est quality data with a substitution rate of 0.1/100 bases
and an indel rate of <0.001/100 bases (146). The frequency
of indels was markedly higher when using the Life Tech-
nologies Ion Torrent Personal Genome Machine (PGM)
and Roche 454 GS Junior systems, featuring 1.5/100 bases
and 0.38/100 bases, respectively. Another publication on
Illumina sequencing reported error rates as low as 0.3%
and an increased frequency of A>C conversion (141). Since
the early days of high-throughput sequencing, significant
improvements in sequencing chemistry and software have
markedly lowered error rates in Illumina data and led to
more robust performance. Still, certain error patters char-
acteristic for the technology and independent of the input
sequence still pertain to newer generations of sequencers
(147). Error rates were shown to be reproducible and pre-
dictable across multiple samples in a recent publication on
cellular barcoding (148). While indels are fairly rare in Illu-
mina data, they can account for up to two thirds of all errors
in 454 pyrosequencing (149). Both Ion Torrent and 454 are
known to struggle with homopolymer stretches that often-
times induce frameshifts. In 454 sequencing, homopolymer
errors are more frequent in A and T rich regions and in-
crease with longer sequences of identical bases, while Illu-
mina errors are more randomly distributed (150).
DATA ANALYSIS - THE DATA ANALYSIS BIAS
Small RNA data analysis
Having successfully avoided any pitfalls and biases dur-
ing experimental setup, library preparation and sequenc-
ing, scientists are challenged by processing the frequently
huge amounts of sequence data, and extracting meaning-
ful and reliable information from millions and millions of
reads. Although digital datasets provide the opportunity to
test and validate a seemingly endless array of analyses with-
out spending more than time and computational resources,
beginners in the field are often overwhelmed and deterred
by the multitude of offered software tools and pipelines.
Since a complete discussion of all possible analyses would
go beyond the scope of this review, the following part will
be centered on the currently prevalent aim of most small
RNA-Seq experiments: the detection and comparison of
small RNA (mainly miRNA) expression profiles in differ-
ently treated samples. In addition, we will focus on ‘free to
use’ software tools or R packages (151) that, while some-
times lacking in user friendliness, are readily available to
anyone. Even though most of the software provides com-
prehensive manuals and tutorials, scientists not already fa-
miliar with command line tools may want to try a more in-
tuitively usable software suite, in particular Galaxy (152–
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154) or eRNA (155), which implement many of the tools
discussed here in a user-friendly graphical interface or in-
vest in commercially distributed programs such as CLC
Genomics Workbench (Qiagen), Ingenuity Pathway Analy-
sis (Qiagen) or Genomatix Genome Analyzer (Genomatix).
Unfortunately, due to the complexity of varying genomes,
small RNA species, data bases and constant updates and
improvements of existing software tools, a uniformly valid
and standardized analysis approach for all datasets has yet
to be established. The fact that most extensive evaluations
of methods are carried out on sequencing runs of longer
RNAs, and do not take into account the special nature of
small RNA datasets further complicates this. The follow-
ing chapter will highlight all major sources of bias or un-
wanted variation that need to be addressed and reported
to nonetheless guarantee reproducibility and comparability
between experimental setups or computational pipelines.
The starting point for all explorations is a fastq file
comprising all read sequences with their associated qual-
ity scores, indicating the probability of a wrong base call
for any given nucleotide. Small RNA data analysis can be
generally divided into four individual parts of equal im-
portance: data preprocessing, including quality control and
adapter trimming, the alignment of reads to the respective
reference genome or small RNA database, normalization of
mapped reads, and differential expression analysis between
samples. A summarizing overview of critical steps and rec-
ommended tools for small RNA-Seq data analysis is pro-
vided in Table 2.
Data preprocessing
As discussed previously, sequencing errors accumulate with
read length, and quality of sequencing data drastically
affects downstream analysis (141). Furthermore, sizes of
many small RNA transcripts such as miRNAs (∼22 nt)
and piRNAs (∼31 nt) (156) fall short of usual sequenc-
ing lengths (∼36–50 nt), and resulting reads inevitably in-
corporate 3′-end adapter sequences from library prepara-
tion. To facilitate correct alignments, small RNA read data
must therefore be trimmed of adapter artifacts. Comple-
mentarily, a significant reduction in false positive align-
ments to multiple genomic locations can be achieved by
filtering for sequences with inadequate lengths (157,158).
Removal of these reads with less than 16–18 nt, represent-
ing almost exclusively degraded RNA or adapter dimers
from library preparation, can also crucially save compu-
tational time and associated costs. With the adapter se-
quences supplied by library preparation kit manufactur-
ers, this can be achieved by a number of programs includ-
ing Btrim (159), the fastx clipper tool from the FASTX-
Toolkit (http://hannonlab.cshl.edu/fastx toolkit/), cutadapt
(160) or FaQCs (161). Although current library prepara-
tion and sequencing protocols, in conjunction with small
read lengths after adapter trimming, do a good job of min-
imizing sequencing errors, low quality datasets can still oc-
cur and will struggle finding accurate alignments. While
there are algorithms such as Quake (162) or ALLPATHS-
LG (163) that try to correct unreliable base callings by su-
perimposing the most frequent, similar patterns on them,
the intrinsically non-uniform sequence abundances found
in small RNA-Seq (164) prohibit their application. Low
quality reads can nonetheless be mitigated in part by re-
moving bases with low Phred scores from reads up to a
minimum length (∼18 nt) or, less preferably, by filtering
them out completely (165). Popular quality trimming algo-
rithms implement either some variation of a running sum
of the quality scores from 3′- to 5′-end looking for a min-
imal (Cutadapt), or a moving window that determines the
longest continuous stretch of nucleotides above the thresh-
old and trims the rest (Btrim, fastq quality trimmer from
FASTX Toolkit, FaQCs, SolexaQA (166)). Prior to align-
ment, filtered and adapter- as well as quality-trimmed reads
should then be evaluated in terms of quality scores and typ-
ical length distribution of reads. Remaining reads should
be free of low quality sequences indicating sequencing er-
rors (quality score <20), and read lengths should show a
distinct peak for the targeted small RNA species (e.g. 21–
23 nt for miRNA, 30–32 nt for piRNA). An absence of
these typical read lengths can originate from a multitude of
causes, including incorrect small RNA isolation, inaccurate
size selection during library preparation, as well as degra-
dation during, for instance, storage of samples. A fairly
uniform increase in read numbers from longer to shorter
reads is further proof of low RNA integrity. Additionally,
read data can be examined for over-represented sequences
potentially deriving from amplification bias during library
preparation or contamination with longer RNAs, especially
rRNA. k-mer distribution can be assessed by, inter alia,
FAQCs or FastQC (http://www.bioinformatics.babraham.
ac.uk/projects/fastqc/). Readers interested in benchmark-
ing performances (computation time, memory consump-
tion, possibility of multi-threading etc.) or further quality
control checks can find short overviews of existing software
tools in (165), (167) or (161).
Small RNA read alignment
To extract meaning from the carefully preprocessed data,
reads must be mapped to their respective reference and
matched with an appropriate annotation. Almost all ex-
isting tools start this process by creating an index for ei-
ther the reads or the reference, which can then be used to
find the corresponding sequence or genomic position. Us-
ing these indices allows alignment tools to quickly reduce
the number of potential locations on the reference by a
first heuristic match of reads, followed by a thorough local
alignment for each possible match to evaluate the correct
alignment. Without this inexact first pass, alignment of mil-
lions of nucleotides would take prohibitively long and over-
tax all but the most sophisticated computational clusters.
Common indexing algorithms include hash tables based on
principles used by the well-known BLAST aligner (168),
or suffix/prefix tries based on Burrows-Wheeler Transform
(169). While hash table based aligners have fewer problems
identifying even complicated mismatches between read and
reference, the computational requirements to do so escalate
quickly. Burrows-Wheeler Transform aligners, on the other
hand, are extremely fast and efficient in mapping closely
matching read-reference pairs, but slow down significantly
when challenged with complex misalignments. In general,
there is no single ‘best’ software tool, and the individual per-
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formance varies, among other things, with the error rate or
genome type of the particular dataset, as well as the allowed
mismatch rate (158), although reference indexing tends to
outperform read indexing. Frequently used aligning soft-
ware for small RNA-Seq include Bowtie (170), BWA (171),
or SOAP2 (172), but an evaluation of mapping sensitivity
and specificity based on an actual dataset is strongly recom-
mended. Readers interested in benchmarking performances
(indexing time, mapping throughput, mapping sensitivity
etc.), as well as software-specific algorithm variations such
as spaced seeding, q-gram filters, and FM-indices can find
short overviews of existing software tools in (173), (174) or
(158). Researchers with exceptionally large datasets or fac-
ing limiting time constraints could benefit from exploring
the possibilities offered by multiple processors in high-end
graphic cards (e.g. BarraCUDA (175) or SOAP3-dp (176)),
or high-performance computing clusters (e.g.MICA (177)).
Classic read alignment strategies include mapping to a
reference genome or a specific small RNA database such as
mirBase (178,179) or Rfam (180). While reference genomes
enable researchers to get the most comprehensive view of
their data, allocating reads to all small RNA classes, as well
as potential degraded mRNAs and rRNAs, their annota-
tions often lack the extensiveness found in specific small
RNA databases, especially in the case of less researched
organisms. Additionally, alignment to a genome can lead
to problems with reads that map to multiple genomic lo-
cations (multireads). Reads without unique genomic loca-
tions are mostly caused by sequencing errors or repetitive
sequences, but can also originate from genes with multiple
genuine copies in the genome (e.g. hsa-let-7a), and incorrect
handling of them can lead to a severe bias (181–183). On
the other hand, mapping to a reference genome allows for
further characterization of unannotated sequences on the
basis of their location or accumulation (e.g. novel miRNA
prediction). Alignment to a specific small RNA database,
however, has its own pros and cons, mostly stemming from
a vastly downscaled mapping reference. Most noticeably,
alignment is significantly faster and has a considerably re-
duced memory footprint. Even though multireads are ex-
tremely improbable to occur, the likelihood of false posi-
tive mappings of reads from non-targeted small RNAs is
increased manifold due to the absence of their sequences in
the reference. A more conservative mapping with less mis-
matches is as crucial in avoiding false positivemappings as is
filtering for non-targeted small RNA classes (184). Further
complicating this is the existence of functionally relevant
isoforms such as isoMirs that often differ substantially from
their canonical sequence, but have to be taken into account
when determiningmismatch thresholds and, ultimately, dif-
ferential expression (185–187). By comparing reads directly
to specific sequences, researchers can also take advantage
of homologous datasets from well-explored organisms due
to the strong conservation of seed sequences between most
small RNA classes in different species (e.g miRNAs or piR-
NAs (188)). After deciding on a mapping strategy, the final
step in alignment is matching the database sequence or ge-
nomic position to its corresponding small RNA and count-
ing all reads related to the same feature. With annotations
available for all major sequenced genomes, these countlists
can be easily generated using HTSEQ (189) or R packages
such as IRanges, GenomicFeatures (190) or, in the case of
an alignment against a specific sequence database, with e.g.
SAMtools (191).
Normalization strategies
Although small RNA-Seq features distinctively less noise
and technical bias compared to former holistic screen-
ing methods such as microarrays (192), it still generates
systematic variation that needs to be addressed prior to
differential expression analysis. Unwanted differences be-
tween libraries commonly occur in size (sequencing depth)
(193) as well as within libraries in GC-content (194) or as
batch effects (128). Variation introduced by different gene
lengths (195), as is frequently encountered in sequencings of
longer RNAs, has a negligible effect. Since usual sequenc-
ing lengths cover the whole transcript and fragmentation is
not necessary during library prep, the still popular Reads-
per-Kilobase-per-Million-mapped-reads (193) is therefore
not suited for small RNA-Seq. Overall, the general impor-
tance of normalization and its impact on differential expres-
sion was clearly shown by Bullard et al. in 2010 (196). Spe-
cial attention has to be paid to experimental setups such as
degradation studies, where read distributions differ funda-
mentally from the underlying assumptions of most meth-
ods. Most of the currently established and preferred nor-
malization strategies evolve around a global scaling factor
per sample to adjust read counts with. Widespread normal-
ization methods include: (i) library size or total mapped
reads, where individual read counts are first divided by their
respective library size and then multiplied by the arithmetic
mean of all library sizes or counts of total mapped reads, re-
spectively. Since individual read counts are not only directly
related to sequencing depth, but also dependent on their rel-
ative expression compared to all other small RNA expres-
sion levels in a sample, this normalization should be avoided
(196). (ii) Upper quartile of reads, where transcripts with
zero counts across all samples are filtered from the dataset,
and a scaling factor is derived for each sample from the 75th
quartile of the remaining reads (196). (iii) Quantile, where
the distribution of each gene is assumed to be identical,
and read counts are adjusted according to a reference ob-
tained from the median of each quantile across all samples
(197). (iv) Trimmed Mean of M-values, where a weighted
trimmedmean of log expression ratios is calculated for each
sample compared to a reference sample. Working under the
assumption that expression of most genes will not be sig-
nificantly altered in the experiment, these means should be
close to 1, and a scaling factor is derived from this differ-
ence, and finally adjusted by the mean of the normalized
libraries (198). (v) Median of expression ratios from geo-
metric means, where a pseudoreference is first created by
computing the geometric mean of all genes across samples,
and then the ratio for each count to its respective mean is
determined. The scaling factor is finally obtained from the
median of all ratios for each sample. Similar to (iv), median
normalization also assumes most genes to not be differen-
tially expressed (199,200). (vi) Artificial spike-in standards,
where reads are quantified using a standard curve derived
from a set of pre-determined small RNAs independent of
the samples (125). (vii) Surrogate variable analysis, which is
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specifically targeted on batch effects, and helps identifying
genomic data affected by artifacts. It adjusts read counts by
estimating these artifacts with the help of singular vectors
of the specific subset of the data (201).
Although the variety in experimental and genomic set ups
so far makes it impossible to universally recommend a sin-
gle normalization strategy, recent evaluations of thesemeth-
ods have found Median normalizing of expression ratios
from geometric means to work favorably with various kinds
of datasets (202,203). Additionally, Zyprich-Walczak et al.
proposed a step-by-step workflow to determine the most
appropriate normalization method for a specific dataset in
terms of bias, variance, sensitivity, specificity and prediction
errors to avoid data distortion by using the wrong normal-
ization (203).
Differential expression analysis
In comparison to normalization strategies that were mostly
extending existing methods for microarrays, the distinctly
different data type of NGS made the development of new
algorithms for differential expression analysis imperative.
While microarray data consists of continuous intensities
coupled with a high background, NGS read counts give dis-
crete measurements for each gene, and should not, unlike
microarray intensities, be modeled on a normal distribu-
tion. Although early RNA-Seq reported a good fit to a Pois-
son distribution for single sample sequencings and techni-
cal replicates (30,196), studies with biological replicates are
extremely likely to show variances greater than the mean
for many genes (204). This so-called overdispersion makes
analyses working under the Poisson assumption prone to
high false-positive rates due to an underestimation of sam-
pling error. One way to overcome this is an extension of
the Poisson model with a quasi-likelihood approach, where
each gene is tested individually for overdispersion (Two-
Stage-Poisson-Model (205)). Another way to account for
biological variability is the negative binomial distribution,
which adds the dispersion to the mean as a second param-
eter (206). Correct estimation of gene-wise dispersion fac-
tors is crucial, but unfortunately also hampered by the still
prevalent low number of sample in most RNA-Seq studies.
To obtain more accurate dispersion factors, analysis tools
share information across all genes in the dataset by, among
other things, a weighted likelihood approach toward the
common dispersion (edgeR (207)) or by modeling the ob-
served mean-variance relationship for all genes via regres-
sion (DESeq (199,200)). Differential expression can then
be tested by either exact tests (edgeR, DESeq) or empirical
Bayesian frameworks (EBSeq (208), baySeq (209)). Apart
from these distribution assumptions, differential expression
can also be assessed by non-parametric approaches based
for instance on Wilcoxon rank statistics and resampling
strategies (SAMSeq (210)), or by comparing the absolute
and relative expression differences between and within ex-
perimental conditions (NOISeq (211)). A major drawback
of these methods is their relatively low power and specificity
in experiments with low sample numbers. In addition, ro-
bust methods established for microarrays (limma (212,213))
can be made applicable through transformation of discrete
read count data (voom (214)). Irrelevant of the employed
algorithm, all tools will produce a list of significantly regu-
lated genes that should be treated with caution. Due to the
large number of tests, the false discovery rate should be con-
trolled for all results to avoid accumulation of type-1-errors
(215). Additionally, the ratio of expression signal to experi-
mental noise should bemonitored for lowly expressed genes
by assessing the biological relevance of the fold change, as
well as absolute read count values.
More so than any other tools, software for differential
expression is subject to frequent updates, which can alter
their behavior dramatically and new algorithms are pub-
lished continually. Even though comparisons of software
performances on small RNA-Seq data are scarce, a num-
ber of independent and extensive evaluations for mRNAs
based on either synthetic data with clearly defined prop-
erties (216), or on biological datasets with validated gene
expressions (217,218) have been made recently. While it
was shown that statistical power of almost all methods is
heavily dependent on the number of samples per condition
and less on sequencing depth, the variability of expression
changes in biological datasets affects each analysis tool dif-
ferently. Outliers, ‘ON/OFF’ expression changes, where a
gene is detected in only one condition, and lopsided ex-
pression patterns, where upregulations drastically outweigh
downregulations or vice versa, influence specificity (false
positive rate) and sensitivity (false negative rate) of each
method unequally. Nonetheless, some methods appear to
capture the true expression status of small RNAs better
than others. Most independent evaluations seem to agree
that calling differential expressionwith SAMSeqworks well
for datasets with sufficient sample sizes of 10 or more. For
smaller datasets, edgeR and especially the more conserva-
tive DESeq (or DESeq2) are found to be the methods of
choice. On top of that, the voom + limma method was re-
ported to generally performwell for different datasets (216).
Additionally, a recent publication onRNA-Seq showed that
most of the frequently used tools correctly assess differen-
tial gene expression when sufficient biological replication is
employed (28). For a low number of replicates, edgeR out-
performed its competitors, while DESeq exceled in exper-
iments with more than 12 replicates, suggesting that data
analysis tools need to fit the respective experimental setup.
Efforts with mixed results have also beenmade to weigh dif-
ferential expression results of variousmethods and combine
them to an optimized consensus bypassing the individual
flaws of each algorithm (219). Considering all this, choos-
ing the optimal tool for differential expression analysis is
still strongly dependent on the individual dataset, highlight-
ing once again the fact that researchers need to thoroughly
acquaint themselves with the details and specifics of their
individual setup and data distribution before starting any
analyses.
BIOMARKER IDENTIFICATION AND VALIDATION
After biomarker candidates have been identified in the dif-
ferential expression analysis, these markers have to be sta-
tistically validated. Since univariate analyses, like most dif-
ferential expression tests, treat each biomarker (i.e. small
RNA) as independent, they are unable to capture the com-
plete reality of highly multivariate (variables >> observa-
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tions) and correlated datasets such as NGS read counts. By
taking the synergies, antagonisms and redundancy inherent
in each NGS dataset into consideration, multivariate anal-
yses can reach much higher discriminative power and sep-
arate noise from signal (19,220). In reality, there will most
likely be no single valid transcriptional biomarker for the
physiological situation of interest. In most cases, only a set
ofmultiple biomarkers can ensure the high sensitivity, speci-
ficity and reliability needed for diagnostic and prognostic
analyses. Appropriately dealing with these data to retrieve
the desired outcome of a stable and valid biomarker signa-
ture is, however, not trivial.
The most promising approach is to first screen read
counts for general trends or potential outliers in an unsu-
pervised manner (no classification information is given to
the algorithm), and subsequently assess the discriminative
power of potential biomarker candidates (221). These anal-
yses generate clusters of similarities, specifically similar gene
expression patterns in the case of RNA-Seq, by using meth-
ods for dimension reduction combined with pattern recog-
nition technologies and visualize them in two- or three-
dimensional graphs (222). Similar to differential expression
profiling, read count lists need to be preprocessed. Input
data for any cluster or classification analysis can either be
normalized read counts, as described previously, or ratios
thereof, and in addition should be transformed to address
their skewed distribution. A simple shifted log transforma-
tion (log2 (n + 0.5)) to make the data conform to normal-
ity is most commonly used, but more sophisticated alter-
natives such as regularized log transformation (rlog, (200))
and variance stabilizing transformation (vst, (223)) might
be better suited for small RNA-Seq data (both algorithms
are implemented in DESeq2, (200)). Cluster algorithms are
implemented, for instance, in the base distribution of R, as
well as more comprehensive packages such as pcaMethods
(224) and the excellentmixOmics (225), or the commercially
available Simca-Q software (Umetrics).
Widely accepted unsupervised multivariate analyses in-
clude clustering analyses such as hierarchical clustering
(HCA), partitioning methods such as k-means and self-
organizing maps (SOM), as well as projections on latent
variables such as the powerful principal component analy-
sis (PCA). In agglomerative HCA, samples (or genes) start
as single entity clusters and are then joined step-by-step
based on a similarity measure and a linkage function, defin-
ing inter-cluster distances. For log-transformed data, it was
shown that Euclidian distances and Pearson correlation
perform well as distance measures, while complete linkage
(orWard’smethod) strictly surpass single or average linkage
functions (226). The result and graphical output of HCA is
a tree dendrogram emphasizing the distances between the
individual samples (or genes) with rising node lengths and
clusters can be obtained by, among others things, cutting at
fixed heights (227,228). Combining HCA of samples and
genes with a two-dimensional color-coded description of
the whole experimental matrix creates a heatmap, which al-
lows for easy detection of similarities and dissimilarities in a
read count list. AlthoughHCA is the still the most common
clustering algorithm, it is in most cases outperformed by
partitioning methods such as k-means and SOM (226,229).
Both work by subdividing the dataset into a predetermined
number of unhierarchical subsets based on randomly cho-
sen centroids. In k-means, samples (or genes) are iteratively
assigned to the closest centroid with each iteration replac-
ing the former centroid by the average of each entity in its
cluster until all samples (or genes) are set. In SOM, the cen-
troids are linked by a grid structure, and with each itera-
tion the closest centroid, as well as its neighbors, is moved
toward a randomly chosen sample (or gene). By gradually
shrinking the radius of each adjacent centroid, this will re-
sult in a grid of clusters comprising all samples (or genes)
with related expression patterns. Since both k-means and
SOM start with randomly placed centroids and the optimal
number of cluster is usually not apparent, these algorithms
should be rerun with random seeds and different numbers
of clusters to obtain a stable classification.
Even more information on potential biomarkers can
be obtained by PCA, which converts a multidimensional
dataset into a lower number of variables called principal
components (PCs) (228,230). The read count data is thus
decomposed in a score matrix describing small RNA genes,
a loadings matrix describing the samples, and a residual
matrix expressing deviations between the original variables
and the projections. PCs are calculated ranked with the first
PC accounting for the greatest variance in the dataset and
subsequent PCs comprising the respective maximum resid-
ual variance. Since PCs are computed orthogonally to each
other, they each describe independent sources of informa-
tion, and with decreasing variance explained by later PCs,
they can be used to separate systematic effects, explained
by the molecular biomarker set, from random expression
noise (227). Variance derived from experimental study de-
sign is expected to be systematic, while confounding vari-
ance is expected to be small and random and can therefore
be found in later PCs. The advantage of PCA in compari-
son to clustering and partitioning methods is obvious, since
it allows amuch clearer recognition andmore precise differ-
entiation of the experimental groups. In PCA, the common-
alities (or differences) in gene expression pattern are clearly
visualized by the symbol interspaces in at least two dimen-
sions (228,231). By plotting scores and loadings plots side
by side and looking at their corresponding positioning, it
is also possible to identify which small RNA genes are re-
sponsible for the separations of samples. Potential biomark-
ers can be assessed by their contribution plots, and outliers
can be detected by either Hotelling’s T2 or by their residual
standard deviation (distance to model, DModX) (232).
All of the unsupervised methods mentioned above gen-
erate groupings of samples (or genes) with similar expres-
sion patterns.While this allows for easy detection of outliers
and inconsistencies in experimental setup, it does not nec-
essarily mean that resulting clusters will reflect the desired
classification of samples or genes. An underlying treatment
effect can sometimes be veiled by other dominating effects,
be they intentional (different cell types, time points etc.) or
not (batch effects). By incorporating information on exper-
imental setup, researchers are able to filter out genes induc-
ing the greatest separation between treatment groups or,
in other words, potential biomarkers. Although a number
of supervised classifications algorithms exist, it was shown
that the widely used partial least squares projection to latent
structures (PLS) and its modifications such as PLS discrim-
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inant analysis (PLS-DA, (233)), sparse PLS-DA (sPLS-DA,
(234)) or orthogonal PLS (OPLS, (235)) are well suited for
dimension reduction and discrimination (233,236).
PLS is related to linear discriminant analyses (LDA), and
is a regression extension of PCA that shares many char-
acteristics with it. By adding a second matrix containing
the responses or dependent variables to the read count ma-
trix, PLS attempts to find latent variables (LV) that pre-
dict the responses from gene expression profiles and de-
scribe the common structure of both matrices. LVs are cal-
culated hierarchically similar to PCs, but LVs maximize co-
variance instead of variance. In PLS-DA, the response ma-
trix is replaced by an optimized dummy matrix containing
only 0 and 1 for every respective class, and the resulting pro-
jection model therefore focuses on maximum discrimina-
tion between classes in the responses rather than ‘optimal
class modeling’ (221). Biomarkers can then be evaluated
by a number of variable selection methods including vari-
able importance in projection (equivalent to a contribution
plot in PCA) or target projection with selectivity ratio test
(237), and by drawing a consensus between differentially ex-
pressed genes and multivariate analyses.
The biological functionality of detected small RNA
biomarkers, mainly based on miRNAs, can be further veri-
fied in functional experimental tests using miRNA overex-
pression, knockdown or even knockout experiments. Var-
ious tools and software packages are available for the in
silico functional analysis of miRNAs. For in silico target
prediction, we recommend the TargetScan package (http:
//www.targetscan.org/) (238,239) or miRanda (http://www.
microrna.org/) (240,241). For analyzing the inverse relation
of expressed miRNAs andmRNAs in conjunction with tar-
get predictions, we recommend using a Lasso regression
model (242,243). If an integrative analysis of miRNAs and
their target genes is of interest, the miRNA–mRNA re-
lations can be tested on the basis of regression analysis,
and further processed by testing for enrichment in gene on-
tology terms or KEGG pathways (http://www.genome.jp/
kegg/pathway.html), amongst others (244,245). In addition,
several all-in-one software packages such asCLCGenomics
Workbench (Qiagen), Ingenuity Pathway Analysis (Qiagen)
or Genomatix Genome Analyzer (Genomatix) are avail-
able to allow a relatively easy, graphic user interface (GUI)-
based in silico functional analysis of miRNAs. Applying
Genomatix Pathway System (GEPS) or Ingenuity Pathway
Analysis facilitates the creation and extension of miRNA
networks based on information extracted from public and
proprietary databases and co-citations in the literature.
Conclusion - where are the real bottlenecks?
Today, liquid biopsies and the small RNA biomarker sig-
natures they may inclose are considered the promising new
generation of transcriptional biomarkers. The RNA is eas-
ily accessible, often by non-invasive procedures, physiolog-
ically stable and protected by microvesicles or associated
proteins. Due to its chemical nature, it can be rapidly am-
plified and quantified using RT and PCR-related methods.
Small RNA-based biomarker signatures can therefore be
detected at low concentrations and early disease stages, and
the discovery workflow can be further optimized and stan-
dardized. This sustains the idea of the MIQE and dMIQE
guidelines previously published by an international consor-
tium (headed by SA Bustin and JF Huggett) in the field of
qPCR and dPCR (21,22).
Thoroughly and accurately following our recommenda-
tions by optimizing and standardizing the small RNA-
Seq workflow will result in reproducible data and, subse-
quently, reliable hypotheses. The digital and holistic na-
ture of the small RNA-Seq approach provides vast tran-
scriptional data that is highly informative in terms of both
quality and quantity (246). The subsequent complex, com-
parative and multivariate data analysis can result in valid
biomarker signatures. The technological developments in
the entire workflow (from sampling to multivariate data
analysis) are very dynamic, and will continue to improve in
the future. While proven standards and optimized method-
ologies to identify promising biomarkers in liquid biopsies
are still lacking, the optimization and validation process will
continue to develop.
Where are the real bottlenecks in small RNA-Seq analysis of
liquid biopsies? The most significant factor leading to suc-
cess is probably the number of variables and conditions be-
ing tested, and the number of real biological replicates used
for sequencing. What appears to be specific in the particu-
lar biological samples analyzed by small RNA-Seq may not
necessarily be reflected in a larger group, or even in the en-
tire population. Therefore, the more individuals tested, and
the more conditions or variables being evaluated, the better
the outcome of the prediction and the validity of the discov-
ered biomarker signature will be (247,248).
No step in the workflow is free of bias, but some are
more prone to produce noise in the resulting data. Due to
financial reasons, researchers still employ too few biolog-
ical replicates. Only biological replicates can explain any
biological difference, while technical replicates are limited
to only report the technical noise researchers introduce. In
our opinion, the largest noise impact is introduced by RNA
extraction and the complex library preparation, which can
be performed in various ways, but always highly depends
on enzyme efficiency. Depending on the respective library
preparation chemistry, numerous individual barcodes are
used. These not only cause technical bias, but also affect
RT efficiency and PCR amplification.
In general, it is recommended to perform as few PCR cy-
cles as possible for pre-amplification, and to only compare
replicates with the identical number of cycles. The sequenc-
ing or clonal amplification as such is not a major source
of variation, since error rates of polymerases are accept-
ably low, sequencing chemistry exhibits high purity and the
hardware operates very precisely and reproducibly. A fur-
ther big challenge is the off-instrument data analysis, which
requires the majority of manpower and time in the quan-
tification workflow. We should put major focus on align-
ment, normalization and differential expression analysis,
since these are the most critical steps. Biases introduced at
earlier stages can in part be corrected and compensated by
an appropriate normalization strategy.
As a final and essential step after small RNA-Seq, we rec-
ommend additional validation of the identified transcrip-
tional biomarker signatures. This confirmation should be
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carried out using established and highly standardizedmeth-
ods such as RT in combination with real-time PCR or digi-
tal PCR. The consistency and correctness of the discovered
transcriptional biomarker signature in the liquid biopsy can
only be assumed after data verification and demonstration
of a statistically validated correlation between small RNA-
Seq and RT-qPCR or dPCR.
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ABSTRACT
Extracellular vesicles (EVs) are intercellular communicators with key functions in physiological and
pathological processes and have recently garnered interest because of their diagnostic and
therapeutic potential. The past decade has brought about the development and commercializa-
tion of a wide array of methods to isolate EVs from serum. Which subpopulations of EVs are
captured strongly depends on the isolation method, which in turn determines how suitable
resulting samples are for various downstream applications. To help clinicians and scientists
choose the most appropriate approach for their experiments, isolation methods need to be
comparatively characterized. Few attempts have been made to comprehensively analyse vesicu-
lar microRNAs (miRNAs) in patient biofluids for biomarker studies. To address this discrepancy, we
set out to benchmark the performance of several isolation principles for serum EVs in healthy
individuals and critically ill patients. Here, we compared five different methods of EV isolation in
combination with two RNA extraction methods regarding their suitability for biomarker discov-
ery-focused miRNA sequencing as well as biological characteristics of captured vesicles. Our
findings reveal striking method-specific differences in both the properties of isolated vesicles
and the ability of associated miRNAs to serve in biomarker research. While isolation by precipita-
tion and membrane affinity was highly suitable for miRNA-based biomarker discovery, methods
based on size-exclusion chromatography failed to separate patients from healthy volunteers.
Isolated vesicles differed in size, quantity, purity and composition, indicating that each method
captured distinctive populations of EVs as well as additional contaminants. Even though the focus
of this work was on transcriptomic profiling of EV-miRNAs, our insights also apply to additional
areas of research. We provide guidance for navigating the multitude of EV isolation methods
available today and help researchers and clinicians make an informed choice about which
strategy to use for experiments involving critically ill patients.
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Introduction
A multitude of isolation methods for extracellular vesi-
cles (EVs) has been developed and commercialized in
the last decade. Many methods claim rapid, reliable
and highly efficient isolation from serum, yet there is
no consensus on each method’s suitability for scientific
and clinical applications. Comparative data on meth-
ods for isolating EVs from patient biofluids are scarce,
despite clear interest in utilizing EVs and their miRNA
cargo for biomarker studies. Further, few attempts have
been made to comprehensively analyse vesicular
miRNAs in biofluid samples from critically ill patients,
a population highly relevant to many clinical situations.
This work compares five different methods of EV iso-
lation and their suitability for miRNA-based biomarker
discovery. We isolated serum EVs from sepsis patients
and healthy volunteers, sequenced their small RNA
cargo and performed differential miRNA expression
analysis. Additional experiments assessed method-spe-
cific differences in vesicle composition and morphol-
ogy. Our data reveal that precipitation and membrane
affinity are highly suitable for both small RNA-Seq and
patient classification based on cell-free miRNAs.
Comparative evaluation demonstrates that miRNA
yield correlates with robust separation of sepsis patients
and healthy individuals, while vesicle purity seems less
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relevant for RNA-based biomarker applications.
Differences in size, quantity and composition of iso-
lated vesicles indicate that each method captures dis-
tinctive, but partially overlapping EV populations
accompanied by varying degrees of contamination
with non-EV material.
EVs are intercellular communicators with key func-
tions in physiological and pathological processes and
have recently garnered significant interest as potential
diagnostic and therapeutic agents. Rapidly increasing
research in this field is accompanied by the demand for
reproducible, time-efficient and economic isolation
methods. A recent survey conducted by Gardiner
et al. revealed that although ultracentrifugation (UC)
remains the most commonly used isolation method,
other approaches have gained preference when starting
volume is limited [1]. Capturing EVs from blood-based
biofluids such as serum and plasma is of particular
interest for clinical applications. As a consequence,
manufacturers offer a wide array of commercial isola-
tion kits. These rely on principles ranging from filtra-
tion, precipitation and sedimentation to size-exclusion
chromatography (SEC) and immunocapture.
One of the most important aspects of EV research is
analysing their nucleic acid cargo, particularly small
RNAs. These are commonly quantified by RT-qPCR
or, increasingly, comprehensive transcriptomic profil-
ing by next-generation sequencing (NGS, small RNA-
Seq). Applications of EV transcriptomics range from
basic research to biomarker discovery and drug devel-
opment, making use of EVs as an easily accessible,
enriched sampling fraction [2,3]. Inferring credible
information from the transcriptome relies on precise
quantification of target RNA, which in turn requires
samples of high quality and integrity [4]. Additionally,
methods for RNA extraction itself influence down-
stream analyses by yielding non-identical, kit-specific
isolates [5]. This holds true particularly for extracellu-
lar RNA, which bears additional challenges such as low
concentrations, diminished RNA integrity and high
variability between individuals. Indeed, recent publica-
tions have highlighted the impact of cell-free RNA
extraction strategies on small RNA-Seq, reporting
quantitative and qualitative differences in resulting
sequencing libraries [6,7].
Similarly, the impact of EV isolation strategies on
RNA quantification assays has been demonstrated for
cell culture supernatant [8], urine [9,10], milk [11] and
serum [12]. Depending on the respective isolation
principle, different populations of EVs with varying
degrees of contamination seem to be isolated, resulting
in only partially overlapping RNA profiles. Being able
to detect specific RNA patterns in bulk populations of
blood-derived EVs is challenging due to the vesicular
secretome’s complexity. Although most EVs in blood
are secreted by erythrocytes, platelets and endothelial
cells, various other tissues also secrete vesicles into the
circulation, further complicating analysis [13,14].
Multiple classes of EVs are secreted from even one
specific cell type, each carrying its individual RNA
signature [15]. Beyond RNA profiles, kit-specific iso-
lates also differ in EV composition, size, concentration,
purity and functionality [16–20]. Selecting appropriate
isolation methods is therefore a critical step in all areas
of EV research.
There are excellent publications comparing different
strategies of isolating EVs from human serum for RNA
analyses. Rekker et al., Andreu et al. and Crossland
et al. relied on RT-qPCR to profile vesicular miRNAs,
comparing isolation based on UC, precipitation and
filtration [12,21,22]. Helwa et al. isolated EVs from
different starting volumes by precipitation and UC
and quantified associated miRNAs by droplet digital
PCR [23]. Analysing EV miRNAs using PCR-based
assays is an important and well-established approach
supported by excellent protocols and methods [24–26].
However, as NGS has become an increasingly popular
downstream application to study miRNAs in EVs, it is
crucial to define the EV isolation method most suitable
for this particular technique. Several previous publica-
tions reported the feasibility and utility of sequencing
small RNA in EVs isolated from serum, plasma, urine,
and cell culture supernatant [2,27–30]. Small RNA-Seq
experiments often focus on valuable applications such as
liquid biopsy-based diagnostics and, consequently, clin-
ical samples. Screening potential isolation methods
should therefore include samples from healthy indivi-
duals as well as diseased patients, who often display
severe anomalies in blood parameters. These matrix
effects could conceivably interfere with EV isolation
and hamper the transfer of methodologies from healthy
to diseased subjects. Prime examples of critically ill
patients are individuals suffering from sepsis and septic
shock. This complex, life-threatening disease comes
along with various clinical complications such as multi-
ple organ failure, dysregulated coagulation and altered
blood lipid profiles [31,32]. Findings derived from com-
paring EV isolation strategies for healthy donors, how-
ever, might not be readily transferred to such challenging
samples. We therefore believe it is important to verify
each method’s applicability in samples relevant for the
respective clinical situation.
The objective of the current study was to compare
several methods of isolating EVs from healthy and
septic sera and to identify the one most suitable for
biomarker-focused small RNA-Seq in this population
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of critically ill patients. Routine biomarker applications
call for time-efficient, simple and streamlined proce-
dures, ideally provided to clinical laboratories as one-
box solutions. We did therefore not screen all potential
combinations of EV isolation and RNA extraction
methods but focused on either recommended RNA
kits by the same manufacturer or combinations com-
monly used in the EV field. Additionally, isolates from
each method were comparatively characterized in order
to assess method-specific differences in captured EV
populations and potential contaminating material.
Material and methods
Ethics approval and consent to participate
The study was approved by the Ethics Committee of the
Medical Faculty of the University of Munich (protocol
#551-14). Written informed consent and approval of a
patient’s legal representative was obtained when the
patient lacked capacity to give informed consent for par-
ticipation in the study. The study was carried out in
accordance with approved guidelines, and all study sam-
ples were anonymized during analysis. Written informed
consent for publication of blinded individual person’s
data was obtained from each participant or the patient’s
legal representative.
Patient recruitment
Four patients with sepsis and five patients in septic shock
were included in the study and sex-matched to 10 healthy
volunteers (Supplemental Table 1). Patients included in
the study were >18 years of age and within 24 h of admis-
sion to the intensive care unit (ICU). Exclusion criteria
were pregnancy, immunosuppression, leukopenia, haema-
tological malignancies or the initiation of palliative care.
Healthy volunteers were recruited from hospital personnel
and by advertisement. Only volunteers with a Charlson
Comorbidity Index [33] of ≤1 were included.
Sample collection
Blood was drawn from 20G catheters within the radial
artery of sepsis patients on the day of admission to the
ICU (day 0) and 24 h later (day 1). Healthy volunteers
were sampled by venipuncture using 20G needles. In
order to prevent haemolysis, aspiration was performed
slowly and evenly for both procedures. Blood was col-
lected in 9 ml serum tubes (S-Monovette, Sarstedt
AG&Co) and centrifuged at 3400 g for 10 min at
room temperature (RT) within 10 min of sampling.
Resulting serum was aliquoted and stored at −80 °C.
Isolation of extracellular vesicles
EVs were isolated from serum using four commercially
available isolation kits as well as differential UC
(Table 1). One millilitre serum from each patient and
volunteer was used as starting material for all isolation
methods. EV isolation was performed as detailed
below, following manufacturer’s recommendations for
pre-clearing of serum and subsequent steps. For all
commercial isolation methods, we sequenced vesicular
RNA from both patients and volunteers. Small RNA-
Seq was performed for all samples except in the case of
UC-derived EVs where it was only performed for
healthy volunteers, but not for sepsis patients, as
serum availability was limited. Serum EVs from day 0
were used for RNA extraction and small RNA-Seq.
Five septic shock patients and five matched volun-
teers from our small RNA-Seq cohort were selected for
additional biological characterization of EVs. In these
supplemental experiments, we isolated EVs from 1 ml
serum sampled on day 1 of intensive care therapy in
patients with sepsis. These day 1 EVs were isolated as
described below, concentrated to 50 µl using Amicon
Ultra-4 30 kDa NMWL spin filters (Merck Millipore)
and split into separate aliquots for protein analysis and
particle characterization, respectively. A schematic dia-
gram that summarizes all steps of the EV isolation and
characterization workflow is provided in Figure 1.
Precipitation
EVs were precipitated from 1 ml serum using the
miRCURY Exosome Isolation Kit (Exiqon) according to
the manufacturer’s instructions. For RNA extraction, EV
pellets were lysed with the provided miRCURY biofluid
Table 1. EV isolation methods and RNA extraction kits utilized in this study.
Principle of EV isolation Method RNA extraction kit
Precipitation miRCURY Exosome Isolation Kit (Exiqon) miRCURY RNA Isolation Kit – Biofluids (Exiqon)
Size-exclusion chromatography Exo-spin Midi Columns (Cell Guidance Systems) miRCURY RNA Isolation Kit – Biofluids (Exiqon)
Size-exclusion chromatography qEV Columns (Izon Science) miRCURY RNA Isolation Kit – Biofluids (Exiqon)
Membrane affinity exoRNeasy Serum-Plasma Midi Kit (Qiagen) exoRNeasy Serum/Plasma Midi Kit (Qiagen)
Sedimentation Differential ultracentrifugation
(Beckman Coulter Optima LE-80K)
exoRNeasy Serum/Plasma Midi Kit (Qiagen)
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lysis solution. Pellets for biological characterization were
resuspended in phosphate-buffered saline (PBS).
Size-exclusion chromatography
For Exo-spin (Cell Guidance Systems), EVs from 1 ml
serum were purified on the provided columns and
eluted in 3 ml particle-free PBS according to the man-
ufacturer’s quick start protocol. For qEV (Izon
Science), columns were equilibrated, overlaid with 1
ml serum and flushed with particle-free PBS, collecting
sequential fractions of 0.5 ml. Fractions 7–9 were
pooled to maximize EV yield.
Membrane affinity
Pre-cleared serum was applied to exoEasy columns
(Qiagen) as per the manufacturer’s protocol. EVs
were captured and washed using reagents provided in
the kit. For RNA extraction, EVs bound to the mem-
brane were lysed by adding QIAzol (Qiagen). Intact
EVs for biological characterization were eluted from
the column by addition of the provided buffer XE
(analogous to the procedures in Qiagen’s exoEasy kit).
Sedimentation
Serum was diluted 1:4 in PBS and subjected to low-
speed centrifugation (12,000 g, 1 h, k-factor: 1401.3).
EVs from the pre-cleared supernatant were then pel-
leted at 120,000 g for 14 h (k-factor: 139.7). All
centrifugation steps were carried out at 4°C using an
Optima LE-80K ultracentrifuge (Beckman Coulter) and
a SW60 rotor. Pellets were lysed in QIAzol for RNA
extraction or resuspended in PBS for EV
characterization.
RNA extraction and characterization
Total RNA was extracted from day 0 serum EVs using
commercial column-based kits listed in Table 1. For all
extraction methods, RNA eluates were reapplied to the
membrane for a second elution.
Precipitation
RNA was extracted from EV lysates using the corre-
sponding miRCURY RNA Isolation Kit for biofluids.
Procedures were carried out according to the manufac-
turer’s protocol, and RNA was eluted in 30 µl nuclease-
free water.
Size-exclusion chromatography
Eluted EVs (Exo-spin: 3 ml; qEV: 1.5 ml) were con-
centrated to 200 µl on Amicon Ultra-4 30 kDa NMWL
spin filters. RNA was subsequently extracted from the
concentrate using the miRCURY biofluids kit as
described above.
Figure 1. Schematic summary of EV isolation, RNA extraction and downstream analyses. EVs were isolated from human serum using
five (healthy donors) or four (sepsis patients) different methods. After extracting total RNA from EV isolates, small RNA species were
profiled by NGS. Differential expression of miRNAs between volunteers and patients was assessed to identify potential biomarker
candidates. Sera from a subset of volunteers and patients were used to additionally characterize isolates from each method by
Western blot (WB), nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM).
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Membrane affinity
RNA was extracted from EVs lysed in QIAzol using
reagents provided in the exoRNeasy kit. Procedures
were carried out according to the manufacturer’s pro-
tocol, and RNA was eluted in 14 µl nuclease-free water.
Differential UC
Following lysis of pellets in QIAzol, RNA was extracted
using the exoRNeasy kit as described above.
In order to compensate for the varying elution
volumes, all RNAs were gently dried in a centrifugal
evaporator and resuspended in 10 µl nuclease-free
water. Yield and size distribution of EV-RNA were
assessed by capillary electrophoresis on the 2100
Bioanalyzer (Agilent Technologies). We used the
RNA 6000 Pico Assay (Agilent Technologies) to assess
the total RNA profile including potential contamina-
tions with cellular RNA.
Next-Generation Sequencing
EV-RNA from sepsis patients and healthy volunteers
was profiled by small RNA-Seq. For all isolation meth-
ods, we used 60% (6 µl) of eluted total RNA as starting
material. Library preparation was performed as
described in Reithmair et al. [34], using the NEBNext
Multiplex Small RNA Library Prep Set for Illumina
(New England BioLabs Inc.). To compensate for the
low RNA input, all adaptors and primers were diluted
1:2 in nuclease-free water. Size selection of PCR pro-
ducts was performed by high-resolution 4% agarose gel
electrophoresis, selecting bands of 130–150 base pairs.
Fragment sizes of purified libraries were assessed using
capillary electrophoresis prior to 50 cycles of single-end
sequencing on the HiSeq2500 (Illumina Inc.).
Data analysis
Sequencing data were processed as described elsewhere
[35]. Briefly, FastQC (version 0.10.1) [36] was used to
assess sequence length distribution and quality. Adaptor
sequences were trimmed using Btrim [37], and all reads
without adaptors were discarded. Additionally, reads
shorter than 16 nt, probably degradation products from
longer coding and non-coding RNA species, were
excluded from the data set before proceeding to align-
ment [4]. To avoid false-positive hits during miRNA
analysis, reads that mapped to sequences from human
rRNA, tRNA, snRNA and snoRNA (obtained from
RNAcentral) were initially removed from the data set
[38]. Remaining reads were then aligned to human
miRNA sequences in the most recent version (21) of
miRBase [39]. Mapping was performed using Bowtie
[40] and the “best” alignment algorithm, allowing one
mismatch for alignment to both RNAcentral and
miRBase. For all RNA classes, final read count tables
were generated directly from Bowtie output by summing
up all hits per sequence. Differential gene expression
(DGE) analysis was subsequently performed via the
Bioconductor Package DESeq2 (version 1.8.1) [41]
using the included normalization strategy based on med-
ian ratios of mean miRNA expression and the
Benjamini–Hochberg method to correct for false discov-
ery. A log2 fold change ≥|1| and an adjusted p-value of
≤0.05 were set as thresholds to identify significantly regu-
lated miRNAs. Only transcripts with a baseMean ≥50
were included in the analysis. Hierarchical clustering
(Euclidean distances, Ward’s method), principal compo-
nent analysis (regularized log-transformed, sizefactor-
corrected counts obtained from DESeq2) and visualiza-
tion of significantly regulated miRNAs in Venn diagrams
were carried out in R (version 3.4.0) using the packages
gplots, ggplots2, RColorBrewer, dendextend, ggfortify
and VennDiagram [42–48]. Trimmed sequence reads
were deposited in the European Nucleotide Archive
under accession number PRJEB24913 (http://www.ebi.
ac.uk/ena/data/view/PRJEB24913).
Nanoparticle tracking analysis
EV suspensions were diluted in particle-free PBS (pre-
pared by a 120,000 g spin at 4°C for 14 h, k-factor:
231.6) and analysed using a NanoSight LM10 (Malvern
Instruments GmbH) equipped with a 405-nm laser and
a high-sensitivity sCMOS camera. Samples were intro-
duced manually, and six videos of 45 s each were
captured at a frame rate of 25 frames/second. With
sample temperatures monitored manually, individual
particles were tracked using NTA 3.0 software
(Malvern Instruments GmbH) at camera level 10 and
the Finite Track Length Adjustment (FTLA) algorithm.
For analysis, we used a conservative detection thresh-
old with blur and minimum track length set to auto
and only considered captures with at least 2000 com-
pleted tracks. Starting from concentrations measured
by NTA, initial particle concentrations in serum were
calculated using the respective dilution factors for each
sample as described elsewhere [49].
Transmission electron microscopy
EVs were fixed in 2% paraformaldehyde and adsorbed
onto formvar/carbon-coated 200-mesh nickel grids
(Electron Microscopy Sciences) for 15 min. Grids
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were then washed with PBS, fixed in 2.5% glutaralde-
hyde for 5 min and washed with milliQ water. After
performing negative staining with 2% uranyl acetate
for 1 min, grids were washed again and air-dried over-
night. Images were acquired on a Zeiss EM900 (Carl
Zeiss Microscopy GmbH) with a wide-angle dual-speed
2K-CCD camera at 80 kV.
Western blot
EV samples were lysed in ice-cold
Radioimmunoprecipitation Assay (RIPA) buffer on
ice for 15 min intermitted by three bouts of sonica-
tion in a water bath. After centrifugation at 13,000 g
for 10 min, protein concentration in the supernatant
was analysed using Bicinchoninic Acid (BCA) assay
(Sigma Aldrich). Input for exoRNeasy, Exo-spin,
miRCURY and UC was normalized to 25 µg total
protein. Due to very low protein concentrations,
maximum volumes were loaded on the gel for qEV.
For electrophoresis, samples were reduced in
Laemmli buffer and heated at 70 °C for 10 min.
Protein lysates for analysis of CD63 were incubated
with non-reducing sample buffer at RT for 20 min.
Proteins were separated using NuPAGE 4–12% Bis-
Tris Gels (Invitrogen) prior to transfer to a 0.45 µm
nitrocellulose membrane (GE Healthcare Life
Sciences). Membranes were blocked with 1% non-
fat milk powder in Phosphate Buffered Saline with
Tween (PBST) for 1 h at RT and incubated with
primary antibodies at 4°C overnight. Secondary anti-
bodies were added for 1 h at RT. After washing with
blocking buffer, blots were developed using the
Clarity Western ECL Blotting Substrate Kit (Bio-
Rad). Primary antibodies were from Abcam (mouse
anti-TSG101 clone 4A10, ab83, 1:800, rabbit anti-
Syntenin clone EPR8102, 1:5000, ab57113, 1:250,
mouse anti-CD63, clone TS63, ab59479, 1:500,
mouse anti-Human Serum Albumin clone 1A9,
ab37989, 1:250), OriGene (rabbit anti-CD81,
TA343598, 1:500) and Biomol (goat anti-Calnexin,
WA-AF1179a, 1:2500). All marker proteins except
CD63 were analysed using reducing conditions.
HRP-conjugated secondary antibodies were pur-
chased from Abcam (goat anti-Mouse, ab97040,
1:10,000, goat anti-Rabbit, ab97080, 1:10,000, rabbit
anti-Goat, ab97105, 1:10,000).
Results
Analysis of isolation-specific EV-RNA composition
by small RNA-Seq
Total EV-RNA was characterized by capillary electro-
phoresis, revealing major differences in quantity and
size distribution across EV isolation strategies
(Supplemental Figure 1). Similarly, sequencing of
small RNA resulted in vastly differing total library
sizes, ranging from 3.68E6 ± 1.72E6 reads (qEV sepsis)
to 1.17E7 ± 3.76E6 reads (UC volunteer). Two EV
samples precipitated from sepsis patients did not prop-
erly amplify during sequencing and were excluded
from subsequent analyses. Method-dependent capture
of miRNAs was assessed by aligning reads to miRBase
and expressing mapped miRNAs as percentages of
library size (Figure 2). miRNA enrichment was highest
for precipitation-based EV isolation, followed by UC,
membrane affinity and SEC. Even though library sizes
were similar for UC, exoRNeasy and miRCURY, the
latter displayed a 3.5–5-fold higher percentage of
mapped miRNAs, respectively. For all isolation meth-
ods, relative frequencies of mapped miRNAs for sepsis
patients were slightly lower than for volunteers
(Figure 2). The top 10 most highly expressed miRNAs
for each method are provided in Supplemental Table 2.
Figure 2. Mean library size and mapped miRNAs for EVs isolated from healthy volunteers (a) and sepsis patients (b). miRNA
mapping frequencies (red diamonds) are expressed as percentages of total library size and plotted against the right x-axes.
Enrichment of miRNA reads was highest for miRCURY (35.08% and 27.56% for volunteers and patients, respectively) and lowest for
qEV (0.79% for volunteers and 0.57% for patients). All data are mean ± SD for 10 volunteers and 9 sepsis patients.
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Similar differences were found when mapping reads
to further classes of small non-coding RNA (Figure 3).
Expressed as the ratio of non-target reads to miRNA
reads, both SEC-based methods tended to isolate more
rRNA fragments than other methods (Supplemental
Figure 2). Increased frequencies of rRNA reads were
also observed in sepsis EVs isolated by membrane
affinity. Additionally, membrane affinity captured sig-
nificantly more tRNA fragments than other methods
from both septic and healthy EVs. SEC-based methods,
particularly qEV, also isolated large numbers of frag-
ments shorter than 15 nt. Mean library sizes, mapped
miRNAs and results from DGE are provided in
Supplemental Table 3.
EV-miRNAs from precipitation and membrane
affinity separate volunteers and patients
DESeq2 was used to assess differential regulation of
miRNA levels between sepsis patients and volunteers
for commercial isolation kits. After applying stringent
filtering criteria (baseMean ≥50, log2 fold change ≥|1|,
adjusted p-value ≤0.05), we found 6 (qEV), 14 (Exo-
spin), 60 (exoRNeasy) and 90 (miRCURY) miRNAs to
be significantly regulated. While there was minimal
overlap between all EV isolation strategies, most
regulated miRNAs were unique for a specific isolation
method (Figure 4). A common set of two significantly
regulated miRNAs was detected for all EV isolation
methods. Data for unfiltered differential expression
analysis are provided in Supplemental Figure 3.
Similarities between miRNA patterns from each
patient and isolation method were assessed by hier-
archical clustering analysis (HCA) (Figure 5). Based
on all miRNA reads, HCA separated isolation by pre-
cipitation, UC and membrane affinity from both SEC-
based methods. Within these principal clusters, preci-
pitation and membrane affinity flawlessly separated
sepsis patients from healthy volunteers. Even though
samples from precipitation and UC showed a high
degree of similarity, UC volunteers were more closely
related to miRCURY sepsis patients. Clustering of
miRNAs from SEC isolation revealed substantial het-
erogeneity within and overlap between qEV and Exo-
spin. Subsequently, these methods did not accurately
distinguish volunteers from patients. This was also
demonstrated by principal component analysis
(Supplemental Figure 4), where separation of patient
groups was achieved exclusively by miRCURY and
exoRNeasy.
The number of differentially regulated miRNAs
detected in DESeq2 analysis varied significantly
Figure 3. Mapping statistics for various classes of small non-coding RNA. Highest frequencies of miRNA mapping were observed in
isolates from precipitation, sedimentation and membrane affinity. Both SEC-based methods were prone to capture short sequences,
while libraries from membrane affinity-derived samples contained an increased share of tRNA fragments. Short: sequence is shorter
than 15 nt; unmapped: sequence did not align to human rRNA, snRNA, snoRNA, tRNA or miRNA. Data are expressed as mean
mapping percentages for 10 volunteers (V) and 9 sepsis patients (S).
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between isolation methods (Figure 4). Differentially
expressed miRNAs as well as corresponding log2 fold
changes and adjusted p-values for each method are
provided in Supplemental Table 4. As predicted by
sequencing output, methods yielding larger libraries
also tended to result in more dysregulated miRNAs
and greater fold changes. A common set of two
miRNAs was found to be differentially expressed in
EVs isolated by all methods. In EVs from sepsis
patients, miR-122-5p was upregulated with log2 fold
changes of 1.86 (Exo-spin) to 4.53 (exoRNeasy). miR-
151a-3p, on the other hand, was downregulated in
septic EVs, displaying log2 fold changes of −1.18
(miRCURY) to −1.65 (exoRNeasy) (Table 2).
EV populations isolated by divergent methods
differ in size, concentration and purity
EVs captured by all isolation methods were analysed by
NTA. Mean and mode particle diameters ranged from
104.46 ± 11.96 nm and 80.02 ± 10.12 nm (miRCURY
volunteer) to 202.86 ± 10.70 nm and 174.48 ± 18.20 nm
(exoRNeasy volunteer), respectively (Figure 6(a)). Size dis-
tributions for sepsis patients were slightly broader for all
Figure 4. Differential expression of miRNAs in EVs isolated by commercial methods. Precipitation and membrane affinity yielded
high numbers of differentially regulated miRNAs (miRCURY: 90; exoRNeasy: 60). Far fewer regulated miRNAs were detected in SEC-
derived samples (Exo-spin: 14; qEV: 6). Two differentially regulated miRNAs were detected in EVs isolated by all methods. Data are
filtered for baseMean ≥50, log2 fold change ≥|1| and adjusted p-value ≤0.05.
Figure 5. Hierarchical clustering analysis of miRNAs in EVs isolated by commercial methods. Samples split up into two clusters,
separating precipitation and membrane affinity from both SEC-based methods. miRCURY (blue) and exoRNeasy (red) accurately
distinguished between healthy volunteers (darker shades, V) and sepsis patients (lighter shades, S). miRNAs isolated from SEC-EVs
(Exo-spin, qEV) showed noticeable heterogeneity and were less capable of separating volunteers and patients.
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isolation methods except qEV, but no significant differ-
ences in particle diameter were detected between volun-
teers and patients. The total number of particles isolated
from 1 ml serum was highest for miRCURY, followed by
Exo-spin, qEV, UC and exoRNeasy (Figure 6(b)).
Additional plots for particle diameter and concentration
are provided in Supplemental Figure 5.
Estimates for sample purity were calculated as ratios
between NTA particle counts and protein concentra-
tions [50]. While calculating these ratios does not
necessarily help characterize a sample’s EV fraction
and their homogeneity, it provides a useful metric for
assessing to which degree a sample is contaminated
with non-EV protein. SEC-based isolation yielded iso-
lates with significantly higher particle to protein ratios
than all other methods, indicating less co-isolation of
soluble protein (Figure 6(b)). Isolates derived from
precipitation and UC, on the other hand, displayed
the lowest ratios due to increased protein contamina-
tion. Additional data on particle size, concentration
and purity are included in Supplemental Table 5.
Next, we assessed particle morphology by TEM.
Confirming our findings from NTA, we detected par-
ticles with EV morphology and size for all isolation
methods (Figure 7). While the majority of vesicles were
less than 200 nm in diameter for all methods, precipi-
tation-derived EVs seem to be additionally enriched for
particles smaller than 100 nm.
Enrichment of contaminating soluble protein in EVs
isolated by precipitation and UC
Prior to immunoblotting, total protein in EV lysates
from each method was quantified by BCA assay.
Table 2. Common set of miRNAs differentially regulated between sepsis and healthy controls for all
EV isolation methods.
miR-122-5p
Isolation method log2FC p-adj
exoRNeasy 4.53 6.72E-17
qEV 2.11 2.73E-04
Exo-spin 1.86 2.72E-04
miRCURY 2.88 1.42E-07
miR-151a-3p
Isolation method log2FC p-adj
exoRNeasy −1.65 4.61E-10
qEV −1.55 4.97E-06
Exo-spin −1.19 3.92E-02
miRCURY −1.18 5.72E-03
Log2FC: log2 fold change; p-adj: DESeq2-adjusted p-value.
Figure 6. Analysis of EVs by NTA demonstrates differences in size distribution (a). Whiskers indicate 1st and 99th percentiles; line:
mean diameter; dot: modal diameter; V: volunteer; S: sepsis patient. Precipitation- and membrane affinity-based methods isolated
the smallest and largest EVs, respectively. Concentration and purity of isolated EVs differed depending on isolation strategies (b).
Black bars indicate the absolute number of vesicles isolated from 1 ml serum; red diamonds plotted against the right x-axis
represent vesicle purity defined as the particle to protein ratio. While precipitation most efficiently isolated EVs from serum, SEC-
based isolation yielded fewer but highly pure vesicles. Asterisks indicate significant differences in particle numbers compared to
miRCURY. *p < 0.05; **p < 0.01; NS: not significant. All data are mean ± SD for five volunteers and five sepsis patients.
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Similar to initial RNA concentrations and sequencing
library sizes, striking differences in protein yield were
observed (Supplemental Table 6). The amount of total
protein in EV isolates ranged from 11.73 ± 5.18 µg
(qEV, volunteer) to 26,202.95 ± 3904.31 µg (precipita-
tion, volunteer). On average, precipitation and UC
captured 50–80 times the amount of protein derived
from SEC and membrane affinity isolations. Protein
recovery from volunteer samples was significantly
higher (p < 0.05) for exoRNeasy, miRCURY and UC,
but failed to reach significance for Exo-spin (p = 0.87).
Isolation by qEV captured significantly more (p = 0.01)
protein from sepsis patients.
EV-specific proteins as well as negative markers
were assessed by Western blot (Figure 8). CD63, a
commonly used vesicle marker, was detected as a
broad smear between 30 and 60 kDa, indicating differ-
entially glycosylated forms of the protein. EVs isolated
by membrane affinity showed high signal intensities for
CD63, while both SEC-based methods resulted in
weaker bands. No CD63 was detected for isolation by
precipitation and UC. A similar pattern was observed
for syntenin, showing clear signals for exoRNeasy, qEV
and Exo-spin, but not for miRCURY and UC. EV
markers CD81 and TSG101 were not detected for any
isolation strategy.
Nonspecific staining of total EV protein by Ponceau
S revealed a very prominent band at 60–70 kDa for
Exo-spin, miRCURY and UC (Supplemental Figure 6),
potentially indicating co-isolation of non-vesicular
material. Human serum albumin (HSA), the most
abundant blood protein, was selected as a likely candi-
date for protein contamination in EV preparations.
Indeed, Western blot analysis revealed extraordinarily
high HSA levels for miRCURY and UC, but also
exoRNeasy and Exo-spin (Figure 8). Only minor
amounts of HSA were detected for qEV isolations.
Protein lysates were also analysed for contamination
with cellular fragments as indicated by the endoplasmic
reticulum protein calnexin. In contrast to HSA, no
calnexin signal was detected for any of the isolation
methods. These findings hint at a contamination with
soluble proteins, but not with non-vesicular membrane
fragments. None of the detected protein markers
showed significant enrichment for either volunteers
or sepsis patients.
Increased contamination with soluble proteins such
as HSA leads to an underrepresentation of marker
proteins in EV lysates. As no EV markers were detected
for miRCURY and UC, we increased the input for
immunoblotting to 50 µg total protein. Additionally,
EVs isolated by these techniques were further purified
Figure 7. Morphology of serum EVs by transmission electron microscopy. Images are representative for three separate biological
replicates for both volunteers (top panel) and sepsis patients (bottom panel). Scale bars are 500 nm (top row) and 100 nm (bottom
row).
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by iodixanol density gradient centrifugation to remove
soluble proteins. Even though increasing total protein
did not lead to the detection of protein markers
(Supplemental Figure 7), floatation into a density gra-
dient effectively separated contaminating HSA from
EVs captured by sedimentation and precipitation.
While the majority of HSA was retained in fractions
of 1.02–1.07 g/ml, EV markers syntenin and CD63
were identified in a fraction of 1.18 g/ml, correspond-
ing to previously reported floatation densities of blood-
derived EVs [51] (Figure 9).
Discussion
EVs fascinate researchers in basic science and translational
applications alike, but our understanding of EV biogenesis,
secretion, tissue retention and potential therapeutic use
depends on the ability to isolate and characterize specific,
well-defined populations of vesicles. The question as to
which EV isolation method to utilize for a given down-
stream application is a frequent subject of controversial
debate that has yet to be settled. In this study, we
qualitatively and quantitatively compared EV isolation
strategies based on different physiochemical mechanisms
ranging from sedimentation and precipitation to mem-
brane affinity and SEC. Importantly, we used serum as a
biofluid relevant to clinical applications and included dis-
eased patients as well as healthy volunteers. As isolation
methods need to be validated using clinical samples, we
opted for sepsis patients, who represent a prime example
for both interindividual variability and complex aberra-
tions in blood parameters.
High-throughput sequencing has evolved into a main-
stream method of analysing nucleic acids. It allows precise
quantification of miRNAs and sheds light on RNA com-
position, co-isolation of non-target molecules and novel
classes of non-coding RNA. Using Illumina small RNA-
Seq, we found that vesicular RNA profiles greatly depend
on the respective EV isolation strategy. While the methods
less specific for EVs (precipitation, sedimentation and
membrane affinity) resulted in higher absolute and relative
numbers of mapped miRNAs, a more stringent size selec-
tion on EVs (SEC) led to lower mapping rates and an
abundance of short RNA fragments in preparations
Figure 8. Analysis of marker proteins in EVs from volunteers (left) and sepsis patients (right). EV markers CD63 and syntenin were
detected in vesicles isolated by membrane affinity (exoRNeasy) and SEC (qEV, Exo-spin), but not precipitation (miRCURY) and UC. All
EV isolates were negative for TSG101, CD81 and calnexin. Significant albumin contamination of EVs was found for non-SEC isolation
methods. Results are representative for three separate biological replicates for both volunteers and sepsis patients.
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(Figure 3). Furthermore, isolates from different methods
were reproducibly enriched in fragments of additional
short non-coding RNA classes such as tRNA. We have
used two different RNA extraction kits in this study, and
varying combinations of EV isolation and RNA extraction
methods might yield slightly different results [5,52].
However, based on the vastly different characteristics of
the material captured by each method, we believe that EV
isolation itself has a far greater impact on downstream
RNA analysis than the respective extraction method
(Figure 6).
The prime objective of this study was to assess EV
isolation methods regarding their suitability for
miRNA-based biomarker studies. In our data, the
ability to separate healthy individuals from diseased
patients strongly correlated with sequencing output
for a given method: EV isolation based on precipitation
and membrane affinity resulted in higher absolute
numbers of mapped miRNA reads, more candidates
in DGE analysis and enhanced separation of groups
in hierarchical clustering. In contrast, low-output
methods (SEC) were also able to identify a core set of
two miRNAs differentially regulated regardless of iso-
lation strategy but did not reliably assign individual
samples to the correct study population (Figure 5).
Interestingly, only SEC-based methods generated simi-
lar or greater numbers of reads from diseased samples,
while precipitation and membrane affinity seemed to
Figure 9. Analysis of EV markers and human serum albumin in EVs isolated by precipitation and sedimentation and further purified
by iodixanol density gradient centrifugation. CD63 and syntenin were detected in a density fraction of 1.18 g/ml, while the majority
of albumin floated in fractions of 1.02–1.05 g/ml. Results are representative for two separate biological replicates for both
volunteers (top panel) and patients (bottom panel).
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work more effectively for healthy individuals
(Supplemental Table 3). This correlated only partially
with particle data from NTA, which indicate that both
qEV and exoRNeasy recover more particles from sepsis
sera. Even though assessing sequencing library size as a
standalone metric is of limited use, results from differ-
ential expression analysis correlated with higher
sequencing output and more diverse libraries in our
data. Library composition might, however, differ
depending on sample preparation, as demonstrated by
Huang et al. [28]. As different library preparation kits
tend to preferentially capture specific RNA sequences,
NGS data in different experiments might be biased for
certain transcripts. Highly abundant miRNAs are less
affected by library preparation-induced biases, which
might be more problematic for low-abundance tran-
scripts or biomarker studies in diseases with less
extreme alterations in miRNA expression. In conclu-
sion, isolation methods less specific for EVs yielded
more RNA, better libraries and, therefore, increased
separation of patient groups. More specific methods,
which purify EVs rather than enrich cell-free material
in general, resulted in less complex libraries, fewer
miRNA reads and poor performance in clustering. It
is worth noting that increasing sequencing depth for
RNA associated with pure vesicle preparations might in
turn improve results from DGE analysis.
Observed variations in RNA composition could be
attributed to a number of factors including a method’s
efficiency of isolating EVs, isolation of non-overlapping
subpopulations of vesicles and co-isolation of non-vesi-
cular RNA. As blood samples from sepsis patients and
healthy donors were drawn using slightly different
methods, potential sampling-related batch effects
might confound genuine disease effects. Yet, as shown
in hierarchical clustering (Figure 5), poor separation of
sample groups for SEC-based isolation indicates the
absence of a systematic batch effect caused by blood
sampling. Additionally, in a separate study on paired
samples collected by arterial and venous catheters from
the same donors, we couldn’t detect any significant
sampling-dependent differences in EV morphology
and associated miRNA profiles (manuscript in prepara-
tion). Differential expression of miRNAs in this study
is therefore likely to be caused by sepsis itself, rather
than by collection methods.
Several of the miRNAs we found to be differentially
expressed (Supplemental Table 4) have previously been
associated with sepsis and inflammation. Reithmair et al.
and Wang et al. reported increased levels of circulating
miR-193b-5p in EVs from sepsis patients and a strong
association with disease mortality [34,53]. miR-30a-5p,
upregulated in samples from exoRNeasy, miRCURY and
Exo-spin, is induced by inflammatory stimuli and discri-
minates sepsis from non-infectious systemic inflamma-
tory response syndrome [54,55]. Several groups reported
that treatingmacrophages with lipopolysaccharides (LPS)
increased expression of miR-155-5p, which, in turn, dam-
pened the immune response, protected septic mice from
cardiac dysfunction and improved survival [56–58].
Additionally, circulating levels of miR-155 were shown
to correlate with disease severity and poor prognosis in a
cohort of 60 sepsis patients [59]. In mice and rats, miR-
150-5p, upregulated in samples captured by membrane
affinity, was increased by polymicrobial sepsis and LPS
treatment, respectively [60,61]. Vasilescu et al. reported
plasma levels of miR-150-5p to correlate with sepsis
aggressiveness in a cohort of 17 sepsis patients [62]. In
concordance with previous findings in critically ill
patients, we detected miR-122-5p as upregulated in sam-
ples derived from all isolation methods. This miRNA is
commonly considered to be liver specific, and increased
serum concentrations have been reported in cases of liver
injury and hepatotoxicity [63]. Increased serum levels of
miR-122-5p were also reported in sepsis patients, corre-
lating with liver damage, coagulation disorders and mor-
tality [53,64,65]. A more recent publication by Roderburg
et al., however, demonstrated thatmiR-122-5p expression
in critically ill patients was dysregulated by hepatic injury
alone, independent of an infectious state [66]. Exclusively
focusing on the septic shock patients in our cohort might
have tightened expression patterns of disease-related
miRNAs, but as our goal was to assess EV isolation
methods capable of also detecting the less severe stage,
we did not perform separate analyses on this subgroup. In
conclusion, our findings match previous reports about
altered profiles of circulating miRNAs in critically ill
patients and animal models of sepsis, and crude prepara-
tions of cell-free RNA allow for more robust detection of
disease-associated differential expression.
In an attempt to shed light on the nature of vesicles
isolated by each method, we characterized intact parti-
cles using NTA. Unsurprisingly, all methods used in
this study isolated particles in the size range of small
EVs. Mean particle diameters, however, differed signif-
icantly: membrane affinity captured EVs with dia-
meters close to 200 nm, while precipitation isolated
vesicles with an exosome-like diameter of
100–120 nm. These differences might be due to captur-
ing different EV populations or manipulation of ori-
ginally identical EVs during isolation by aggregation
[67] or coating with serum proteins [68]. In line with
our findings, Stranska et al. recently reported larger
particle diameters for EV samples isolated from
human plasma by membrane affinity compared to
SEC [69]. For most kits, variability of particle
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diameters was greater in sepsis samples, indicating
disease-specific changes in circulating vesicles, or inter-
ferences caused by matrix effects in serum from criti-
cally ill patients. It is also conceivable that an increased
proportion of immune cell-derived EVs or bacterial
outer membrane vesicles, typically ranging from 20 to
300 nm in diameter, might contribute to the broader
range of particles recovered from septic sera [70,71].
Quantitative analysis of particles revealed another layer
of complexity, as precipitation captured both the smallest
and the highest number of EVs, whereas particles isolated
bymembrane affinity were larger andmuch less abundant.
For a given isolation method, seemingly high standard
deviations of particle sizes can most likely be attributed to
endogenous variability within patient groups. Recent work
by Eitan et al. revealed individual-specific set points for EV
concentration and composition, indicating the need for
larger cohorts in descriptive and clinical EV studies [49].
The slightly decreased concentration of EVs recovered
from sepsis patients by most methods could be due to less
efficient capture from patient sera, or genuinely lower EV
concentrations in serum caused by decreased secretion,
increased clearance from the bloodstream, dilution of
EVs by therapeutic blood products administered in the
ICUor a combination thereof. It should be noted, however,
that lipoproteins such as low-density lipoprotein (LDL)
outnumber EVs in cell-free blood by at least one order of
magnitude and are known to co-purify with EVs [72]. As
LDL and other common contaminants such as protein
aggregates mimic characteristics of genuine EVs, particle
quantification using NTA might overestimate EV concen-
trations in low-purity preparations and skew isolation-
dependent size profiles [73–75]. Interestingly, the ability
of extracellular RNA to separate healthy and diseased indi-
viduals did not seem to be tied to the diameter of the
corresponding EVs since methods isolating both very
small (precipitation) and very large (membrane affinity)
EVs performed best in differential expression analysis. As
these methods are prone to contamination with soluble
material (Figure 8), we cannot rule out the possibility that
separation of patient groups is based on RNA not asso-
ciated with EVs, but co-isolated from the non-vesicular
serum compartment. SEC-based methods, on the other
hand, isolated EVs contaminated with large quantities of
short RNA fragments, rendering them less suitable for
robust classification of patient samples. This discovery
raises questions about the origin of these fragments and
whether they are encapsulated in EVs or co-isolated from
non-vesicular blood compartments. While part of the
population of short fragments might be derived from
RNA degradation and library preparation artefacts such
as adaptor dimers, non-human RNA sequences could also
contribute to this category. Certain bacteria secrete cell-free
RNA, some of it vesicle-associated, which might have been
captured from septic sera by the EV isolationmethods used
here [76,77]. Additionally, reads categorized as unmapped
(Figure 3) might be derived from bacterial RNA, even
though the frequency of unmapped reads was not signifi-
cantly increased in sepsis samples. As differential contam-
ination of libraries with non-human sequences would
impair normalization to library size or reads per million,
we strictly normalized expression values for confirmed
human miRNAs. Analysing particle morphology by TEM
demonstrated that all methods isolated vesicles in the
100–200 nm size range. Isolates from precipitation did
not display significantly more vesicles than other methods,
indicating that non-vesicular particles such as protein
aggregates might have contributed to increased particle
counts in NTA [78]. The number of particles per field
shown in Figure 7 does not necessarily correlate to particle
concentrations from NTA since different dilution factors
were used for samples from each isolationmethod in TEM
imaging. In accordance with recent reports [79], we also
observed double vesicles and vesicles containing two or
more smaller vesicles.
Further profiling of EV isolates demonstrated an enrich-
ment in CD63 and syntenin for SEC-based andmembrane
affinity-based isolations, but not for precipitation and UC.
Potentially owing to insufficient starting material or tech-
nical factors, and in contrast to preexisting publications
[23,34,80], we did not detect TSG101 and CD81 for any
isolation method. Similar findings were recently presented
in a publication by Stranska et al., which demonstrated the
absence of CD81 and TSG101 in plasma EVs isolated by
membrane affinity [69]. Additionally, recent advances in
the field have demonstrated that so-called exosome mar-
kers can also be present on other classes of EVs and that EV
isolates are a heterogeneous mixture of various subpopula-
tions with specific protein profiles [81,82]. It is therefore
conceivable that isolationmethods are biased towards only
partially overlapping EV populations, resulting in different
protein profiles. Additionally, modifications of EVs during
isolation, including coating with precipitation polymers or
serumproteins,mightmask antigens and impede detection
of marker proteins as observed elsewhere [83,84]. Even
though increasing the input for protein analysis helped
other investigators to detect markers in crude EV samples
[23], it was not sufficient for samples from precipitation
and sedimentation in our study. Additional purification by
density gradient centrifugation, however, established the
presence of EV markers syntenin and CD63 in fractions
with a density of 1.18 g/ml (Figure 9). While serum albu-
min and other soluble proteins overpowered EV markers
in crude isolates, floatation into a density gradient could be
used to specifically purify vesicles from pre-enriched sam-
ples. The endoplasmic reticulum marker calnexin could
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not be detected in lysates from any of the isolation princi-
ples, indicating the absence of contaminating cellular frag-
ments and vesicles not originating from endosomes [85].
Contamination of EV preparations with highly abundant
blood proteins is a well-known problem, particularly for
proteomic analyses [86]. In line with earlier publications,
we demonstrate that precipitation- and sedimentation-
based isolations co-fractionate significant amounts of
serum albumin that mask genuine EV-enriched proteins.
Additionally, we herein confirm previous findings
[69,83,87] that SEC-based methods represent an efficient
way of removing high-abundance serum proteins
(Supplemental Figure 6), trading decreased vesicle yield
for higher purity [88].
Highly pure and well-defined populations of EVs, how-
ever, might not be prerequisite for all research questions.
Whilemechanistic and descriptive scrutinies are crucial for
basic research and developing EV therapeutics, biomarker
applications rely heavily on pronounced and reproducible
changes in the molecules of interest. A recent publication
by Quek et al. suggests that impurities in vesicle prepara-
tions have little effect on downstream nucleic acid quanti-
fication and states the utility of time-efficient, but rather
crude EV isolation methods for biomarker discovery [89].
In line with this, we report precipitation-based isolation to
yield samples with lower purity and significant protein
contamination, but excellent potential for transcrip-
tomics-driven biomarker discovery. We agree with pre-
vious publications stating that enriching serum EVs by
precipitation might be a viable strategy for biomarker dis-
covery studies [21,23]. Alvarez et al. presented similar
findings for profiling RNA biomarkers in urinary EVs
[9]. Decreased purity does not have to be a limitation if
the objective is enriching cell-free miRNAs rather than
purifying specific EV populations. If researchers strive to
identify extracellular miRNA signatures that separate
patient populations, these could be analysed regardless of
their carriers [90]. As long as samples isolated by a given
method reproducibly provide strong divisional capabilities
for patient populations of interest, comprehensively char-
acterizing isolated vesicles might not be a mandatory
requirement for clinical biomarker applications. Given
that precipitation is time efficient, inexpensive and
demands no specialized equipment, it also seems to con-
veniently lend itself to integration into clinical usage.
However, in a research field as vibrant and international,
standardizing reagents and protocols utilized for EV pre-
cipitation and characterization are crucial for generating
valid and reproducible data across laboratories [22,85,91].
In conclusion, we herein report that enriching cell-free
miRNAs by precipitation allows for reliable separation of
sepsis patients and healthy volunteers in sequencing-based
analyses. As extracellular RNA can be encapsulated in
vesicles or stabilized by binding to circulating proteins
such as argonaute 2 (Ago2), further investigations using
additional purification steps such as density gradient cen-
trifugation or SEC are needed to conclusively verify if
miRNAs dysregulated in this study are genuinely encapsu-
lated in EVs [92]. Based on our experiments, we cannot
rule out the possibility that miRNAs separating patients
and volunteers are associated with non-vesicular carriers
rather than EVs [93]. Should this be the case, additional
validation of sepsis-related miRNA signatures might be
carried out on total cell-free RNA without prior enrich-
ment of EVs, reducing time and cost of analysis. Even
though exosomes have been shown to provide an enriched
source of miRNA with higher predictive value than total
cell-free blood, miRNAs of diagnostic potential might be
associated with different carriers in a disease-specific man-
ner, calling for the careful validation of previous findings in
each biomarker discovery process [2,94]. In diseases with
less drastic clinical manifestation than sepsis, extracellular
signalling could be more clearly detectable in pure EVs as
opposed to crude preparations of cell-free RNA. Our find-
ings might therefore not be generalizable to all clinical
applications, as a different approach may be more appro-
priate for diseases other than sepsis.
Even though the focus of this work was on transcrip-
tomic profiling of EVs, our findings could be transferred to
different routes of analysis as well. It has become increas-
ingly clear that the optimal method of EV isolation differs
depending on the respective research setting and down-
stream analyses. Both failing to choose appropriate isola-
tion methods for a particular experiment and trying to
integrate results from multiple studies conducted with
inappropriate or incompatible methodology squander
resources decrease experimental validity andhamper trans-
lation of research findings into practical applications. This
work therefore provides valuable guidance for navigating
the wide array of EV isolation methods available today.
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Abstract. Triple-negative breast cancer (TNBC) is a particu-
larly aggressive subtype of breast cancer with limited options 
for clinical intervention. As with many solid tumors, TNBC 
is known to promote invasiveness and metastasis by secreting 
extracellular vesicles (EVs) capable of modulating the behav-
iour of recipient cells. Recent investigations have demonstrated 
that high expression levels of glucocorticoid receptor (GR) 
in TNBC are linked to therapy resistance, higher recur-
rence rates and increased mortality. In addition to activating 
protein-coding genes, GR is also involved in the expression of 
short non-coding RNAs including microRNAs (miRNAs or 
miRs). The molecular mechanisms responsible for the onco-
genic effects of GR on TNBC have yet to be fully elucidated; 
however, emerging evidence suggests that miRNAs may play a 
pivotal role in tumorigenesis and metastasis. Thus, the aim of 
this study was to identify GR-regulated cellular and vesicular 
miRNAs that might contribute to the particularly oncogenic 
phenotype of TNBC with a high GR expression. We analyzed 
miRNA profiles of three TNBC cell lines using an in vitro 
model of GR overexpression. Next-generation sequencing 
revealed minor, cell line-specific changes in cellular miRNA 
expression, whereas vesicular miRNAs were not significantly 
regulated by GR. Additionally, the analysis of predicted 
miRNA targets failed to establish a causal link between 
GR-induced miRNA expression and oncogenic signaling. On 
the whole, given that GR influences miRNA profiles to only a 
small degree, other mechanisms are more likely to be respon-
sible for the increased mortality of patients with TNBC with a 
high GR expression.
Introduction
Breast cancer (BC) is the most prevalent type of cancer 
affecting women, and the second most common type of 
cancer as a whole. Globally, the incidence of BC is one in nine 
women (1). Despite substantial advancements in diagnosis and 
treatment, the mortality rates for BC are still at 15% (2).
One of the most aggressive variants of BC is triple-negative 
BC (TNBC). This subgroup of BC cells does not express the 
receptors for estrogen (ER), progesterone receptor (PR) and 
human epidermal growth factor 2 (HER2). The absence of 
these proteins renders commonly used clinical interventions, 
such as inhibiting aromatase and blocking hormone receptors 
ineffectual for TNBC therapy (3,4). Treatment is therefore 
limited to surgical resection and adjuvant chemotherapy, 
making TNBC a significant unmet clinical need (5).
Synthetic glucocorticoids, such as dexamethasone are 
commonly used in tumor therapy (6). However, recent data have 
indicated that mortality is increased in patients with TNBC 
variants overexpressing glucocorticoid receptor (GR). GR 
signaling activates oncogenes, inhibits apoptosis and represses 
tumor suppressor genes in TNBC, leading to unfavorable 
clinical outcomes (7). A high GR expression is also associated 
with therapy resistance and increased recurrence (8).
In addition to regulating protein-coding genes, GR is 
known to activate non-coding RNAs, including microRNAs 
(miRNAs or miRs) (9). These molecules of18-22 nt in length 
modulate cellular gene expression by specifically binding 
complementary mRNA sequences and repressing their 
translation. Highly malignant tumor cells commonly display 
dysregulated miRNA profiles, leading to oncogenic and 
anti-apoptotic signaling (10). For TNBC, previous studies 
have discovered signatures of altered miRNA expression that 
distinguish cancer cells from surrounding tissues, and predict 
the receptor status for ER, PR and HER2 (11,12). Additionally, 
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the analysis of miRNAs highlights the heterogeneity of TNBC 
phenotypes and their respective signaling pathways (13). 
Unraveling miRNA regulation for individual TNBC vari-
ants is therefore crucial to understand pathogenesis and draw 
consequences about potential therapeutic interventions.
Recent studies have indicated that TNBC modulates 
distant cells by secreting signaling factors, including extracel-
lular vesicles (EVs). EVs shed from tumor cells are enriched in 
specific miRNAs that might contribute to tumor progression 
and metastasis (14). Indeed, BC EVs have been found to induce 
the proliferation, migration and invasion of recipient cells, thus 
enhancing disease progression (15-17). Exploiting circulating 
miRNAs for the diagnosis and prognosis of TNBC patients 
might yield powerful biomarkers that are easily accessible via 
liquid biopsy (18).
To the best of our knowledge, however, to date, there is no 
study available investigating the effects of GR signaling on 
miRNA regulation in TNBC. Thus, in this study, to address 
this knowledge gap, we analyzed cellular and vesicular 
miRNA profiles in an in vitro model of GR-overexpressing 
TNBC by high-throughput next-generation sequencing (NGS). 
Surprisingly, no statistically significant alterations in EV 
miRNAs were detected in two TNBC cell lines upon GR 
overexpression. We did, however, detect a small set of cellular 
miRNAs regulated by GR in a cell line-specific manner. As the 
validation of miRNA target genes yielded ambiguous results, 
we concluded that the unfavorable influence of a high GR 
expression on TNBC phenotypes is not mediated by miRNAs 
to a significant extent.
Materials and methods
TNBC cell culture and transfection. The human TNBC cell 
lines, mDA-mB-231, mDA-mB-436 and mDA-mB-468, 
were purchased from the Leibnitz Institute DSmz-German 
Collection of microorganisms and Cell Culture (Braunschweig, 
Germany) and Cell line services (Eppelheim, Germany).
The cells were cultured in T75 flasks in a monolayer in 
DmEm (Sigma-Aldrich, Hamburg, Germany) containing 
4.5 g/l glucose, 1% L-glutamine, 10% exosome-depleted fetal 
bovine serum (FBS) (BioCat GmbH, Heidelberg, Germany), 
160 ng/l cortisol and 1% penicillin/streptomycin (Invitrogen, 
karlsruhe, Germany). Cultures were maintained in a humidi-
fied atmosphere at 37˚C and 5% CO2. For the experiments 
studying cellular miRNAs, the mDA-mB-231, mDA-mB-436 
and mDA-mB-468 cells were seeded 4.5 h prior to transfec-
tion at a concentration of 1x105 cells per well in 24-well plates 
(Greiner Bio-One, Frickenhausen, Germany) using 0.5 ml 
culture medium.
GR overexpression was induced by transfecting the 
TNBC cells with nuclear receptor subfamily 3 group C 
member 1 (NR3C1)-encoding DNA plasmids. The coding 
sequence (CCDS4278.1) of the predominant glucocorticoid 
receptor gene NR3C1 transcript variant 1 (Nm_000176.2) 
was synthesized with the restriction sites KpnI and XhoI on 
the 5' and 3' end, respectively (MWG Eurofins, Ebersberg, 
Germany), and cloned in frame into the pcDNA6/V5-His A 
vector (Life Technologies, Darmstadt, Germany). The cells 
were transfected with the NR3C1 plasmid (0.4 µg) for 24 h 
using Lipofectamine 2000 transfection reagent (Invitrogen). 
Following 30 h of cultivation, the cells had reached 90% conflu-
ency, and were rinsed once with HBSS before proceeding to 
total RNA extraction.
For experiments studying EV miRNAs, the mDA-mB-231 
and mDA-mB-468 cells were seeded at a concentration of 
3x106 cells per well in 6-well plates (Greiner Bio-One). Both 
parental and transfected cells were seeded in 3 wells with 
2.5 ml culturing medium each. Transfection was performed 
with 2.5 µg of plasmid harboring the coding sequence of 
NR3C1.
For all experiments, untransfected cells with endogenous 
GR expression were used as control samples. Three indepen-
dent technical replicates per cell line were analyzed.
Validation of NR3C1 overexpression. To evaluate the effec-
tiveness of transfection, the NR3C1 mRNA levels were 
quantified by reverse transcription-quantitative (real-time) 
PCR (RT-qPCR). Total RNA from each cell line was initially 
reverse transcribed using the QuantiTect Reverse Transcription 
kit (Qiagen, Hilden, Germany) according to the manufacturer's 
instructions. Quantitative PCR was performed using the 
Prime PCR Assay NR3C1 and GAPDH human SsoAdvanced 
universal supermix (Bio-Rad, munich, Germany) and 10 ng 
of template cDNA. PCR reactions were run on a miniOpticon 
real-time PCR system (Bio-Rad). Additionally, the transcrip-
tion levels of NR3C1 downstream targets dual specificity 
phosphatase 1 (DUSP1; Nm_004417), serum/glucocorticoid 
regulated kinase 1 (SGK1; Nm_005627.3) and glucocorticoid-
induced leucine zipper protein (GILZ; Nm_198057.2) were 
assessed by RT-qPCR. For each cell line, total RNA from 
three biological replicates was reverse transcribed using the 
QuantiTect Reverse Transcription kit (Qiagen). Subsequently, 
8 ng cDNA were analyzed in a 10 µl reaction volume of 
SsoFast EvaGreen Supermix (Bio-Rad) and 300 nm primers 
(Sigma-Aldrich). Real-time PCR was carried out on triplicate 
samples using a Rotor-Gene Q thermal cycler (Qiagen) and 
a thermal profile for polymerase activation (95˚C for 1 min) 
and 45 cycles of amplification (95˚C for 10 sec 60˚C for 
15 sec, 65˚C for 45 sec). The primer sequences are provided in 
Table I. The expression of NR3C1 and its downstream targets 
was normalized to GAPDH, a stable reference gene for breast 
cancer cells (19). Relative quantification was carried out using 
the ∆∆Cq method (20). Statistical significance was determined 
using the Student's t-test. Values of P<0.05 were considered to 
indicate statistically significant differences.
Extracellular vesicle isolation and characterization. For EV 
isolation, 7.5 ml of cell culture supernatant were collected 
from the parental and transfected cells after 30 h of cultiva-
tion, and centrifuged (3,200 x g, 5 min) to remove the cellular 
debris. EVs were isolated from pre-cleared supernatant using 
the miRCURY Exosome Isolation kit - Cells, urine and CSF 
according to the manufacturer's instructions (Exiqon, Vedbaek, 
Denmark). EV pellets were resuspended in either lysis buffer 
for RNA extraction, or PBS for vesicle characterization.
For nanoparticle tracking analysis (NTA), the EVs were 
diluted in particle-free PBS and analyzed on a NanoSight 
Lm10 (malvern Instruments GmbH, Herrenberg, Germany) 
using a 408 nm laser and NTA 3.0 software. Four videos of 
30 sec each were captured, and analyzed using default settings 
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for blur and minimum track length, and a detection threshold 
of two.
RNA extraction and NGS library preparation. Total RNA was 
isolated from the cells and EVs using the miRCURY RNA 
Isolation kit – Cell and Plant (Exiqon,) according to the manu-
facturer's instructoins. Cellular RNA was quantified using a 
nanophotometer (Implen GmbH, munich, Germany), and 
RNA integrity was assessed by capillary electrophoresis on 
the Bioanalyzer 2100 using the RNA 6000 Nano kit (Agilent 
Technologies, Waldbronn, Germany). EV RNA was analyzed 
using the Agilent Small RNA kit (Agilent Technologies).
Sequencing libraries were constructed from 190 ng of 
cellular RNA, or the entire EV RNA isolated from 7.5 ml 
conditioned culture medium, respectively. Library preparation 
was performed as previously described by Spornraft et al (21). 
Briefly, the RNA was adaptor-ligated, reverse-transcribed, 
amplified by PCR and barcoded using the NEBNext Multiplex 
Small RNA Library Prep Set for Illumina (New England 
BioLabs Inc., Frankfurt, Germany). Adaptors and primers were 
diluted 1:2 in nuclease-free water to accommodate the low RNA 
input. Size selection of pooled PCR products was performed by 
agarose gel electrophoresis (4%), cutting out bands with 130 to 
150 bp fragments. The purity and concentration of the libraries 
extracted from the gel were verified by capillary electrophoresis 
using the High Sensitivity DNA kit on the Bioanalyzer 2100 
(Agilent Technologies). Finally, the libraries were subjected to 
Illumina single-end sequencing-by-synthesis using 50 cycles 
on the HiSeq 2500 (Illumina Inc., San Diego, CA, USA).
Data processing and differential gene expression analysis. 
FastQC (version 0.11.5) was used to assess the sequence length 
distribution and quality of the NGS data, as previously described 
(22). Adaptor sequences were trimmed using BTRIm, and all 
reads without adaptors were discarded (23). Additionally, reads 
shorter than 15 nt were excluded from the data set (24). Prior to 
miRNA analysis, reads pertaining to ribosomal RNA (rRNA), 
transfer RNA (tRNA), small nuclear RNA (snRNA) and 
small nucleolar RNA (snoRNA) were removed by mapping to 
sequences obtained from RNAcentral (25). The remaining reads 
were then aligned to miRBase (version 21) (26). mapping was 
carried out using Bowtie and the ‘best’ alignment algorithm, 
allowing one mismatch for both RNAcentral and miRBase (27). 
Final read count tables were generated by sorting and indexing 
aligned reads using SAmtools, and calling the sum of hits per 
miRNA sequence (28). Differential gene expression analysis 
was subsequently performed via the bioconductor package 
DESeq2 (version 1.8.1), using the Benjamini-Hochberg method 
to correct for false discovery (29). A log2 fold change ≥|1| and 
an adjusted p-value (Padj) of ≤0.05 were set as thresholds to 
identify significantly regulated miRNAs. Only miRNAs with 
a mean expression of at least 50 counts were included in the 
analysis. Principal component analysis (regularized log-trans-
formed, sizefactor-corrected counts obtained from DESeq2), 
and data visualization were performed in R (version 3.4.0) using 
the packages gplots, ggfortify, genefilter and RColorBrewer.
Validation of regulated miRNAs. Based on the NGS data, 
differentially regulated cellular miRNAs were validated by 
RT-qPCR. First, 111 ng of RNA were reverse transcribed in 
triplicate using the miScript II RT kit (Qiagen) according to 
the manufacturer's instructions. A total of 1 µl cDNA was 
subjected to real-time PCR in a 10 µl reaction volume using the 
miScript SYBR-Green PCR kit (Qiagen). Reactions were run 
on a CFX384 real-time PCR detection system (Bio-Rad) using 
the recommended protocol of polymerase activation (95˚C 
for 15 min) and 45 cycles of amplification (94˚C for 15 sec, 
55˚C for 30 sec, 70˚C for 30 sec). Quantification cycle (Cq) 
values were determined automatically using default threshold 
settings, and Cq values above 37 were manually set to 40. The 
NGS data was utilized to assess potential reference miRNAs 
using the geNorm and NormFinder algorithms (30,31). Cq 
values of regulated miRNAs were subsequently normalized 
to the geometric mean of the following reference miRNAs: 
miR-24-3p, miR-25-3p and miR-148b-3p for mDA-mB-231 
and mDA-mB-436, and miR-24-3p, miR-25-3p and let-7a-5p 
for MDA-MB-468. Relative quantification was carried out 
using the ∆∆Cq method (20). Statistical significance was 
assessed using Student's t-test. Values of P<0.05 were consid-
ered to indicate statistically significant differences.
Prediction and quantification of miRNA target genes. 
miRWalk 2.0 was used to predict mRNAs targeted by 
miR-203a-3p (32). Four target genes known to be associated 
with metastasis in solid tumors [Actin, gamma 2, smooth 
muscle, enteric (ACTG2), calponin 1 (CNN1), major histo-
compatibility complex, class II, DP beta 1 (HLA-DPB1) and 
myosin light chain kinase (MYLK)] were selected for analysis 
by RT-qPCR (33). The expression of these genes was quanti-
fied in the same cellular MDA-MB-436 samples previously 
used for NGS. Initially, RNA was reverse transcribed in trip-
licate using the QuantiTect Reverse Transcription kit (Qiagen) 
according to the manufacturer's instructions. Quantitative PCR 
was then performed using Prime PCR Assays, SsoAdvanced 
Universal Supermix (Bio-Rad) and 10 ng of template cDNA. 
PCR reactions were run on a miniOpticon real-time PCR 
Table I. Primer pairs used for validation of NR3C1 overexpression.
Name Forward primer (5'-3') Reverse primer (5'-3')
DUSP1 GCCATTGACTTCATAGACTCCATC ATGATGCTTCGCCTCTGCTT
SGK1 GACGGTGAAAACTGAGGCTG AGAAGGACTTGGTGGAGGAGA
GILZ TCTTCTTCCACAGTGCCTCC TCTTCAGGGCTCAGACAGGA
DUSP1, dual specificity phosphatase 1; SGK1, serum/glucocorticoid-regulated kinase 1; GILZ, glucocorticoid-induced leucine zipper.
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system (Bio-Rad). Target gene Cq values were normalized to 
GAPDH (19).
Results
Plasmid transfection induces the expression of NR3C1 and 
downstream effectors. The transfection of the TNBC cells with 
NR3C1-coding plasmids was validated by RT-qPCR (Fig. 1A). 
GR expression was significantly increased in the transfected 
mDA-mB-231 (111-fold, P=1.75E-4), mDA-mB-436 (172-fold, 
P=2.51E-4) and mDA-mB-468 (335-fold, P=6.39E-6) cells.
To assess overexpression-induced changes in GR signaling, 
we additionally quantified the expression levels of GR target 
genes DUSP1 (Fig. 1B), SGK1 (Fig. 1C) and GILZ (Fig. 1D). 
While DUSP1 and SGK1 were significantly upregulated in 
all cell lines, GILZ expression was not altered significantly in 
the mDA-mB-468 cells (P=0.51). In the mDA-mB-231 and 
mDA-mB-436 cells, however, GILZ expression was signifi-
cantly increased (P=2.79E-3 and P=3.79E-7, respectively).
TNBC secretes extracellular vesicles carrying RNA. 
EVs isolated from the conditioned media of the parental 
mDA-mB-231 and mDA-mB-468 cells were characterized by 
NTA (Fig. 2). Single-particle analysis revealed a narrow size 
distribution with mean particle diameters of 119.0±74.4 nm 
(mode, 87.5 nm) and 140.0±116.7 nm (mode, 117.5 nm) for the 
mDA-mB-231 and mDA-mB-468 cells, respectively. Despite 
Figure 1. Validation of NR3C1 overexpression. (A) Transfection with NR3C1-coding plasmids significantly increased glucocorticoid receptor (GR) expression 
in the mDA-mB-231, mDA-mB-436 and mDA-mB-468 cells. Analysis of GR downstream effectors (B) DUSP1, (C) SGK1 and (D) GILZ, DUSP and SGK1 
were significantly upregulated in all GR-overexpressing TNBC cell lines, while the expression levels of GILZ were not altered significantly in the transfected 
MDA-MB-468 cells. Numbers below significance indicator display corresponding fold change. **P<0.01; ***P<0.001; NS, not significant; FC, fold change.
Figure 2. Particle size distribution in extracellular vesicle (EV) preparations 
from mDA-mB-231 and mDA-mB-468 cells. The area under the curve repre-
sents the absolute number of particles isolated from 7.5 ml conditioned media.
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the similarities in diameter, significantly more particles were 
isolated from the mDA-mB-231 cells (P<0.001).
Prior to sequencing, RNA extracted from EV preparations 
was analyzed by capillary electrophoresis. Samples from both 
cell lines were found to be enriched in small RNA species 
<150 nt without obvious differences in size profiles between 
the parental and transfected cells. Full electropherograms for 
small RNA analysis are provided in Fig. 3.
GR overexpression does not alter vesicular miRNA profiles. 
EV RNA from the mDA-mB-231 and mDA-mB-468 cells 
was profiled by small RNA-Seq. The mean per-replicate 
library sizes are provided in Table II. After mapping to 
miRBase, between 736 (mDA-mB-468, transfected) and 796 
(mDA-mB-231, parental) distinct miRNA transcripts were 
detected in at least one sample. For EVs from both cell lines, 
there was significant overlap in the 10 most highly expressed 
miRNAs between the treatment groups (Table III).
Differential expression of miRNAs was assessed in 
EVs from the parental and transfected mDA-mB-231 and 
mDA-mB-468 cells. While individual cell lines were clearly 
distinguished by principal component analysis (Fig. 4), the 
overexpression of GR did not lead to noticeable changes in 
Figure 3. Bioanalyzer electropherograms for small RNA analysis in extracellular vesicles (EVs) from parental (left panels) and transfected (right panels) of 
MDA-MB-231 and MDA-MB-468 cells. FU, fluorescence unit; nt, nucleotide.
Table II. Library sizes and number of detected miRNA species 
in mDA-mB-231 and mDA-mB-468 EVs.
 mDA-mB-231 cells
 ----------------------------------------------------------------------
 Parental Transfected
Library size ± SD 1.11E7±1.66E6 1.27E7±1.64E6
Distinct miRNAs 796 788
 mDA-mB-468 cells
 ----------------------------------------------------------------------
 Parental Transfected
Library size ± SD 1.09E7±1.25E6 1.25E7±1.50E6
Distinct miRNAs 762 736
EV, extracellular vesicle; SD, standard deviation.
Figure 4. Principal component analysis of miRNA expression in 
mDA-mB-231 and mDA-mB-468 extracellular vesicles (EVs). Even though 
the cell lines were clearly separated, expression patterns in EVs from parental 
and transfected cells overlapped.
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miRNA expression. None of the miRNAs detected in small 
RNA-Seq displayed statistically significant regulation between 
endogenous and artificially induced GR expression.
Changes in cellular RNA profiles upon GR overexpression. 
Cellular RNA was initially analyzed by capillary electropho-
resis to assess its suitability for NGS analysis. For all cell lines, 
samples from both parental and transfected cells featured 
excellent RNA integrity, as indicated by the RNA integrity 
number (RIN) values >9. Bioanalyzer electropherograms for 
cellular RNA are shown in Fig. 5.
In the NGS data, both the mean size of sequencing libraries 
and the number of detected miRNAs were higher than in the 
EV samples (Table IV compared with Table II). The most 
highly expressed miRNAs in all of the three parental cell 
lines displayed a high degree of similarity, sharing 8 of the top 
10 miRNAs (Table V). Similarly, 7 of the top 10 most highly 
expressed miRNAs were common to all transfected cell lines.
Differential gene expression analysis revealed slight, yet 
statistically significant changes in specific miRNAs during 
GR overexpression (Table VI). Of note, a different set of 
GR-responsive miRNAs was detected in each of the TNBC 
cell lines studied herein, highlighting the heterogeneity of 
molecular signaling. As shown in Fig. 6, miRNA expression 
Table III. Top 10 most highly expressed miRNAs in EVs from parental and transfected mDA-mB-231 and mDA-mB-468 EVs.
 mDA-mB-231 parental mDA-mB-231 transfected
 ----------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
miRNA Count ± SD miRNA Count ± SD
miR-100-5p 32,896.06±15,567.28 miR-100-5p 28,093.64±1,746.75
miR-21-5p 20,517.88±6,132.81 miR-21-5p 20,563.67±13,352.19
let-7f-5p 14,534.16±7,389.27 let-7i-5p 16,700.98±7,018.44
let-7i-5p 13,851.26±3,041.99 let-7f-5p 13,224.79±6,215.57
miR-486-5p 12,773.16±9,474.51 let-7a-5p 13,170.83±7,480.14
let-7a-5p 12,044.75±4,144.34 miR-486-5p 12,251.12±9,557.67
miR-92a-3p 9,763.94±5,940.53 miR-451a 11,594.65±13,346.77
let-7g-5p 9,167.48±3,312.17 let-7g-5p 9,583.62±3,853.93
miR-451a 8,899.87±5,035.93 miR-92a-3p 8,909.74±4,096.12
miR-27b-3p 7,298.91±2,952.47 miR-27b-3p 7,004.21±4,888.94
 mDA-mB-468 parental mDA-mB-468 transfected
 ----------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
miRNA Count ± SD miRNA Count ± SD
let-7f-2-3p 20,174.15±3,134.83 miR-505-3p 17,483.16±12,287.71
miR-103b 14,956.91±4,896.68 miR-4742-3p 15,703.77±5,227.01
miR-4742-3p 14,411.10±5,455.42 miR-103b 14,095.48±11,598.41
let-7a-3p 13,768.25±2,884.00 let-7f-2-3p 13,819.32±4,499.01
miR-505-3p 10,494.01±2,170.28 let-7a-3p 9,814.04±2,947.26
let-7f-5p 10,065.30±2,199.66 let-7i-3p 8,987.19±3,015.38
let-7i-3p 9,369.82±1,379.22 let-7f-5p 8,452.97±2,966.55
miR-22-5p 7,455.85±526.85 miR-22-5p 7,692.73±2,962.41
let-7b-3p 5,176.99±1,522.35 miR-196b-5p 4,445.60±5,386.47
miR-196b-5p 3,375.73±1,780.00 miR-27b-3p 3,582.84±1,131.12
Data are mean normalized readcounts for 3 replicates each. EV, extracellular vesicle; SD, standard deviation.
Table IV. Library sizes and number of detected miRNA species 
in mDA-mB-231, mDA-mB-436 and mDA-mB-468 cells.
 mDA-mB-231 cells
 ----------------------------------------------------------------------
 Parental Transfected
Library size ± SD 9.42E6 1.56E6 7.98E6±8.10E5
Distinct miRNAs 1,025 949
 mDA-mB-436 cells
 ----------------------------------------------------------------------
 Parental Transfected
Library size ± SD 9.25E6±8.75E5 8.28E6±5.92E5
Distinct miRNAs 1,187 1,216
 mDA-mB-468 cells
 ----------------------------------------------------------------------
 Parental Transfected
Library size ± SD 8.32E6±1.23E6 7.27E6±9.70E5
Distinct miRNAs 1,096 1,016
SD, standard deviation.
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Figure 5. Bioanalyzer electropherograms for total RNA analysis in parental (left panels) and transfected (right panels) mDA-mB-231, mDA-mB-436 and 
MDA-MB-468 cells. RIN, RNA integrity number; FU, fluorescence unit; nt, nucleotide.
Figure 6. Principal component analysis of intracellular miRNA expression. (A) Based on all miRNAs, individual cell lines were clearly separated on 
principal components 1 and 2 with subtle differences between parental and transfected cells. (B) Analysis of the top 500 highest variance miRNAs reduced 
the separation of groups.
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clearly separated individual cell lines, but exhibited only minor 
differences between the transfected and parental cells. Based on 
the expression profiles of all miRNAs, principal component 3 
(PC3), distinguished parental and GR-overexpressing cells 
(Fig. 7A). Limiting the input for analysis to the 500 miRNAs 
with highest variance, however, a reduced separation of groups 
was observed (Fig. 7B).
We then assessed differential miRNA regulation between 
endogenous and induced GR expression using RT-qPCR and 
the Student's t-test. Of the 7 miRNAs found to be significantly 
regulated in the NGS data, only miR-203a-3p was validated 
with statistical significance. In the transfected MDA-MB-436 
cells, it was upregulated with a log2 fold change of 0.63 
(Fig. 8).
Table V. Top 10 most highly expressed miRNAs in parental and transfected mDA-mB-231, mDA-mB-436 and mDA-mB-468 
cells.
 mDA-mB-231 parental mDA-mB-231 transfected
 ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
miRNA Count ± SD miRNA Count ± SD
miR-100-5p 963,722.05±111,405.87 miR-100-5p 1,348,718.94±345,916.54
let-7i-5p 663,458.05±68,993.69 let-7i-5p 774,622.60±97,337.13
let-7f-5p 267,434.97±31,684.39 let-7f-5p 324,183.97±17,197.04
let-7a-5p 195,527.39±12,006.56 let-7a-5p 204,938.44±20,414.46
miR-151a-3p 106,021.75±1å1,082.05 miR-151a-3p 163,277.67±56,462.79
let-7g-5p 90,178.84±13,127.37 miR-21-5p 80,090.23±21,445.21
miR-21-5p 67,628.11±16,283.91 let-7g-5p 78,292.35±25,760.59
miR-92a-3p 57,221.86±7,227.13 miR-92a-3p 61,589.95±11,515.77
miR-99b-5p 51,137.53±9,440.27 miR-10a-5p 60,968.56±16,758.93
miR-26a-5p 46,946.37±4,194.59 miR-99b-5p 57,331.95±10,509.88
 mDA-mB-436 parental mDA-mB-436 transfected
 ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
miRNA Count ± SD miRNA Count ± SD
let-7f-5p 374,536.91±26,561.27 let-7f-5p 340,698.27±40,869.66
miR-148a-3p 184,192.97±10,352.18 miR-148a-3p 226,502.28±169,068.63
let-7a-5p 153,782.25±10,424.01 let-7a-5p 163,998.51±24,567.84
let-7i-5p 146,573.76±5,731.89 let-7i-5p 157,923.40±59,299.50
miR-92a-3p 138,702.18±11,122.50 miR-151a-3p 148,161.03±108,764.69
miR-151a-3p 123,436.41±9,688.08 miR-92a-3p 116,819.87±14,412.48
miR-100-5p 71,942.27±10,410.65 miR-100-5p 74,514.77±19,201.37
let-7g-5p 71,876.07±1,749.76 miR-21-5p 66,313.38±31,125.38
miR-21-5p 55,083.27±6,735.91 let-7g-5p 62,873.25± 0,847.78
miR-99b-5p 38,293.24±5,041.04 miR-27a-3p 46,550.47±14,720.23
 mDA-mB-468 parental mDA-mB-468 transfected
 ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
miRNA Count ± SD miRNA Count ± SD
let-7f-5p 265,322.95±28,671.87 let-7f-5p 284,627.19±31,730.98
let-7i-5p 235,059.66±20,017.95 let-7i-5p 187,056.07±30,924.33
let-7a-5p 92,998.25±9,551.52 let-7a-5p 92,984.74±14,147.88
miR-99b-5p 78,640.71±22,892.91 miR-92a-3p 85,018.48±14,067.98
miR-92a-3p 75,727.64±7,097.75 miR-99b-5p 64,627.71±7,761.79
miR-151a-3p 73,088.61±32,556.30 let-7g-5p 62,517.17±6,768.50
let-7g-5p 50,292.17±10,045.56 miR-21-5p 49,269.32±7,542.30
miR-21-5p 43,287.45±14,869.30 miR-151a-3p 43,104.23±13,278.15
miR-25-3p 38,646.33±3,045.93 miR-25-3p 40,277.41±1,076.45
miR-30a-3p 35,921.06±9,828.02 miR-26a-5p 33,429.91±3,036.12
Data are mean normalized readcounts for three replicates each. SD, standard deviation.
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To assess the potential biological functions of miR-203a-3p 
in the MDA-MB-436 cells, in which it was found to be signifi-
cantly increased in, we quantified the mRNA levels of 4 of its 
predicted target genes. Using RT-qPCR, we detected a 3-fold 
increase in MYLK expression during GR overexpression 
(P=0.03). The expression of ACTG2, CNN1 and HLA-DPB1 
was not significantly altered between the parental and trans-
fected cells (data not shown).
Discussion
TNBC is a particularly aggressive form of BC, leading to 
a poor prognosis for patients. Both the absence of hormone 
receptors and its molecular heterogeneity render TNBC a 
difficult target for therapeutic intervention. Additionally, a 
high GR expression was recently linked to therapy failure 
and worse outcomes in patients with TNBC, as well as other 
solid tumors. As Chen et al have previously reported, dexa-
methasone-mediated GR activation induced the expression of 
genes involved in carcinogenesis and tumor progression (7). 
These pro-oncogenic processes may also be fostered by 
GR-responsive non-coding RNAs, including miRNAs. This 
study therefore aimed at deciphering potential alterations in 
extracellular and intracellular miRNAs during GR overex-
pression.
GR biology is fascinatingly complex, involving ligand- 
dependent receptor activation and isoform-specific tran-
scriptional activity (7,34). In this study, we focused on 
NR3C1 transcript variant 1, as this is not only the most 
common isoform in epithelial cells, but also more transcrip-
tionally active than others. Additionally, previous studies 
have demonstrated notable increases in NR3C1 variant 1 in 
Figure 7. Principal component analysis of intracellular miRNA expression. (A) Analysis of all miRNAs in the dataset separated cell lines (PC1) and treatment 
groups (PC3). (B) Distances between parental and transfected cells were reduced when limiting the analysis to the top 500 highest variance miRNAs.
Table VI. Cellular miRNAs significantly regulated by GR.
 miRNA log2FC basemean P-adj
mDA-mB-231 miR-221-5p  1.13 223.75 0.0010
 miR-576-3p  1.11   53.47 0.0071
 let-7b-3p -1.10   88.78 0.0118
mDA-mB-436 miR-203a-3p  1.35 134.76 0.0301
 miR-4746-5p -1.07   74.25 0.0444
mDA-mB-468 miR-1260a -1.54 291.24 0.0003
 miR-1260b -1.54 335.12 0.0001
Positive fold changes indicate upregulation during GR overexpres-
sion. GR, glucocorticoid receptor; log2FC, log2 fold change; P-adj, 
DESeq2-adjusted P-value. Figure 8. Results from RT-qPCR validation of miR-203a-3p. In transfected mDA-mB-436 cells, miR-203a-3p was upregulated with a log2 fold change 
of 0.63.
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TNBC (35,36). As expected, the transfection of TNBC cell 
lines with NR3C1-coding plasmids induced both a strong 
overexpression of GR mRNA and the increased the expres-
sion of several downstream targets (37-39). In concordance 
with previous reports, we found that TNBC cell lines secrete 
EVs in an exosome-like size range (15-17). Small RNA from 
cells with endogenous and artificially increased GR expres-
sion was sequenced, and miRNAs compared in differential 
expression analyses. Although a total of 419 and 442 miRNAs 
were detected in the mDA-mB-231 and mDA-mB-468 EVs, 
respectively, there were no statistically significant changes in 
miRNA profiles for either cell line. Increased metastasis and 
the progression of GR-overexpressing TNBC may therefore 
not be mediated by the secretion of soluble mediators to a 
significant extent. On the other hand, Harris et al recently 
identified vesicular proteins involved in BC metastasis, indi-
cating a signaling function of vesicle components other than 
miRNAs (15). Circulating miRNAs are, however, not restricted 
to EVs, but can also be transported by lipoproteins and protein 
complexes, such as Argonaute2 (Ago2) (40,41). Given that this 
study focused exclusively on vesicular miRNAs, no conclu-
sions can be drawn about the impact of GR expression on 
secreted miRNAs associated with other carrier vehicles.
When assessing the impact of GR overexpression on 
intracellular expression profiles, we detected a slight, cell 
line-specific modulation of 7 miRNAs. Even though the 
impact of GR signaling on TNBC miRNAs has not yet been 
elucidated, previous studies have reported GR-responsive 
miRNAs in primary lymphocytes, as well as in liver and 
spleen cells (42-44). In our data, the non-overlapping profiles 
of regulated miRNAs in the studied cell lines may be reflec-
tive of the inherent transcriptional heterogeneity of TNBC 
phenotypes (13,45,46). Rainer et al reported similar findings 
for several lymphoma cell lines that, although featuring 
GR-reactive miRNAs, only displayed moderate and non-
uniform changes in miRNA profiles upon GR activation by 
dexamethasone (47). In our data, the parental and transfected 
cells were separated by changes in the global expression 
profile of miRNAs (Fig. 7). Distances between groups 
decreased when reducing the number of analyzed miRNAs, 
indicating that GR slightly shifts the expression patterns 
of many miRNAs, instead of inducing large changes in the 
abundance of a few specific transcripts.
Of note, miR-203a-3p, upregulated by GR expression 
in mDA-mB-436 cells, is controversially discussed in BC 
literature. Several studies have reported its overexpression in 
BC, as well as an association with a poor prognosis (48-50). 
Different data, on the other hand, have suggested that 
miR-203a-3p serves as a tumor suppressor miRNA, and have 
stated a decreased expression in BC (51-53). In this study, 
we found miR-203a-3p to be significantly upregulated in 
the mDA-mB-436 cells upon the overexpression of GR. As 
GR is known to be associated with tumor progression, this 
finding may corroborate the postulation of miR-203a-3p as an 
oncogenic factor in BC. However, considering the magnitude 
of expression changes, its biological impact may be of minor 
relevance. In line with our findings, a previous study reported 
an upregulation of miR-203 in dexamethasone-treated bone 
cells, potentially indicating a common miRNA response to 
GR activation across cell types (54).
The myosin light chain kinase (MYLK, MLCK) has 
been shown to interact with PI3k-AkT and p38 signaling, 
increasing cell motility and inhibiting apoptosis in BC 
cells (55,56). Furthermore, Sundararajan et al pointed out the 
ability of MYLK to promote invasiveness in several BC cell 
lines (57). Additionally, using LC-mS/mS-based proteomic 
profiling, Lawrence et al reported TNBC to feature particu-
larly high levels of MYLK compared to less aggressive BC 
variants (58). As MYLK is a predicted miR-203a-3p target, 
we quantified its expression in MDA-MB-436 levels using 
RT-qPCR. Surprisingly, an increased miR-203a-3p expression 
in the transfected cells was accompanied by a 3-fold increase 
in MYLK mRNA levels. This finding was not in concordance 
with our expectations, as canonical miRNA regulation 
involves binding of mRNAs and repressing their translation. 
Consequently, the observed upregulation indicates that MYLK 
is not directly bound and downregulated by miR-203a-3p.
Taken together, our data suggest that MYLK may be regu-
lated by GR, and can be regarded as a candidate gene involved 
in the poor survival rates of TNBC patients overexpressing 
GR. GR's mode of action on MYLK, however, seems not to be 
mediated by major alterations in cellular miRNAs.
In conclusion, we did not observe any prominent alterations 
in cellular or vesicular miRNA profiles upon overexpression of 
GR. The patterns of miRNA expression seem to be influenced 
by GR to only a small degree, and other mechanisms may 
therefore be the primary driver for the higher mortality rates 
of patients suffering from TNBC with GR overexpression.
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Abstract
Septic shock is a common medical condition with a mortality approaching 50% where early diagnosis and treatment are of particular impor-
tance for patient survival. Novel biomarkers that serve as prompt indicators of sepsis are urgently needed. High-throughput technologies
assessing circulating microRNAs represent an important tool for biomarker identification, but the blood-compartment specificity of these miR-
NAs has not yet been investigated. We characterized miRNA profiles from serum exosomes, total serum and blood cells (leukocytes, erythro-
cytes, platelets) of sepsis patients by next-generation sequencing and RT-qPCR (n = 3 9 22) and established differences in miRNA expression
between blood compartments. In silico analysis was used to identify compartment-specific signalling functions of differentially regulated miR-
NAs in sepsis-relevant pathways. In septic shock, a total of 77 and 103 miRNAs were down- and up-regulated, respectively. A majority of these
regulated miRNAs (14 in serum, 32 in exosomes and 73 in blood cells) had not been previously associated with sepsis. We found a distinctly
compartment-specific regulation of miRNAs between sepsis patients and healthy volunteers. Blood cellular miR-199b-5p was identified as a
potential early indicator for sepsis and septic shock. miR-125b-5p and miR-26b-5p were uniquely regulated in exosomes and serum, respec-
tively, while one miRNA (miR-27b-3p) was present in all three compartments. The expression of sepsis-associated miRNAs is compartment-
specific. Exosome-derived miRNAs contribute significant information regarding sepsis diagnosis and survival prediction and could serve as
newly identified targets for the development of novel sepsis biomarkers.
Keywords: sepsis exosome blood compartment liquid biopsymiRNA biomarker
Introduction
Sepsis has been described as one of the oldest and most pressing
problems in medicine [1]. Even with treatment in modern intensive
care units (ICUs), mortality rates of patients with septic shock are in
the range between 30% and 44.3% [2] with an even higher in-hospital
mortality of up to 50% [3].
Pathobiological models of sepsis emphasize the important role of
host immunity in disease development. Current theories postulate
that organ injury and death from sepsis are the result of an unabated
activation of innate-immunity-driven inflammation accompanied by a
down-regulation of genes that modulate the adaptive immune
response. On the other hand, there is clear evidence for a prolonged
phase of immunosuppression.
Despite these controversies, there is a consensus that rapid cell-
to-cell communication between the immune system and afflicted
organs plays an important role during the cascade of events leading
from initial contact with an invasive pathogen to the fulminant clinical
syndrome of septic shock.
A growing body of literature suggests that nano-sized extracellular
vesicles, including exosomes, play a critical role in cell-to-cell com-
munication, especially in inflammatory processes and malignancy
[4]. Interestingly, small non-coding microRNAs (miRNAs) are highly
enriched in exosomes and certain miRNAs are over-represented com-
pared to their fraction in the donor cell [5, 6].*Correspondence to: Marlene REITHMAIR MD
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These miRNAs play a crucial role in exosome-mediated pheno-
typic modulation of recipient cells. It is well known that miRNAs are
capable of influencing gene expression by specifically binding to the
30-untranslated region (UTR) of complementary mRNA sequences
and thus repressing their translation. Previous publications were able
to demonstrate that exosomes from platelets under septic insult
induce myocardial dysfunction and apoptosis in endothelial cells, and
may thus contribute to the vascular abnormalities commonly
observed in patients with sepsis [7, 8]. Consequently, cell-to-cell
delivery of miRNAs through circulating exosomes could represent an
important mechanism of long-range signalling during sepsis and
offers promising opportunities for assessing biomarkers in minimally
invasive liquid biopsies.
In this study, we examined serum-derived exosomes from
patients with septic shock and compared their miRNA expression
levels to those from total serum and blood cells (leukocytes, erythro-
cytes, platelets) using comprehensive high-throughput next-genera-
tion sequencing (NGS).
Materials and methods
Patient recruitment and sample collection
In total, 22 critically ill patients with sepsis were included in the study
and matched to 23 healthy volunteers (Table S1). Patients were
recruited from two anaesthesiological ICUs caring for a mixed medical/
surgical patient population of an academic medical centre of the Univer-
sity of Munich and a city hospital of Munich.
Healthy volunteers were recruited from hospital personnel and by
advertisement.
Seven patients with septic shock were initially selected for NGS and
matched to seven age and gender comparable healthy volunteers. RT-
qPCR confirmation of expression levels of selected miRNAs was per-
formed in another 15 patients with varying disease severity and in a
matched control group of equal size.
Blood samples were drawn from healthy subjects via venipuncture
and from patients through intravascular catheters on day 0 and day 4
(if available). Samples to obtain serum were collected into 9 ml serum
tubes (S-Monovette; Sarstedt AG&Co, N€umbrecht, Germany), immedi-
ately centrifuged at 3400 9 g for 10 min. and frozen. Whole blood
samples designated for extraction of cellular miRNAs were collected in
RNA tubes (PAXgene; Qiagen, Hilden, Germany) according to the manu-
facturer’s protocol. Serum aliquots and RNA tubes were stored at
80°C.
Exosome isolation and quality control
3 ml serum was digested with 34 ll thrombin for 5 min. After centrifu-
gation (10,000 9 g, 5 min.), exosomes were isolated from the super-
natant using miRCURYTM Exosome Isolation Kit according to the
manufacturer’s protocol (Exiqon A/S). The presence and purity of exo-
somes were confirmed by transmission electron microscopy (TEM) and
nanoparticle tracking analysis (NTA). Exosomal marker proteins (CD81,
TSG101, syntenin-1) were substantiated by immunoblotting (Fig. 1).
For TEM, exosomes were diluted in PBS and deposited on formvar-
coated copper grids (Plano GmbH, Wetzlar, Germany) for 60 sec. Grids
were negative stained in 2% uranyl acetate (Sigma Aldrich Co., Tauf-
kirchen, Germany) before imaging on a Zeiss EM900 (Carl Zeiss Micro-
scopy GmbH, Munich, Germany) with a wide-angle dual-speed 2K-CCD
camera at 80 kV.
For NTA, exosomes were analysed using a NanoSight LM10 instru-
ment (Malvern Instruments GmbH, Malvern, UK) equipped with a
monochromatic 405 nm laser and a high-sensitivity sCMOS camera.
Exosome preparations were diluted in PBS and recorded by the NTA
software (Malvern Instruments GmbH, Malvern, UK). Five videos of
30 sec. with a frame rate of 25 frames/sec were recorded. Each particle
was subsequently tracked on a frame-by-frame basis by the Finite Track
Length Adjustment algorithm, and the recorded Brownian motion was
used to infer particle sizes by applying the Stokes–Einstein equation.
For Western blot analysis (WB), miRCURYTM precipitates were
washed in PBS and pelleted by ultracentrifugation at 100,000 9 g for
2 hrs (Beckman Coulter Optima LE-80K using a SW60 Ti rotor, k-factor:
167.9, 4°C). The pellets were lysed in ice-cold RIPA buffer with a pro-
tease inhibitor cocktail (Roche Deutschland Holding GmbH, Grenzach-
Wyhlen, Germany). Lysates were sonicated, and then centrifuged at
13,000 9 g for 5 min., and protein concentration in the supernatant
was measured using a BCA assay (Sigma Aldrich) before separation by
SDS-PAGE. Lysates were boiled in reducing sample buffer for 10 min.,
and fractionated using NuPAGE 4–12% Bis-Tris Gels (Invitrogen, Carls-
bad, California, USA). Proteins were transferred to a nitrocellulose
membrane (GE Healthcare Life Sciences, Freiburg, Germany). Primary
antibodies were from antibodies-online.com (rabbit anti-syntenin-1,
ABIN1881779, 1:1000) or OriGene Technologies, Inc., Rockville, Mary-
land, USA (rabbit anti-CD81, TA343281, 1:1000 and rabbit anti-TSG101,
TA343598, 1:500). Secondary antibodies were from Santa Cruz Biotech-
nology, Dallas, Texas, USA (goat anti-rabbit IgG-HRP, sc-2030, 1:5000).
Extraction of extracellular and cellular RNA
After exosome isolation from 3 ml serum, exosomal RNA was extracted
with the miRCURYTM RNA Isolation Kit—Biofluids (Exiqon, Vedbaek,
Denmark) and eluted in 30 ll nuclease-free water.
Serum of 600 ll were extracted with the miRCURYTM RNA Isolation
Kit—Biofluids (Exiqon) according to the manufacturer’s protocol. RNA
was eluted in 30 ll nuclease-free water.
For extraction of blood cell RNA, PAXgene blood tubes were pro-
cessed with the PAXgene blood miRNA kit (Qiagen) according to the
manufacturer’s protocol. Integrity of total blood cell-derived RNA was
assessed with the RNA 6000 Nano assay on the Bioanalyzer 2100 (Agi-
lent Technologies, Inc., Santa Clara, California, USA). Small RNA frac-
tions in cellular and extracellular samples were analysed using the Small
RNA assay and RNA yield for cell-derived RNA was quantified on the
Qubit 2.0 Fluorometer with the RNA HS Assay Kit (Life Technologies,
Carlsbad, California, USA) according to the manufacturer’s protocol.
Calculation of haemolysis scores
Blondal et al. [9] found that in RT-qPCR a delta Cq of miR-23a–miR-
451a >7–8 indicates a high risk for haemolysis bias in the
samples. Haemolysis was assessed for each patient sample by
calculating the Cq ratio of these miRNAs accordingly. All samples
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included in the study showed a delta Cq < 7 and thus a low risk for
haemolysis.
Next-generation sequencing
Blood cell, exosomal and serum RNA from seven patients diagnosed
with septic shock as well as seven healthy volunteers were sequenced
for small RNA.
Blood cell-derived RNA of 100 ng was used as starting material,
while the entire RNA yields from 3 ml, or 600 ll serum were used for
exosomal RNA and serum RNA, respectively. Library preparation was
performed as described in Spornraft et al. [10]. Libraries were subse-
quently subjected to Illumina single-end sequencing by synthesis, using
50 cycles on the HiSeq 2500 (Illumina Inc., San Diego, California, USA).
Sequencing data were processed as described previously [10]. A
log2 fold change ≥|1| and an adjusted p value (Padj) of ≤0.05 were set
as thresholds to identify significantly regulated miRNAs. Only transcripts
with a baseMean ≥50 were included in the analysis. For technical NGS
data, see Figure S1.
Bioinformatic analysis
Ingenuity Pathway Analysis (IPA) (Qiagen) was used for the identifica-
tion of causal networks in our high-throughput miRNA expression data.
In our analyses, we only considered pathways with a negative log P
value >20. Only miRNAs meeting the pre-defined cut-off values
mentioned above were entered into IPA, and only experimentally con-
firmed or highly predicted relationships were considered for the analysis
of miRNA effects.
Significantly regulated miRNAs exclusively present in one of the
compartments (exosomes, serum and blood cells) but not in any of the
others were entered into IPA microRNA Target Filter to identify target
genes of relevance to sepsis. For this purpose, disease filtering was set
to Antimicrobial Response, Inflammatory Response and Infectious Dis-
ease. miRNAs from all three compartments were then included in a
Core Analyses step, which identified pathways and causal networks reg-
ulated within each compartment. In a final step, IPA Comparison Anal-
ysis was used to generate heat maps to visualize and compare the
canonical pathways and disease states of relevance to miRNAs regu-
lated within the three compartments.
RT-qPCR validation
In all, 20 miRNAs covering baseMeans from 69 to 279,000 were inves-
tigated by RT-qPCR in a new cohort of 15 septic patients on day 0
(= day of hospitalization) and day 4, as well as 16 healthy volunteers.
geNorm [11] and NormFinder [12] were used to predict the most stable
miRNAs for each of the three compartments based on the NGS data
set, and six potential reference miRNA candidates were selected. For
RT-qPCR, 10 ng of blood cell-derived RNA was reverse transcribed with
the universal cDNA synthesis kit II according to the manufacturer’s pro-
tocol (Exiqon). Exosomal and serum RNA were normalized to the vol-
ume of starting material (3 ml serum and 600 ll serum, respectively),
Fig. 1 Exosome characterization by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA) and WB. TEM revealed vesicles
with an average size range of about 100–150 nm (A). NTA showed a sharp size distribution with a mean particle diameter of 154.4  40.2 nm for
sepsis patients (black) and 225.2  24.3 nm for volunteers (grey) (B). Exosomes were detected by WB using the exosomal markers CD81, TSG101
and syntenin-1 (C).
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and 2 ll of a 30 ll eluate were subjected to reverse transcription. RT-
qPCR was performed in a 10 ll total reaction volume of ExiLENT
SYBR Green master mix and 1 ll of each miRNA LNATM PCR primer
(Exiqon). PCR reactions were performed on a Rotor-Gene Q (Qiagen) or
CFX384 (Bio-Rad) real-time cycler. Relative quantification was carried
out using the DDCq method [13].
Statistical analysis
Demographic characteristics between volunteers and sepsis patients
were compared using analysis of variance (ANOVA) with post-hoc testing.
For comparison of demographic and clinical parameters between the
NGS group and the RT-qPCR confirmation sample, Student0s t-test was
applied in case of normally distributed data and the Wilcoxon rank-sum
test for non-parametric continuous variables. The Chi-square or Fisher0s
exact test was used for comparison of categorical variables. Data in the
text and in tables are given as mean  SD. To increase clarity in some
of the figures, NGS and RT-qPCR data are expressed as mean  SEM.
Statistical calculations were performed using SPSS (version 24.0, IBM
GmbH, Ehningen, Germany).
Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Medical Faculty
of the University of Munich (protocol #551-14). The study was carried
out according to the World Medical Association Declaration of Helsinki
and all study samples were anonymized during analysis.
Written informed consent for publication of blinded individual
personal data was obtained from each participant or the patient’s legal
representative.
Results
Exosome isolation and characterization
WB analysis revealed the presence of exosome markers CD81,
TSG101 and syntenin-1. Single particle analysis by NTA revealed a
narrow size distribution with mean particle diameters of
154.4  40.2 nm (mode: 110.7  23.5 nm) and 225.2  24.3 nm
(mode: 169.7  21.8 nm) for septic patients and healthy volunteers,
respectively. No significant differences in particle number were
observed between the two groups. TEM revealed a homogeneous
population, no morphological differences were observed in vesicles
from healthy volunteers and sepsis patients (Fig. 1).
Differential gene expression analysis
For each of the three analysed compartments, miRNA reads were
compared between septic shock patients and healthy volunteers.
Compared to healthy volunteers, 77 distinct miRNAs were down-
regulated, whereas 103 distinct miRNAs were up-regulated in septic
shock patients. The majority of regulated miRNAs was found
exclusively in blood cell-derived samples and amounted to 62.14%
for up-regulated and 64.94% for down-regulated miRNAs, respec-
tively. The extracellular compartment accounted for 23.38% of all
down-regulated (exosome: 14.29%; serum: 3.90%; both: 5.19 %)
and 28.16% of all up-regulated (exosome: 15.53%; serum: 3.88%;
both: 8.74%) miRNAs. A small fraction of miRNAs was found to be
simultaneously up- or down-regulated in all three compartments
(2.91% and 3.90%, respectively) (Table S2).
Newly identified sepsis-associated miRNAs
The literature was searched for previously sepsis-associated miRNAs
and compared to significantly regulated miRNAs from this study. For
this purpose, each miRNA was searched for in PubMed in combina-
tion with the terms ‘sepsis’; ‘lipopolysaccharide’ and ‘lps’. miRNAs
with ambiguous literature results were considered as PubMed hits
and thus categorized as previously sepsis-associated. Applying the
mentioned criteria, our NGS dataset provided 32 newly identified sep-
sis-associated miRNAs in exosomes, 14 in serum and 73 in blood
cells (Table S2). Seventeen of these miRNAs were found exclusively
in exosomes, respectively, four and 67 miRNAs in serum or blood
cells. One miRNA, miR-423-5p, was present in all three compart-
ments, showing down-regulation in the sepsis shock cohort.
RT-qPCR validation
Subsequent to normalization with the geometric mean of the reference
miRNAs miR-185-5p and miR-25-3p, differential miRNA expression
between healthy volunteers and patients with sepsis or septic shock
were assessed. For exosome and serum samples, seven out of 12 miR-
NAs (58.3%) selected from NGS results could be validated in RT-qPCR,
while nine out of 14 miRNAs (64.3%) were validated for cellular sam-
ples. Log2 fold changes of validated miRNAs for septic shock patients
in NGS (n = 7) and RT-qPCR (n = 6) were correlated for each com-
partment (Fig. S2). One of the validated miRNAs was present in all
compartments while one, one and eight were unique to exosomes,
serum and blood cells, respectively. Five miRNAs were present in both
extracellular compartments, but not in blood cells (Fig. 2).
Disease detection by miRNAs
RT-qPCR data were screened for miRNAs distinguishing patients with
both sepsis and septic shock from healthy volunteers on the day of
admission to the ICU. One miRNA, cellular miR-199b-5p, also indi-
cated the less severe stage with high confidence (P < 0.001) (Fig. 3).
miRNA expression levels across sepsis stages
In order to assess potential regulations of miRNAs across disease
stages, expression levels from healthy volunteers (n = 16) and patients
at study inclusion (day 0) suffering from sepsis (n = 9) and septic
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shock (n = 6) were compared. Almost linear correlations of expression
level and disease severity were found for 11 different miRNAs in at least
one compartment (three exosomal, one serum, nine cellular) (Fig. 4).
With the exception of cellular miR-150-5p and let-7b-5p, all miRNAs
correlating to disease severity were up-regulated. Two miRNAs showed
correlations in two compartments: miR-27b-3p was simultaneously up-
regulated in exosomes and blood cells from septic patients, while miR-
193a-5p was exclusively up-regulated in extracellular samples. All 11
miRNAs showed significant differences (P < 0.05) in expression levels
between the healthy state and septic shock. Additionally, multiple miR-
NAs in exosomes (miR-21-5p, miR-193a-5p), serum (miR-26b-5p) and
cells (let-7b-5p, miR-27b-3p, miR-143-3p, miR-150-5p, miR-199b-5p,
miR-223-3p) were also able to differentiate (P < 0.05) between healthy
volunteers and septic patients (Fig. S3).
Survival prediction by extracellular miRNAs
RT-qPCR patients were grouped according to outcome (death, n = 4;
survival, n = 11) irrespective of sepsis stage. On the day of admis-
sion to the ICU, three extracellular miRNAs (exosomal miR-30a-5p
and miR-125b-5p, miR-193a-5p in serum) were able to predict sur-
vival with high confidence (P < 0.001) (Fig. 5). Septic shock was
markedly associated with death (75.0% of non-survivors and 27.3%
of survivors were characterized to be in septic shock) with signifi-
cantly different expression levels between disease stages for miR-
193a-5p and miR-125b-5p.
Longitudinal analysis of miRNAs correlating with
disease stage
Expression levels of selected miRNAs on day 0 and day 4 were
assessed by RT-qPCR in a separate experiment on patients with
Fig. 2 Venn diagram of differential miRNA
expression profiles from septic shock
patients validated by RT-qPCR.
Fig. 3 Sepsis detection by miRNAs: Only cellular miR-199b-5p detected
both sepsis and septic shock with high confidence (n = 6).
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Fig. 4 Relationship between miRNA expression level and disease severity. Eleven miRNAs in at least one compartment display stringent correlation
of normalized Cq values and disease severity in septic patients upon admission to the ICU.
Fig. 5 Survival prediction by miRNAs. Exosomal miR-30a-5p and miR-125b-5p and serum miR-193a-5p predict survival of septic patients with high
confidence.
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sepsis (n = 3) and septic shock (n = 5). Some miRNAs showed a
normalization of expression levels on day 4 (miR-100-5p exosomes,
miR-26b-5p serum, miR-143-3p cells), while exosomal miR-199b-5p
was found to become more up-regulated compared to healthy volun-
teers (n = 16) (Fig. 6).
In silico analyses of differentially expressed
miRNAs
Top canonical pathways identified by the target disease-driven
approach mentioned above were Pathogen Influenced Signalling, Cellu-
lar and Humeral Immune Response including Cytokine Signalling, Cellu-
lar Stress Response and Injury and Cardiovascular Signalling (Fig. S4).
Discussion
There are a number of earlier studies that have investigated miRNAs
in the context of sepsis. However, only two studies took a genome-
wide approach for assessing the complete miRNA expression profile
in human patients with sepsis in comparison with non-septic controls
by means of NGS [14, 15]. Another study by Vasilescu et al. [16] pro-
filed miRNAs derived from peripheral blood leukocytes by microarray
analysis and validated the most dysregulated miRNA in their sepsis
cohort, miR-150, in plasma samples from septic patients. Although
their clinical study used a less sensitive approach (microarray instead
of NGS), it is the only one investigating at least one miRNA in both
cellular and extracellular blood compartments in human sepsis
patients. In light of the scarcity of miRNA profiling studies in patients
with this disorder, and taking into consideration the limited possibility
of inter-study comparison due to different compartments, it is essen-
tial to comprehensively profile the blood miRNA signature of critically
ill patients based on all compartments.
Comprehensive small RNA-Seq of blood compartments in septic
individuals, performed in this study, revealed compartment-specific
differences in miRNA profiles. While exosomes and serum were
found to share a significant number of miRNAs, there was very lim-
ited overlap in the miRNA profiles of cellular and extracellular sam-
ples. Individual sampling compartments in blood thus differ not only
in RNA quantity, but also display qualitatively distinct profiles of
bioactive nucleic acids. Particularly, exosomes, released by various
cell populations in the body and thus present in the extracellular blood
fraction, play a major role as miRNA carriers and mediators of inter-
cellular communication [17–19]. Considered an enriched sampling
fraction, the exosomal miRNA profile may serve as an excellent
source of diagnostic biomarkers for identifying sepsis patients early
on, discriminating different sepsis stages or even predicting the
course of the disease. In this context, it is worth mentioning that, to
our knowledge, no clinical study characterizing miRNAs derived from
exosomes as a miRNA-relevant compartment in blood has been car-
ried out in sepsis patients before.
Fig. 6 Significantly different miRNA
expression levels between days 0 and 4.
Samples on day 4 were available from
eight of the patients with sepsis or septic
shock previously used in RT-qPCR
expression analysis at day 0. Grey bars
indicate notable changes in expression
within a group of patients. Tested miRNAs
were exosomal miR21-5p, miR27b-3p,
miR100-5p, miR193a-5p, miR199b-5p,
serum miR26b-5p and miR193a-5p, as
well as blood cellular miR27b-3p,
miR143-3p, miR150-5p, miR199b-5p,
miR223-3p and let-7b-5p.
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When profiling miRNAs differentially regulated in sepsis patients on
the day of admission to the ICU by RT-qPCR, only one blood cell-
derived miRNA (miR-199b-5p) distinguished both sepsis and septic
shock from healthy volunteers. Conversely, the miRNAs significantly
associated with survival (miR-30a-5p, miR-125b-5p, miR-193a-5p)
were found to be extracellular. Due to this non-uniform distribution of
miRNA information across sample types, it seems prudent to choose
the appropriate blood compartment for the respective question at hand.
In our data, tracking miRNAs in patients upon admission to the
ICU and 96 hrs afterwards revealed varying courses of regulation
which were, again, compartment specific. While expression of some
up-/down-regulated miRNAs normalized over time, others were found
to deviate even further from healthy volunteers. This might be due to
heterogeneous patient responses to clinical care, differences in type
of treatment and medication received or a combination thereof. Serial
measurements of compartment-specific miRNAs might therefore also
hold value for sepsis management.
As a conclusion, this study presents the first comprehensive profil-
ing of cellular and extracellular miRNAs in sepsis patients. We found a
distinctly compartment-specific regulation of miRNAs between sepsis
patients and healthy volunteers. NGS-based profiling allowed the identi-
fication of sepsis patients as opposed to healthy volunteers, prognosis
of patient survival and elucidation of miRNA disease functions. Addi-
tionally, we detected multiple compartment-specific, highly regulated
miRNAs that had not previously been associated with sepsis. Most
importantly, our data demonstrate the benefit of including exosomal
miRNAs in disease assessment protocols. The practicality and applica-
bility of sampling miRNAs in liquid biopsies will enhance biomarker
research and eventually the clinical management of sepsis.
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